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Abstract 
Through introduction of antigenic materials into hosts, vaccines can elicit adaptive immunity which 
confers protection to the hosts from subsequent exposure to pathogens and cancerous cells. As active 
immunizations require immune-competent hosts, passive immunotherapy can be a complementary 
treatment in which protective biologics are directly administered for more immediate protection. However, 
GMP production of both vaccines and immuno-therapies can be costly and time-consuming, impeding 
translation and deployment of promising therapeutic candidates. Prior work has demonstrated the use of 
synthetic DNA and adaptive electroporation (EP) for in vivo delivery of vaccines and immunoglobulins. In 
this dissertation, I explored the use of synthetic DNA/EP for in vivo folding, assembly, and secretion of 
more complex anti-HIV-1 biologic eCD4-Ig, and simultaneous delivery of four distinct HIV bNAbs in a 
single host. Prolonged expression of both eCD4-Ig and HIV bNAbs were observed, demonstrating the 
host’s own myocytes can be efficient bio-factories for the assembly of biologics. In the case of eCD4-Ig, 
the neutralization potency can be improved when the biologic is post-translationally modified in vivo 
through a co-administered DNA-encoded enzyme. Harnessing engineering lessons learnt for in vivo 
expression of complex protein domains, I studied if DNA/EP can be used to launch designed self-
assembly nanoparticle vaccines in vivo. Using three complementary techniques, I directly demonstrated 
that DNA-launched HIV-1 priming antigen eOD-GT8-60mer can assemble in vivo and can induce 
significantly faster sero-conversion, higher setpoint antibody titers and CD8+ T-cell responses (CTL) in 
both mice and guinea pigs than a DNA-encoded GT8-monomer. Importantly, induction of CTL was unique 
to DNA-launched nano-vaccines and not observed for protein nano-vaccines, due to differences I 
observed regarding the mechanisms of antigen presentations for each. This observation was used to 
construct the next-generation DNA-launched nano-vaccines scaffolding melanoma tumor-associated 
antigens, which exerted strong protection to mice challenged with B16F10 melanoma cells. In summary, 
my work has demonstrated that DNA/EP can be a robust mechanism through which complex biologics 
and vaccines can be delivered to induce unique immunological features highly relevant in the treatment of 
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ABSTRACT 
DESIGNING SYNTHETIC DNA ENCODED IMMUNOTHERAPEUTICS AND 
NANOPARTICLE VACCINES FOR ENHANCED IMMUNITY-MEDIATED PROTECTION 
Ziyang Xu 
Dr. David B. Weiner 
Through introduction of antigenic materials into hosts, vaccines can elicit adaptive 
immunity which confers protection to the hosts from subsequent exposure to pathogens 
and cancerous cells. As active immunizations require immune-competent hosts, passive 
immunotherapy can be a complementary treatment in which protective biologics are 
directly administered for more immediate protection. However, GMP production of both 
vaccines and immuno-therapies can be costly and time-consuming, impeding translation 
and deployment of promising therapeutic candidates. Prior work has demonstrated the 
use of synthetic DNA and adaptive electroporation (EP) for in vivo delivery of vaccines 
and immunoglobulins. In this dissertation, I explored the use of synthetic DNA/EP for in 
vivo folding, assembly, and secretion of more complex anti-HIV-1 biologic eCD4-Ig, and 
simultaneous delivery of four distinct HIV bNAbs in a single host. Prolonged expression of 
both eCD4-Ig and HIV bNAbs were observed, demonstrating the host’s own myocytes can 
be efficient bio-factories for the assembly of biologics. In the case of eCD4-Ig, the 
neutralization potency can be improved when the biologic is post-translationally modified 
in vivo through a co-administered DNA-encoded enzyme. Harnessing engineering lessons 
learnt for in vivo expression of complex protein domains, I studied if DNA/EP can be used 
to launch designed self-assembly nanoparticle vaccines in vivo. Using three 
complementary techniques, I directly demonstrated that DNA-launched HIV-1 priming 
antigen eOD-GT8-60mer can assemble in vivo and can induce significantly faster sero-
conversion, higher setpoint antibody titers and CD8+ T-cell responses (CTL) in both mice 
vi
and guinea pigs than a DNA-encoded GT8-monomer. Importantly, induction of CTL was 
unique to DNA-launched nano-vaccines and not observed for protein nano-vaccines, due 
to differences I observed regarding the mechanisms of antigen presentations for each. 
This observation was used to construct the next-generation DNA-launched nano-vaccines 
scaffolding melanoma tumor-associated antigens, which exerted strong protection to mice 
challenged with B16F10 melanoma cells. In summary, my work has demonstrated that 
DNA/EP can be a robust mechanism through which complex biologics and vaccines can 
be delivered to induce unique immunological features highly relevant in the treatment of 
cancer and other diseases and provide new tools for study for the betterment of human 
and animal health.   
vii
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CHAPTER 1: INTRODUCTION 
Adaptive immunity is an important branch of the immune system that helps prevent 
and clear viral infections (Braciale and Hahn, 2013), as well as mediating surveillance 
against tumor cells (Swann and Smyth, 2007). Humoral immunity refers to protection 
mediated by circulating antibodies which are secreted by B cells. These immunoglobulins, 
by direct interaction with their specific epitopes on the surfaces of pathogens, serve to 
neutralize these pathogens by blocking viral entry into the target cells (Burton and 
Hangartner, 2016). Alternatively, the constant portion of immunoglobulin heavy chain (Fc) 
can also interact with a host of downstream effector cells, including macrophages and NK 
cells, or serum proteins, such as the complements, to facilitate clearance of infected cells 
(Seidel et al., 2013). Cytotoxic T lymphocyte (CTL) responses, on the other hand, are 
mediated by CD8+ T-cells, which can directly kill target cells through T-cell receptor (TCR) 
peptide-MHC I complex interaction, which triggers the release of effector molecules such 
as IFNγ and perforin (Zhang and Bevan, 2011). Several clinical trials reported a direct 
correlation between tumor-infiltrating CD8+ T-cells and tumor regression or disease-free 
survival in the cancer patients, alluding to their important role in this context.  
Induction of the adaptive immune responses through active vaccination is the most 
important approach to prevent human-to-human or animal-to-human transmission of 
infectious diseases and is also now being actively explored in the treatment of cancer 
(Guo et al., 2013). Vaccines have, over the past century, led to eradication of once lethal 
infectious agents such as smallpox (Voigt et al., 2016), and also significantly reduced the 
incidences of many diseases, including measles, mumps, rubella, diphtheria, tetanus, 
hepatitis B, Polio, and also cervical dysplasia caused by high risk HPV (Greenwood, 
2014). Annual influenza vaccines, additionally, have also significantly lowered influenza-
2 
related hospital admissions and mortality on a year-to-year basis, even though the 
seasonal inactivated vaccines currently licensed by the FDAs are still inadequate to deal 
with antigenic drift and shift in the virus (Ramsay et al., 2019). 
While crucial, there are still significant limitations with regard to current approaches for 
active vaccination. For example, individuals who are immunocompromised, such as 
newborns, elderlies, chronic AIDS patients or patients who need to be on constant 
immunosuppressive regimen because of prior organ transplants, cannot mount effective 
immune responses upon vaccination (Arvas, 2014) and may not be allowed to take live 
attenuated vaccines. Additionally, time is required for the development of effective immune 
responses upon vaccination, limiting the initial utility of active vaccination in an outbreak 
situation (Bonanni et al., 2013). Prior studies demonstrate that seroconversion in 
vaccinated individuals may occur between 2 weeks and 2 months following their first 
immunization; and in some scenarios, a second dose may be required (Bonanni et al., 
2013; Grassly, 2014). Finally, even in immune-competent individuals, breadth of the 
induced immune responses may not be sufficient to prevent viral infection (van Schooten 
and van Gils, 2018). For example, due to the error prone process of reverse transcription, 
tremendous sequence diversity has been observed for HIV-1 (Lee et al., 2019). The HIV-
1 envelope proteins, which mediate viral entry through their interaction of CD4 receptor 
and CCR5/CXCR4 co-receptor on T cells and macrophages (Wilen et al., 2012), can be 
extremely different for different HIV-1 isolates, such that autologous neutralizing antibody 
response against a particular isolate may fail to prevent infection by another isolate 
(Overbaugh and Morris, 2012). 
Passive transfer of immunotherapeutics has been explored as a complementary 
strategy to active vaccination (Overbaugh and Morris, 2012). These immunotherapeutics 
may include antibodies isolated from patients or animals, or maybe designed de novo with 
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various protein engineering techniques (Holliger and Hudson, 2005). Several clinical 
studies have already explored the utility of this concept in humans, for which intravenous/ 
subcutaneous infusion of these immunotherapeutics may allow protective circulating 
levels of immunotherapeutics to be present for several weeks (Johnson et al., 2019), 
depending on the half-life and biodistribution of the construct (Mackness et al., 2019). As 
compared to active vaccination, passive transfer immunotherapeutics will confer 
protection in recipients within just hours of administration (Nasser et al., 2010). They have 
additionally been demonstrated to exert therapeutic benefits against diseases including 
HIV-1, for which broadly neutralizing antibodies may be hard to generate with active 
vaccination (Gruell and Klein, 2018). 
While promising, manufacturing of the recombinant forms of vaccines and 
immunotherapeutics may be time-consuming and costly, impeding their clinical translation 
and broad usage (Nagasawa et al., 2012; Schlake et al., 2019). GMP grade materials 
need to be used for both production and purification with these immunotherapeutics. 
Therefore, a method to simplify manufacturing of these constructs through direct nucleic 
acid mediated direct in vivo production may be highly advantageous for the rapid global 
deployment of new approaches. 
1.1 Passive Immunotherapeutics against HIV-1 and cancer 
Passive transfer of immunotherapeutics has been explored in both preclinical and 
clinical trials for HIV-1 and cancer, generating promising results in several studies (Kruger 
et al., 2019; Puronen et al., 2019). In the case of HIV, passive transfer of broadly 
neutralizing antibodies (bNAbs), which target various epitopes on HIV envelope such as 
the CD4 binding site, V2-glycan patch, V3-glycan patch, gp120/gp41 interface, and MPER 
region have been isolated from HIV-infected individuals (Burton and Hangartner, 2016), 
has been demonstrated to confer protection to rhesus macaques from Simian-Human 
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Immunodeficiency Virus (SHIV) challenge (Julg et al., 2017a). In SHIV-infected anti-
retroviral therapy (ART)-suppressed aviremic monkeys, latency reversal agent, such as 
TLR7 agonist, and passive transfer of bNAbs have been observed to eradicate HIV 
reservoir in several monkeys (Borducchi et al., 2018). Additionally, for both chronically 
infected viremic patients and ART suppressed individuals who went through temporary 
withdrawal of ART (analytical therapeutic interruption, ATI), passive transfer of bNAbs, 
especially the combination of 3BNC117 and 10-1074, can transiently suppress viremia or 
delay viral rebound (Bar-On et al., 2018; Scheid et al., 2016); and in some cases, help 
elicit endogenous CTL responses to facilitate maintenance of viral suppression 
(Mylvaganam et al., 2019; Yamamoto and Matano, 2016).  
Other than bNAbs, de novo designed biologics have also been observed to potently 
neutralize HIV-1. eCD4-Ig is a promising example of such biologic. It consists of 
extracellular D1 and D2 domains of the CD4-receptor, fused to CH2 and CH3 domains of 
human IgG1 Fc, and incorporates a short peptide fragment that mimics human CCR5 co-
receptor on the C-terminus. In principle, the CD4 domain on eCD4-Ig will interact HIV 
envelope to expose the co-receptor binding site on Env, and subsequent binding of CCR5 
mimetic peptide with Env will potently neutralize the virion by blocking Env receptor co-
receptor interaction (Gardner et al., 2015). On a diverse panel of HIV pseudoviruses 
evaluated, eCD4-Ig has been demonstrated to neutralize broadly with more potent IC50 
values than several well-characterized bNAbs. In addition, resistance mutation against 
eCD4-Ig is less likely to arise without imposing a fitness cost to the infectivity of the virus 
(Fellinger et al., 2019). It has been also previously demonstrated that post-translational 
modification, such as tyrosine sulfation, is important for the interaction of CCR5 co-
receptor with HIV envelope (Farzan et al., 1999). As such, tyrosine sulfation of CCR5 
mimetic peptide is also considered to be important for maximizing the potency of eCD4-Ig 
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(Xu et al., 2018). In a non-human primate (NHP) study, co-administration of AAV-encoded 
eCD4-Ig with AAV-encoded TPST2, a Golgi enzyme which promotes tyrosine sulfation of 
eCD4-Ig, can protect rhesus macaques from escalating doses of SHIV-AD8 challenges 
(Gardner et al., 2015). In a separate NHP study, AAV-encoded eCD4-Ig also transiently 
suppressed viremia in SHIV-infected NHPs, demonstrating potency and utility of such 
engineered biologics (Gardner et al., 2019a).  
Antibody-based therapy has also shown great promises in the treatment of cancer. 
Immune checkpoint inhibitors such as anti-PD1, anti-PDL1, and anti-CTLA4 antibodies 
used either singly or in combination has significantly improved survival of late-stage 
cancer patients, and are currently licensed for treatment of breast, colon, lung and liver 
cancers (Azoury et al., 2015; Darvin et al., 2018). Monoclonal antibody against tumor 
specific targets, such as Herceptin which binds to and blocks the signaling of HER2/neu 
receptor, is also efficacious in the treatment of some cancer types, including breast cancer 
(Nahta and Esteva, 2007).  
However, administration of passive immunotherapies for both HIV and cancer can be 
limited by their cost of production. Frequent dosing may also be required due to limited 
half-lives of the constructs. For example, Herceptin is usually administered at an initial 
dose of 8mg/kg via 90-minute-long intravenous (IV) infusion. The patient subsequently 
needs to be re-dosed every three weeks via IV infusion until disease progression (Leyland-
Jones, 2001). On average, each patient costs are approximately $70,000 per year for 
Herceptin and will need to return to the healthcare facility for each IV infusion (Aboutorabi 
et al., 2014). As such, financial and logistic hurdles associated with administration of 
recombinant protein form of these immunotherapeutics can impede broader use of these 
agents for patients’ benefits and limit their use globally. 
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1.2 DNA-encoded Monoclonal Antibody (DMAb) platform 
Our lab, in collaboration with others, has established the method of using synthetic 
DNA to facilitate direct in vivo production of monoclonal antibodies. When coupled with 
adaptive electroporation, synthetic DNA plasmids will be directly taken up by muscle cells 
at the site of transfection (Flingai et al., 2013). Transcription and translation of the gene 
inserts by transfected myocytes will lead to in vivo expression of the DMAb transgene 
(Muthumani et al., 2013). Secretion of the gene product by myocytes will then lead to 
systemic expression of the construct. As DNA is extremely stable in host cells, encoded 
gene product is continuously expressed and can be detected in circulation for over a year 
(Wise et al., 2019). 
 Using this approach, in the infectious disease space, we have designed DNA-
encoded bispecific antibody against pseudomonas and attained potent protection of mice 
challenged with the bacteria. Similarly, DMAbs encoding two broadly neutralizing 
antibodies against influenza head and stem domains effectively protected mice in both 
Influenza A and Influenza B challenges (Elliott et al., 2017; Patel et al., 2017). Co-
administration of DNA-encoded vaccine and DMAb against Chikungunya enables both 
early protections, mediated by DMAb, and late protections, mediated by DNA vaccine, of 
virally challenged mice (Muthumani et al., 2016). Through several iterations, optimizations 
in construct sequences (codon and mRNA sequence optimizations), synthetic DNA 
formulation, adaptive electroporation parameters have contributed to significantly 
improved in vivo expression of DMAbs, allowing DMAb expression in NHP to improve from 
ng/mL range to ug/mL range. Recently, we have shown that DMAb encoding an anti-ZIKA 
antibody (ZK-190) can be expressed at potent level in NHPs to protect them from viral 
challenge (Esquivel et al., 2019).  
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In the cancer space, DMAb encoding anti-human CTLA4 antibody (ipilimumab) can 
be expressed at potent level in vivo and leads to complete regression of tumors in both 
prophylactic and therapeutic treatment models (Duperret et al., 2018a). Recently, we have 
also reported the use of synthetic DNA to encode bi-specific T-cell engager (BiTE) for 
treating cancer. These BiTE constructs consists of a Fab fragment targeting human CD3+ 
on one arm and another Fab fragment targeting a tumor-associated antigen on the other 
arm. They serve to cross-link tumor target cell with effector T-cell, while simultaneously 
activating T-cell (with CD3 receptor binding) to enable potent killing of target cells (Slaney 
et al., 2018). However, clearance of the recombinant protein form of BiTE is extremely 
fast, with reported half-lives ranging from minutes to few hours, requiring patients to 
receive treatments in clinic very frequently (Huehls et al., 2015). The DNA BiTE (DBiTE) 
approach significantly prolonged in vivo expression of BiTE even with a single round of 
injection, with observable expression in the mice sera, as assessed by the ability to 
facilitate effector-mediated killing of target cells, for several months. In NSG mice, single 
treatment of DBiTE, followed by passive transfer of human PBMCs, lead to complete 
response in 80% mice challenged with OVCAR3 tumors (Perales-Puchalt et al., 2019). 
A potential drawback with the DMAb approach is the hosts’ anti-DMAb immune 
responses. Anti-drug antibodies (ADA) against the foreign transgene in this scenario can 
lead to rapid clearance of DMAb from systemic circulation, leading to significantly 
attenuated systemic expression of DMAb seven days post treatment when DNA-encoding 
human antibodies were administered to mice (Esquivel et al., 2019). It was, however, 
found that transient immune-modulation at the time of DMAb treatment, either with 
antibody-mediated depletion of CD4+ and CD8+ T cells or blocking of CD40L/CD40 
signaling pathway, can abolish observed ADA response and enable prolonged in vivo 
DMAb expression (Wise et al., 2019; Xu et al., 2018). Regardless, our work with DMAb 
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demonstrates that synthetic DNA may be a versatile tool for direct in vivo production, 
folding and assembly of complex biologics for passive immunotherapy or active 
vaccination. 
1.3 Synthetic nanoparticle vaccines 
In the past decade, advances in material engineering has allowed for the development 
of a nanoparticle vaccines for clinical use (Al-Halifa et al., 2019; Gregory et al., 2013; Zhao 
et al., 2014). It was observed that vaccine efficacy can be significantly enhanced through 
multivalent antigen display, presumably by cross-linking of B-cell receptors for enhanced 
signaling. Nanoparticles may come in several shapes and forms. Inorganic materials such 
as gold, silica and aluminum hydroxide (or alum), can be used to present multiple copies 
protein antigens electrochemically adsorbed to the materials (Cheng et al., 2012; Stone 
et al., 2013). Nontoxic phospholipids may be used to directly encapsulate antigens for 
presentation as liposomes (Giddam et al., 2012). Alternatively, virus-like particles (VLPs) 
or naturally occurring non-viral protein cages, de novo designed protein shells and coiled-
coil assemblies can each be reengineered as nanoparticle scaffolds to display vaccine 
antigens as self-assembling protein nanoparticles (SAPN). These approaches have 
demonstrated remarkable utility in enhancing vaccine potency (Table 1.1). 
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Ferritin Helicobacter pylori Octahedral 24 12 
HA stem (Yassine et 
al., 2015) 
HA RBD (Kanekiyo et 
al., 2019) 
HIV BG505.MD39 
(Tokatlian et al., 2019) 
Lumazine 
synthase 
Aquifex Aeolicus Icosahedral 60 30 
HIV eOD-GT8 




Icosahedral 20 23 
HIV BG505.gp140 (He 
et al., 2016) 
I3-01 De novo design Icosahedral 20 25 
HIV BG505.gp140 (He 
et al., 2018) 
Encapsulin T. maritima Icosahedral 60 24 
EBV 
gp350.D123 (Kanekiy











bacteriophage Icosahedral 180 26 
Malaria Pfs25 (Brune 
et al., 2016; Leneghan 
et al., 2017) 
Coiled-coil-based 
cages 
De novo design Octahedral 24 20 
HA Helix C/M2e 
(Karch et al., 2017) 
Table 1. 1 Summary of self-assembly protein nanoparticle scaffolds used to present 
immunogens 
For example, several recent studies reported that ferritin nanoparticles decorated with 
engineered influenza hemagglutinin (HA) (Kanekiyo et al., 2013; Yassine et al., 2015) or 
HIV Env (Morris et al., 2017; Sliepen et al., 2015; Tokatlian et al., 2019) elicit stronger 
humoral responses than the corresponding monomers. Georgiev et al. recently 
demonstrated that two-component ferritin nanoparticles composed of both HA and HIV 
antigens could induce neutralizing antibodies to both viruses, demonstrating the feasibility 
of using nanoparticle vaccine cocktails (Georgiev et al., 2018). Kanekiyo et al. created 
‘mosaic’ ferritins from HA receptor-binding domains of eight influenza isolates and 
reported that the mosaic nanoparticles induce broader responses than either a mixture of 
eight individual ferritin nanoparticles or equivalent sequential immunizations (Kanekiyo et 
al., 2019). The potency of these nanoparticle vaccines may be further enhanced. While 
the ferritin scaffold is capable of displaying 8 copies of a trimeric immunogen or 24 copies 
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of a monomeric immunogen, 60-subunit icosahedral protein assemblies can display 20 
trimers or 60 monomers. For example, native-like HIV-1 Env trimers have been 
engineered to be displayed on E2p and I3-01 scaffolds (He et al., 2016; He et al., 2018). 
Lumazine synthase has been used to decorate 60 copies of HIV-1 priming antigen eOD-
GT8 (Abbott et al., 2018; Jardine et al., 2015). The multivalency of GT-60mers is important 
for priming broadly neutralizing antibody responses in knock-in mice (Jardine et al., 2015) 
and activating rare bnAb precursors (Abbott et al., 2018). Encapsulin is a 60-mer scaffold 
that has been used to display Epstein–Barr Virus antigens (Kanekiyo et al., 2015). Coiled-
coil driven assemblies, where homotrimeric and heterodimeric coiled-coils are fused 
together, were used to present two influenza epitopes (the ectodomain of the M2 protein 
and helix C of the HA protein) along with a TLR5 agonist (flagellin) to induce high titers of 
antibodies against both epitopes (Karch et al., 2017). Recent structures of an engineered 
major vault protein in fusion with HIV Gag consist of 78 subunits may pave the way for 
using this nanoparticle scaffold for future vaccine studies (Ding et al., 2018). Overall, using 
nanoparticles to scaffold and present immunogens has been demonstrated as a viable 
strategy for the induction of more potent functional humoral immunity. 
However, some intrinsic production challenges with these inorganic nanoparticle 
vaccines or SAPN remain and have impeded their broader translation into the clinical 
space (Desai, 2012; Feng et al., 2019). VLP vaccines are often produced at low yields in 
mammalian cell lines and are difficult to purify, requiring complex reassembly processes 
and additional post-hoc characterization (Fuenmayor et al., 2017; Lua et al., 2014; 
Urakami et al., 2017). Production of HPV VLPs, for example, requires three sequential 
purification steps of strong cation exchange chromatography, size-exclusion 
chromatography, and hydroxyapatite chromatography (Jiang et al., 2011). Large-scale 
production of liposome-based nano-vaccines is challenging, as slight variations in the 
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methods of production result in heterogeneity of the liposomes produced (Desai, 2012). 
Production of nano-vaccines for a global market could therefore require specialized 
pipelines which raise costs. In addition, regulatory approval of drugs for use in humans 
can be complex for development of multicomponent nano-medicines (Eifler and Thaxton, 
2011). Technologies that would allow de novo nanoparticle assemblies directly in the 
hosts from materials that are inexpensive, simple and stable, which bypass complex 
biochemical processes and downstream purifications, may be of interest. 
1.4 DNA vaccines 
DNA vaccines were first brought to the attention of scientific community in the early 
1990s, when Tang et al. reported delivery of DNA-encoding human growth hormone with 
a gene gun as a gene therapy could induce anti-transgene antibodies unexpectedly (Tang 
et al., 1992). Coincident with that report, at the Cold Spring Harbor Vaccine meeting 
(September 1992), the first presentations on development of DNA vaccines against true 
pathogens or tumors were featured. Presentations by Dr.Liu (Merck) and Dr. Robinson 
(UMASS) reported that influenza vaccine antigens cloned into plasmids could induce 
immune responses in animals when the DNA was injected intramuscularly (IM) and Dr. 
Weiner (UPenn) reported that HIV antigens could be delivered as vaccines via the IM 
route to induce immune responses. Additionally, Dr. Weiner also reported that delivery of 
tumor antigens encoded into plasmids could impact tumor growth in a mouse challenge 
models. Their publications rapidly followed (Fynan et al., 1993; Ulmer et al., 1993; Wang 
et al., 1993). Within two years of this meeting, the first DNA vaccine human trial started 
and was led by MacGregor, Gluckman and co-workers at UPenn to evaluate DNA 
encoded HIV envelope constructs, initially developed at Dr. David Weiner’s laboratory, as 
immunotherapy (MacGregor et al., 1998). Soon after, Lessen, Rook, Williams and co-
workers at UPenn examined DNA vaccine in the treatment of human CTCL cancer. By 
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1995, DNA vaccine encoding HIV Env immunogen was allowed to be evaluated in a 
healthy population (led by joint efforts amongst UPenn, Apollon and the NIH), which was 
followed rapidly by another effort to evaluate an influenza DNA vaccine in healthy 
individuals (led by Drs. Clemons, White and Liu at Merck and John’s Hopkins). 
Subsequently, a plethora of work on DNA vaccines that targeted a range of different 
diseases, from cancer, influenza, malaria, hepatitis B, to HIV-1, emerged (Giri et al., 2004; 
Jin et al., 2005; Kutzler and Weiner, 2008; Stachyra et al., 2014; Stevenson et al., 2004; 
Tuteja, 2002). As compared to other routes of vaccination (recombinant proteins and viral 
vector), DNA plasmids encoding antigen transgenes can be rapidly and cost-efficiently 
manufactured. Simple DNA plasmids do not provoke antigen specific immunity against the 
DNA backbone, enabling vaccine boosting in the same individuals with the same plasmid 
vector, and focusing the host immunity on the transgene. Synthetic DNA is highly stable, 
thereby obviating the need for cold chain transport/storage and facilitating global 
deployment of the vaccines during outbreaks (Hobernik and Bros, 2018; Saade and 
Petrovsky, 2012).  
However, one major limitation with the first-generation DNA vaccine is that, as 
compared to recombinant protein or viral-vectored vaccine, immunogenicity of DNA 
vaccine was lower than optimal in larger mammals (NHPs) and in humans, impeding 
enthusiasm for this approach (Redding and Weiner, 2009; Suschak et al., 2017). Several 
strategies have been attempted to improve the overall immunogenicity of DNA vaccines. 
One such strategy is the co-delivery of DNA-vaccine with DNA-encoded cytokine adjuvant 
(such as IL-12) to enhance co-stimulation of antigen-presenting cells (APCs) (Kalams et 
al., 2012). It was observed that induced immune responses were significantly enhanced 
with the co-delivery of cytokines; in several NHP studies, cytokine-augmented DNA 
vaccination was observed to improve control of viremia in SHIV monkeys (Kulkarni et al., 
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2013; Kutzler et al., 2016). More importantly, it was observed that induced immune 
responses were significantly increased when DNA vaccines were delivered with adaptive 
electroporation (Mann et al., 2014; Todorova et al., 2017). Membrane electrochemical 
permeabilization and electric field created by applied voltages can significantly improve 
uptake of DNA plasmids by the transfected cells, improving transfection efficiency by up 
to 1000-fold in some scenarios (Donate et al., 2011; Roos et al., 2006). Additionally, as 
compared to recombinant protein vaccines, DNA vaccines adjuvanted by electroporation 
have been observed to uniquely elicit strong CD8+ T-cell responses, potentially through 
direct transfection of APCs at the site of transfection, or enhanced APC infiltration/ cross-
presentation through the creation of unique pro-inflammatory environments (Cho et al., 
2001; Rush et al., 2002; Walters et al., 2017). DNA responses, in conjunction with newer 
adaptive electroporation technologies, have now started to induce more potent and 
consistent responses in humans, and have been evaluated in a series of clinical trials 
against ZIKA, EBOLA, MERS and HIV-1 (Tebas et al., 2017; Kalams et al., 2013; 
Modjarrad et al., 2019; Tebas et al., 2019). Promising results have been obtained in recent 
ZIKA and MERS trials, for which both binding and neutralizing antibody responses, as well 
as CD8+ T-cell responses have been observed (Tebas et al., 2017; Modjarrad et al., 
2019). The unique ability of DNA vaccines to induce CTL, additionally, has been explored 
in the treatment of cancer patients. In a Phase II study, it was observed that DNA 
vaccination of HPV E6/E7 antigens in patients with HPV-induced cervical dysplasia can 
lead to infiltration of CD8+ T-cells into cancer tissues and profound regression of pathology 
and infection in 50% of treated patients (Trimble et al., 2015).  
  With intramuscular administration of DNA vaccines, however, a relatively high 
plasmid dose of 2mg would be required during each vaccination for the induction of 
immune responses. While manufacturing of DNA is relatively cheap, high dose 
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requirement may still impede broader translation of this approach during global 
pandemics. Several attempts have been made to reduce the dose requirement for DNA 
vaccination (dose-sparing). One promising approach involves intradermal (ID) delivery of 
DNA plasmid in combination with electroporation (Smith et al., 2017). As there is a 
relatively higher abundance of APCs in the skin as compared to in the muscles, ID DNA 
vaccination may provide a more direct route for both plasmids and expressed antigens to 
be delivered to the relevant APC populations (Romani et al., 2012). For example, in a 
recent MERS Phase I trial, it was observed that ID DNA vaccination could confer dosing 
sparing by approximately 4-fold (Modjarrad et al., 2019). Strategies that could further 
reduce the dose requirement for DNA vaccines while simultaneously improving their 
immunogenicity will significantly improve utility and translatability of such approach.  
1.5 Nucleic acid encoded nanoparticle vaccines for direct in vivo production 
Due to technical challenges and significant costs associated with in vitro 
production and purification of nanoparticle vaccines, alternative strategies that prompt de 
novo assembly of nanovaccines in the hosts have been explored. In the nucleic acid 
space, liposome-encapsulated mRNA has been used as a vehicle for in vivo gene delivery 
(Michel et al., 2017). Pardi et al., for example, has reported the use of mRNA for in vivo 
delivery of HIV bNAb VRC01. Single infusion of liposome-encapsualted mRNA encoding 
VRC01 has allowed for potent in vivo expression of the bNAb in humanized mice, and 
which also confers them with protection from intravenous HIV-1 challenge (Pardi et al., 
2017). More recently, mRNA has been explored for in vivo expression of an HIV-1 priming 
nanoparticle vaccine eOD-GT8-60mer. A single immunization of mRNA-encoded GT8-
60mer in mice elicited high titers of HIV-1 gp120-specific binding antibodies, as well as 
increased germinal center B cell responses. In transgenic mice harboring the germline 
VRC01 heavy chain allele, mRNA GT8-60mer immunization induced somatic mutations 
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in the heavy chain locus consistent with VRC01-class antibody development (Melo et al., 
2019). While the mRNA approach is extremely promising, however, it had been noted that 
both local and systemic administration of mRNA vehicle would result in expression of the 
transgene in the liver (Pardi et al., 2015). Additionally, elevations in liver enzymes (such 
as AST and ALT) have been observed to be associated with liposome-mRNA infusion 
(Sedic et al., 2018). Additional toxicology study with this approach is likely important while 
alternative safer approaches of biologic and nanovaccine delivery should be considered. 
 Synthetic DNA, which has demonstrated a strong safety profile in the clinic, has 
also been explored for direct in vivo production of these nano-vaccines. One example 
included the use of MLV gag and a modified MLV Env to display T-cell epitopes on in vivo 
produced VLPs (plasmo-retro VLPs) (Masavuli et al., 2017). In comparison to a control 
DNA plasmid harboring a point mutation in MLV gag which disrupts VLP assembly, DNA 
encoding intact plasmo-retro VLPs enabled superior induction of both CD4+ and CD8+ T-
cell responses to the displayed peptides. Additionally, simple structural motifs have also 
been explored for in vivo multimerization of antigens. An example is IMX313P, a motif that 
closely resembles naturally occurring complement C4 binding protein (C4bp) to facilitate 
heptamerization of antigens (Ogun et al., 2008). More recently, DNA-vaccine encoding 
IMX313P scaffolded HIV-antigen Tat had been shown to elicit superior antigen-specific 
humoral and cellular responses (Tomusange et al., 2016). Similarly, DNA-vaccines 
encoding IMX313P scaffolded hepatitis C virus (HCV) envelope protein induced improved 
neutralizing antibody responses in mice, demonstrating nucleic acid can support in vivo 
formation of more complex immunogens to induce stronger responses (Masavuli et al., 
2019). The main drawback for DNA-encoded VLPs is that encoded ancillary viral genes 
to facilitate VLP assembly may be immune-dominant, thereby distracting the immune 
responses away for intended target epitopes (Sant et al., 2007). The DNA heptamerization 
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strategy is promising. It can, however, be envisioned that DNA vaccines can be used to 
encode structurally designed, more potent nanoparticle scaffolds to further enhance 
vaccine efficacy. Since in vivo produced nano-vaccines cannot be further purified, a 
greater emphasis should be placed on ensuring the encoded nanoparticle antigen can 
assemble relatively homogenously in vitro through various protein engineering 
approaches and thereby bypassing the need for further downstream purification.  
1.6 Dissertation Aims 
As highlighted in the introduction, our lab and several others have provided a proof 
of principle that synthetic DNA alongside with adaptive electroporation (DNA/EP) can be 
used for in vivo delivery of not only vaccine antigens but also monoclonal antibodies 
against different disease targets. In my thesis, I have built on such foundation to further 
demonstrate DNA/EP can be used to fold highly structured biologics and macromolecular 
vaccines in vivo (Chapters 3, 4 and 5), and additionally, that functionalities of these 
proteins can be further modulated through post-translational modification by another DNA-
encoded enzyme (Chapter 3). Functionalities of DNA-encoded biologics/ nanovaccines 
were evaluated with both in vitro assays and in vivo challenge models (Chapters 5 and 6). 
Finally, different vaccination modalities (protein nano-vaccine and DNA-encoded nano-
vaccines) were compared head-to-head and mechanistic studies were pursued to elicit 
observed differences in terms of induced immune responses (specifically CTL) between 
protein and DNA vaccination (Chapters 5 and 6). 
Aim 1: Determination of DNA/EP as a vehicle for in vivo folding and delivery of complex 
biologics (immunoglobulins and immunoadhesins) against HIV-1 and characterization of 
the strategy to modulate their in vivo functionalities with DNA-encoded enzymes for post-
translational modifications.  
17 
 
 While we have previously demonstrated that single treatment of DMAb encoding 
an influenza antibody can protect mice from lethal influenza A challenge, HIV-1 pose 
several unique challenges for DMAb to be viable as a possible preventative strategy. Due 
to the significant sequence diversity amongst different HIV-1 strains and the high likelihood 
for resistant clones to arise, a single anti-HIV antibody clone is unlikely to confer significant 
protection to treated individuals from infection on a population scale (Overbaugh and 
Morris, 2012). Two strategies were evaluated in this work: first, an immunoadhesin eCD4-
Ig, which consisted of artificially designed CCR5 mimetic peptide and naturally occurring 
extracellular protein domain of CD4 fused to immunoglobulin Fc to improve its breadth of 
coverage, was re-engineered for in vivo expression with DNA/EP; and second, a cocktail 
of HIV bNAbs targeting four distinct epitopes on HIV Env have been optimized and 
encoded in separate plasmid vectors for simultaneous in vivo delivery. This study expands 
upon our existing platform by allowing us to evaluate whether a cocktail of different 
antibodies can be simultaneously delivered by DNA/EP for in vivo expression, and 
whether an artificially engineered biologic can also be expressed by the system. 
 Additionally, it may be highly desirable to devise strategies to further fine-tune and 
regulate the activities of in vivo produced biologics. While the variable fragment of an 
antibody can directly bind to its target epitope and inhibits the biological activity of its target 
(neutralization in the case of virus), the constant Fc portion of an immunoglobulin can 
mediate a range of activities, from antibody-dependent cellular cytotoxicity (ADCC) to 
complement dependent cytotoxicity (CDC) (Saunders, 2019). The Fc effector functions 
are in turn tightly linked to the post-translational modifications of Fc. Fc sialyation, for 
example, can significantly prolong the in vivo half-life of a monoclonal antibody, potentially 
through enhancing interaction between Fc and FcRn (Bas et al., 2019). Fc afucosylation, 
on the other hand, can significantly enhance the ADCC effector function of an antibody 
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(Pereira et al., 2018). In the case of eCD4-Ig, tyrosine sulfation of CCR5 mimetic peptide 
may directly impact its neutralization potency (as the extracellular domains of CCR5 on 
CD4 T-cells are constitutively tyrosine sulfated (Farzan et al., 1999)). Therefore, we intend 
to use eCD4-Ig as a model system to investigate whether we can impact post-translational 
modification of in vivo produced biologics to influence their functions through co-delivery 
of DNA-encoded enzyme. 
Aim 2: Determination of DNA/EP as a vehicle for in vivo folding and assembly of complex 
macromolecular nanoparticle vaccines, as well as characterization of induced immune 
phenotypes with in vitro assays and animal challenge models 
I intended to harness insights obtained from Aim 1 to design DNA-cassettes 
encoding significantly more complex nanoparticle vaccines and evaluate whether they can 
be launched by adaptive electroporation delivery for direct in vivo assembly. Through 
different protein engineering techniques, I, in collaboration with Dr. Kulp’s group, have 
engineered several nanoparticle vaccines scaffolding up to 180 copies of an HIV-1 priming 
antigen eOD-GT8-60mer that expressed and assembled relatively homogenously in vitro, 
as characterized by various biophysical techniques. DNA-vaccines encoding simpler 
multimerized antigens have been investigated before. In this study, we intend to 
characterize in vivo assembly of significantly more complex nanoparticle vaccines both 
directly (direct observation of their in vivo formation) and indirectly (through interrogation 
of immune systems induced by these more advanced immunogens). Induction of both 
humoral and cellular responses will be examined. In addition, we will determine whether 
enhancement in responses, if any, will correlate to improved protection of mice from viral 
challenge, using influenza as a model. 
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Lastly, it has been previously observed that as compared to recombinant protein 
vaccine, DNA vaccination of an identical immunogen may result in significantly higher level 
of CTL responses (Zoller and Christ, 2001). We intend to examine if this observation also 
applies to DNA-launched nanoparticle vaccines in comparison to protein nanoparticle 
vaccines, and if so, we intend to examine both forms of vaccination in the cancer model, 
in which CTL serves as an extremely important correlate of protection. Upon completion 
of these aims, I intend to further immunologic understandings of using synthetic DNA/ EP 
for in vivo delivery of complex and folded biologics or next-generation vaccines to further 
evaluate/ advance the technology as a strategy to simplify manufacturing of highly needed 
therapeutics
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CHAPTER 2 Materials and Methods 
2.1 DNA design and plasmid synthesis 
Protein sequence for ReCD4-Ig was as previously reported (Gardner et al., 2015). 
Protein sequences for HIV-1 antibodies were obtained from NCBI GenBank. Protein 
sequences for human TPST2 and HS3SA were obtained from UniProt (accession 
numbers: O60704 and Q9Y663). Protein sequence for SIVmac239 was obtained from 
GenBank (accession number M33262). Protein sequences for IgE Leader Sequence and 
eOD-GT8-60mer were as previously reported (Briney et al., 2016; Xu et al., 2018). Protein 
sequences for 3BVE-ferritin, PfV and HA_CA09 were obtained from UniProt (accession 
numbers: Q9ZLI1, I6U7J4, and C3W5X2). Protein sequence for HA1_NC99 was obtained 
from GenBank (accession number AY289929.1). DNA encoding protein sequences were 
codon and RNA optimized as previously described. (Elliott et al., 2017; Patel et al., 2017) 
The optimized transgenes were synthesized de novo (GenScript, Piscataway, NJ) and 
cloned into a modified pVAX-1 backbone under the control of the human CMV promoter 
and bovine growth hormone poly-adenylation signal. Plasmids that encode HIV envelope 
gp160 for TRO11, 25710, 398F1, CNE8, X2278, BJOX2000, X1632, CE1176, 246F3, 
CH119, CE0217 and CNE55 were obtained from NIH-AIDS reagent. 
2.2 Structure modeling and design of 3BVE, ferritin, LS, PfV and flu nanoparticles 
The nanoparticle structures for ferritin (PDB ID: 3BVE), lumazine synthase (PDB 
ID: 1HQK) and PfV (2E0Z) were used to seed the modeling simulations. The structure of 
eOD-GT8 (PDB ID: 5IDL) and HA1 (PDB ID: 3GBN) were used to decorate the 
nanoparticles. N-linked glycans with missing density were added using glycan modeling 
modules of Rosetta (Labonte et al., 2017). Next, we wrote a new algorithm 
(simpleNanoparticleModeling) in the Molecular Software Library (Kulp et al., 2012). Briefly, 
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we aligned the appropriate number of immunogens at the nanoparticle surface using 
coordinate frames constructed by 3C atoms of the terminal positions of each protein. 
Immunogens were then tilted by random rotations around the x- and y- axes up to 30 
degrees for the first ¾ of the simulation and up to 75 degrees for the last ¼ of the 
simulation, with a 120-degree rotation allowed for the z-axis. The immunogens were also 
translated by 10Å to 200Å along an axis projected away from the nanoparticle surface. 
Clashes were detected at each iteration and the models with the lowest number of clashes 
at each translation was written out as a potential structural model. The models were 
manually inspected and utilized to construct linkers as glycine-serine repeats using 30Å 
per 9 linker residues as a guide. The sequence of the HA isolate H1 NC99 (A/New 
Caledonia/30/1999 (H1N1)) from residues 65-276 was used to construct the flu 
nanoparticle.   
2.3 Cell lines, transfection and ReCD4-Ig/HIV DMAb purification 
HEK293T cells (ATCC Cat# CRL-3216) and TZM-bl cells (NIH-ARP Cat# 8129-
442) were maintained in DMEM (Corning Cat# 10-013CV) supplemented with 10% fetal
bovine serum (Atlas Biologicals Cat# EF-0500-A) and grown at 37°C and 5% CO2. 
Expi293F cells (ThermoFisher Cat # A14527) were maintained in Expi293 expression 
medium (ThermoFisher Cat# A1435101) at 37°C and 8% CO2. To determine in vitro 
sulfation of ReCD4-Ig, cells were seeded at a density of 0.5×106 cells/mL in a 6-well plate 
and transfected with 1.0μg of p-ReCD4-Ig and varying doses of plasmid encoded enzymes 
with GeneJammer (Agilent Cat# A204130). Forty-eight hours after transfection, 
supernatants were collected and centrifuged at 1500g for 5 minutes to remove cellular 
debris. Adherent cells were lysed with cell lysis buffer (Cell Signaling Cat# A204130) 
modified with protease inhibitor cocktail (Roche Cat# 26733200). To obtain ReCD4-Ig 
standards for quantitative ELISA, Expi 293F cells were plated at a density of 2.5×106 
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cells/mL in Expi293 expression medium, rested overnight and transfected with p-ReCD4-
Ig and ExpifectamineTM (ThermoFisher Cat# A14525) in OPTI-MEM (ThermoFisher Cat# 
31985070). Transfection enhancers were added 20 hours after transfection, and 
supernatant was harvested 5 days after transfection. Magnetic protein G beads (GenScript 
Cat# L00673S) were used for purification of ReCD4-Ig, and purity was confirmed with 
Commassie staining of the SDS-Page gels (data not shown) (ThermoFisher Cat# 
NP0321). 
2.4 HIV Trimer production 
Expi293F cells were transfected with plasmid expressing the HIV-1 gp160 Env 
trimer BG505_MD39_His construct. Cell supernatants containing trimer were clarified by 
centrifuging (4000xg, 25mins) and filtering (0.2um Nalgene Rapid-Flow Filter). Trimers 
were then purified from supernatants by nickel affinity chromatography on a HIS-TRAP 
HP column (GE Healthcare). The trimers were then purified over a size-exclusion 
chromatography column (GE S200 Increase) in PBS. The molecular weight and 
homogeneity of the trimers were confirmed by protein conjugated analysis from ASTRA 
software (Wyatt Technology) with data collected from a size-exclusion chromatography-
multi-angle light scattering (SEC-MALS) experiment run in PBS using a GE S6 Increase 
column, followed by DAWN HELEOS II and Optilab T-rEX detectors. The trimers were 
aliquoted at 1mg/ml and flash frozen in thin-walled PCR tubes prior to use. 
2.5 Production of His-Tagged GT8-monomer and recombinant protein DLnanos 
Expi293F cells were transfected with pVAX plasmid vector carrying the DLnano or 
His-Tagged GT8-monomer transgene with PEI/OPTI-MEM and harvested 6 days post-
transfection. Transfection supernatant was first purified with affinity chromatography using 
the AKTA pure 25 system and an IMAC Nickel column (for His-tagged GT8) and gravity 
flow columns filled with GNL Lectin beads (for DLnanos). The eluate fractions from the 
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affinity purification were pooled, concentrated and dialyzed into 1X PBS buffer before 
being loaded onto the SEC column and then purified with size exclusion chromatography, 
for which the Superdex 75 10/300 GL column was used to purify His-tagged GT8-
monomer and the Superose 6 Increase 10/300 GL column was used for DLnanos (run at 
0.5 mL/min). Identified eluate fractions were then collected and concentrated to 1mg/mL 
in PBS. 
2.6 Animals 
2.6.1 Mice experiments 
All animal experiments in Chapters 3 and 4 were carried out in accordance with 
animal protocol 112776 approved by the Wistar Institute Institutional Animal Care and Use 
Committee (IACUC) (Philadelphia, PA). Six-eight week old female BALB/c (Charles River 
Cat# 028) and B6.Cg-Foxn1nuJ (Jackson laboratory Cat# 000819, 
RRID:IMSR_JAX:000819) and housed in the animal facility. For transient immune-
modulation for eCD4-Ig study, mice were given single intraperitoneal injection of 500ug of 
anti-mouse CD40L (Bio X Cell Cat# BE0017-1). Mice were then given 160ug (2 injections) 
or 320ug (4 injections) of DNA co-formulated with hyaluronidase (SigmaAldrich Cat# 
H4272). One minute after injections, IM-EP was performed at each injection site with the 
CELLECTRA® 3P device (Inovio Pharmaceutical, Plymouth Meeting, PA).  
For mice  experiments where a single HIV dMAb was delivered, mice were injected 
with 100µg (25µg of heavy chain and 25µg of light chain per site, 2 sites total) dMAb 
plasmids formulated with hyaluronidase (200U/L, Sigma Aldrich) and injected into the 
tibialis anterior muscles followed by intramuscular electroporation (IM-EP) using the 
CELLECTRA® 3P device (Inovio Pharmaceuticals). For experiments with two dMAb 
delivery, mice were injected with 100µg (25µg of heavy chain and 25µg of light chain per 
site, 2 sites total) of each dMAb plasmids formulated with hyaluronidase and injected into 
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the tibialis anterior and quadriceps muscles followed by intramuscular electroporation (IM-
EP). For experiments with four dMAb delivery, single dMAb control mice were injected 
with 50µg (25µg of heavy chain and 25µg of light chain per site, 1 site total), formulated 
and injected into the tibialis anterior. Mice receiving four dMAb plasmids were injected with 
50µg (25µg of heavy chain and 25µg of light chain per site, 2 sites total) of each dMAb 
plasmid, formulated and injected into the tibialis anterior and quadriceps muscles followed 
by IM-EP. Mice were serially bled to obtain serum for analysis. 
All mouse experiments in Chapter 5 were carried out in accordance with animal 
protocols 1127760 and 112782 approved by the Wistar Institute Institutional Animal Care 
and Use Committee (IACUC) (Philadelphia, PA). For DNA-based immunization, 6-8 week 
old female C57BL/6, BALB/c and CD1 mice or 6-8 week old male BALB/c mice purchased 
from Jackson Laboratory or Charles River Laboratories were immunized one to three 
times (three-weeks apart) with DLmono_GT8, DLmono_HA_NC99, DLmono_HA_CA09, 
DNA-encoded LS_HA_CA09, DL_GT8_IMX313P or DLnano_LS_GT8, 
DLnano_CD4MutLS_GT8, DLnano_3BVE_GT8, DLnano_PfV_GT8, 
DLnano_LS_HA_NC99 and DLnano_3BVE_HA_CA09  via intramuscular injections into 
the tibialis anterior muscles (over two sites), followed by intramuscular electroporation with 
the CELLECTRA 3P device (Inovio Pharmaceuticals). For electroporation, 2 sets of 2 
pulses (at 0.1 Amps) were delivered. Each set of 2 pulses lasts 52 milliseconds with a 1 
second delay. For all DNA-encoded GT8-based immunizations (except for dosing 
studies), 25ug of plasmid DNA was used, a standard DNA dose as in prior study (Duperret 
et al., 2018b). For the control experiment to assess the importance of antigen decoration 
on nanoparticle, balb/c mice were immunized with 1:1 co-formulated (25ug each) 
DLmono_GT8 with pVAX, DLmono_GT8 with DLnano_LS (core), and DLnano_LS_GT8 
with pVAX and followed for seven d.p.i for sero-conversion. For all DNA-encoded HA-
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based immunizations, doses of 1ug were used for each immunization for studies of 
humoral responses and 10ug for studies of cellular responses. MBL knockout mice 
(B6.129S4-Mbl1tm1Kata Mbl2tm1Kata/J) and CR2 knockout mice (B6.129S7(NOD)-
Cr2tm1Hmo/J) purchased from Jackson Laboratory were immunized in the same fashion. 
For protein-based immunization in Chapter 5, 6-8 week old female C57BL/6, MBL 
knockout and CR2 knockout mice were immunized subcutaneously over two sites with a 
high dose of 10ug of recombinant eOD-GT8-60mer protein in 50uL co-formulated with 
50uL Sigma adjuvant system (SigmaAldrich); the protein dose was 2.7-times higher than 
a prior study (Tokatlian et al., 2019). 
All animal experiments in Chapter 6 were carried out in accordance with animal 
protocols 201214, 201115, and 201221 approved by the Wistar Institute Institutional 
Animal Care and Use Committee (IACUC). For DNA-based immunization, 6 to 8 week old 
female C57BL/6 or BALB/c mice (Jackson Laboratory) were immunized with DNA 
vaccines via intramuscular injections into the tibialis anterior muscles, followed by 
intramuscular electroporation with the CELLECTRA 3P device (Inovio Pharmaceuticals). 
For DNA immunizations using DLnano_LS_GT8 and DLnano_LS_HA(NC99) as antigens, 
25ug of plasmid DNA was used, a standard DNA dose that has been utilized in prior study 
(Duperret et al., 2018b). For DNA immunizations involving DLnano_LS_Trp2188, 
DLnano_LS_Gp10025, DLmono_Trp2188, and DLmono_Gp10025, 10ug of individual 
plasmid DNA was used either alone or in combination. For vaccinations involving 
recombinant protein, 6 to 8 week old female BALB/c or C57BL/6 mice were immunized 
subcutaneously with a relative high dose of 10ug of recombinant eOD-GT8-60mer protein 
or HA(NC99)-60mer, and 4ug dose for LS_Trp2188-60mer and LS_Gp10025-60mer in 50uL 
PBS co-formulated with 50uL Sigma Adjuvant System (SigmaAldrich); a high protein dose 
was used in this study as compared to prior studies(Tokatlian et al., 2019). 
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For vaccinations in mechanistic study in Chapter 6, C57BL/6 mice received 
intramuscular injections of 80ug of DLnano_LS_GT8 co-formulated with 12U 
Hyaluronidase (SigmaAldrich) followed by intramuscular electroporation or 20ug of protein 
eOD-GT8-60mer co-formulated 1:1 with Sigma Adjuvant System. For in vivo macrophage 
depletion, 6 to 8-week-old female C57BL/6 mice received one or three intravenous 
injection of 750ug clodronate disodium formulated in clodrosome (150uL injection, 
Encapsula Nanoscience) via retro-orbital injections; control mice each received 150uL of 
encapsosome (Encapsula Nanoscience) IV at the same timepoints. 
For tumor challenge, B16-F10 (ATCC) were maintained in 10% FBS/ DMEM under 
low passage (less than 10) and B16-F10-Luc2 cells (ATCC) were maintained in 10% FBS/ 
DMEM enriched with 10ug/mL blasticidin (Gibco) with routine testing for mycoplasma 
contaminations. Cells were trypsinized and strained through 70um strainer to generate 
single cell suspensions. They were then administered sub-cutaneously to mice (105 cells 
to each mouse in 100uL PBS). Tumor size was measured every two days with a digital 
caliper, and tumor volume was determined with the formula V=0.5W2L (V=tumor volume, 
W= tumor width, L=tumor length). Mice with tumor volume greater than 2000mm3 or with 
any dimension exceeding 2cm were euthanized for humane purposes. For recombinant 
anti-PD1 (Bio X Cell) administration in melanoma therapeutic treatment model, 200ug of 
antibody was injected intraperitoneally in 100uL PBS to each mouse weekly. 
2.6.2 Guinea pig experiments 
Female Hartley guinea pigs (8–10 weeks old) purchased from Charles River 
Laboratories (Wilmington, MA) were group housed and handled at BTS Research (San 
Diego, CA) with ad libitum access to food and water according to the standards of the 
Institutional Animal Care and Use Committee (IACUC). Following acclimation, each 
guinea pig was given a single immunization of 50ug of DLnano_LS_GT8 or DLmono_GT8 
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over 2 sites on the flank followed by intradermal EP with CELLECTRA 3P device. The 
animals were then bled at the indicated timepoints for humoral analyses. 
2.6.3 NHP experiments 
Two groups of cynomolgus macaques (N=4) (Primgen) were treated with plasmid 
dMAb constructs encoding either PGDM1400 or PGDM1400 and PGT121, with animals 
receiving a total of 6mg plasmid DNA. DNA was co-formulated with hyaluronidase 
(Hylenex – 135 U/ml). Multi-depth IM injection was performed followed by electroporation 
using the Elgen1000 Twinjector (Inovio Pharmaceuticals).  Macaques were serially bled 
to obtain serum over 60 days. 
2.7 ELISA 
2.7.1 eCD4-Ig ELISA 
For ELISA-based quantification of ReCD4-Ig, MaxiSorp plates (ThermoFisher 
Cat# 44-2404-21) were coated with 1ug/mL of JR-FL gp140 (Immune Technology Cat# 
IT-001-0024∆TMp) overnight at 4°C. Plates were washed 4 times with Phosphate Buffered 
Saline + 0.1% Tween 20 (BioRad Cat# 1706531) (PBS-T) and blocked with 10% FBS in 
PBS for 1 hour at room temperature. Plates were subsequently washed and incubated 
with serum samples diluted in PBS-T for one hour at room temperature. Plates were 
washed again and incubated with secondary goat anti-human Fc HRP (Jackson 
ImmunoResearch Labs Cat# 109-035-008) at 1:5000 dilution for 1 hour. The plates were 
subsequently developed with SigmaFast OPD (SigmaAldrich Cat# P9187) for 10 minutes 
before OD450 measurements were performed with Biotek Synergy2 plate reader. 
To detect sulfation of ReCD4-Ig in transfection supernatants or sera, MaxiSorp 
plate were coated at 4°C overnight with 5ug/mL JR-FL gp140. Plates were washed and 
blocked with 10% FBS/PBS for 3 hours at room temperature. Plates were washed, and 
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samples diluted in PBS-T were added for 1hour incubation at room temperature. Plates 
were washed again and incubated with 1:250 dilution of mouse anti-sulfotyrosine antibody 
(Millipore Cat# 05-1100) for 1 hour at room temperature. Finally, the plates were washed 
and incubated with 1:5000 dilution of anti-mouse IgG2a HRP secondary antibody (Bethyl 
Cat# A90-107P) for 1 hour at room temperature. The plates were developed with 
SigmaFast OPD for 10 minutes and OD450 signals were measured.  
2.7.2.1 HIV dMAb quantification ELISA- mouse 
DNA encoded monoclonal antibody levels were quantified as previously described 
(Patel et al., 2018a). Briefly, high binding polystyrene 96 well plates (ThermoFisher) were 
coated with unconjugated purified goat anti-human IgG-Fc (1µg/ml) overnight in PBS. 
After blocking with 10% newborn calf serum (NCS) plates were washed with PBS 
containing 0.05% Tween-20. Mouse serum and standards were serially diluted and 
incubated for one hour at room temperature. Purified human IgG-Kappa (P80-111, Bethyl 
Laboratories) and human IgG-Lambda (P80-116, Bethyl Laboratories) were used as 
standards. After washing, plates were incubated with 1:20,000 dilution of either goat anti-
human kappa (A80-115P, Bethyl Laboratories) or goat anti-human lambda (A80-116P, 
Bethyl Laboratories) light chain secondary antibodies conjugated to horseradish 
peroxidase (HRP) for one hour at room temperature. For quantification of total antibody 
levels in the mice dosed with four dMAb constructs, a secondary goat anti-human IgG H+L 
conjugated to horseradish peroxidase (A80-119P, Bethyl Laboratories) was used. After 
washing, plates were developed with o-phenylenediamine dihydrochloride (OPD) 
substrate (SIGMAFAST OPD, Sigma Aldrich). Plates were stopped with 2N H2SO4. Plates 
were read on a BioTek Synergy 2 plate reader (BioTek) at 450nm and 570nm 
wavelengths. Quantification of serum dMAb levels were determined by interpolating the 
unknown OD values to the standard curve.  
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2.7.2.2 dMAb quantification ELISA- Non-human primate 
Quantification for human IgG dMAb in NHP sera was determined using the human 
therapeutic IgG1 ELISA kit from Cayman Chemicals following the manufacturer’s protocol. 
Serum was serially diluted to obtain two OD values within the linear range of the standard 
curve. Quantification measurements were repeated twice for Days 7-21.  
2.7.2.3 dMAb binding to trimer ELISA 
Binding curves of HIV serum-expressed dMAbs compared to recombinant proteins 
were obtained by coating 96 well half-area high binding polystyrene plates (ThermoFisher) 
with 1µg/ml of rabbit anti-His antibody (25B6E11, Genscript) in PBS at 4oC. Plates were 
blocked with 5% skim milk in PBS with 1% newborn calf serum (NCS) (Atlas Biologicals) 
and 0.2% Tween-20 for one hour at room temperature. His-BG505 MD39 trimer protein 
was then added at 1µg/ml in PBS with 1% NBS and 0.2% Tween-20 for two hours at room 
temperature. Serum was normalized based on the quantification concentration and serially 
diluted 2-fold from there. A similar amount of purified recombinant monoclonal antibody 
was added to match the serum concentration. Plates were incubated for one hour at 37oC. 
After washing, a 1:20,000 dilution of secondary goat anti-human kappa (A80-115P, Bethyl 
Laboratories) or goat anti-human lambda (A80-116P, Bethyl Laboratories) light chain 
secondary antibodies conjugated to horseradish peroxidase were added and incubated 
for one hour at room temperature. Plates were then developed with 1-step ultra-3,3’,5,5’- 
tetramethylbenzidine (TMB) substrate (ThermoFisher) and read on a BioTek Synergy 2 
plate reader (BioTek) at 450nm and 570nm wavelengths.   
2.7.2.4 Anti-antibody detection ELISA 
To determine the development of anti-drug antibody development, 96 well half-
area high binding polystyrene plates (ThermoFisher) were coated with 1µg/ml of purified 
PGT121 or PGDM1400 (produced in-house) overnight in PBS at 4oC. Plates were then 
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blocked with 5% skim milk in PBS with 1% newborn calf serum (NCS) (Atlas Biologicals) 
and 0.2% Tween for one hour at room temperature.  NHP sera was diluted 1:100 and 
added to plates for each time point and incubated for one hour at 37oC. After washing, a 
1:20,000 dilution of secondary goat anti-NHP H+L min human secondary antibody 
conjugated to HRP (A140-202P, Bethyl Laboratories) was then added and incubated for 
1hr at room temperature. Plates were then developed with 1-step ultra-TMB substrate 
(ThermoFisher) and read on BioTek Synergy 2 plate reader (BioTek) at 450nm and 570nm 
wavelengths.   
2.7.3.1 GT8-binding ELISA 
Corning 96-well half area plates were coated at room temperature for 6 hours with 1ug/mL 
MonoRab anti-His antibody (GenScript), followed by overnight blocking with solution 
containing 1x PBS, 5% skim milk, 10% goat serum, 1% BSA, 1% FBS, and 0.2% Tween-
20. The plates were then incubated with 2ug/mL of his-tagged GT8-monomer at room
temperature for 2 hours, followed by addition of mice sera serially diluted with PBS with 
1% FBS and 0.1% Tween and incubation at 37C for 2 hours. The plates were then 
incubated at room temperature for 1 hour with Peroxidase AffiniPure Goat Anti-Mouse 
IgG, Fcγ fragment specific at 1:5,000 dilution (Jackson Immunoresearch) or AffiniPure 
Goat Anti-Mouse IgM, µ chain specific, (Jackson Immunoresearch) at 1:5000 dilution 
followed by addition of TMB substrates (ThermoFisher) and then quenched with 1M 
H2SO4. Absorbance at 450nm and 570nm were recorded with BioTEK plate reader. 
Endpoint titer is defined as the highest dilution at which the OD of the post-immune sera 
exceeds the cut-off (mean OD of naïve animals plus standard deviations of the OD in the 
naïve sera multiplied with standard deviation multiplier f at the 99% confidence level). 
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2.7.3.2 VRC01 competition ELISA 
The plates were coated, and blocked, followed by addition with GT8-his as described in 
the last section. Serially diluted mice sera were then incubated with the plates at 37C for 
1 hour, followed by addition of purified VRC01 antibody (NIH AIDS Reagent) for an 
additional 1 hour at room temperature. The plates were then incubated with anti-human 
Fc (cross-adsorbed against rabbits and mice) (Jackson Immunoresearch) at 1:10,000 
dilution for 1 hour, followed by addition of TMB substrate for detection. Absorbance at 
450nm and 570nm were recorded with BioTEK plate reader. 
2.7.3.3 MBL binding ELISA 
The plates were coated with 5ug/mL recombinant mouse MBL protein (R&D system) in 
0.1M CaCl2 at room temperature for 6 hours, followed by blocking with 1% BSA in 0.1M 
CaCl2 in PBS overnight at 4C.Transfection supernatant or muscle homogenates 
containing DLmono_GT8 or DLnano_LS_GT8 were then added to the plates for 2 hour 
incubation at 37C, followed by Week 5 sera of BALB/c mice previously immunized twice 
with 25ug DLnano_LS_GT8. The plates were next incubated with anti-mouse IgG H+L 
(cross-adsorbed against human) HRP (Jackson Immunoresearch) at 1:10,000 dilution, 
followed by addition of TMB substrates. Absorbance at 450nm and 570nm were recorded 
with BioTEK plate reader. 
2.7.3.4 VRC01 binding ELISA 
ELISA format as described in the MBL binding ELISA section except that the recombinant 
MBL used in the coating step is replaced by 5ug/mL of VRC01 (NIH AIDS Reagent). 
Absorbance at 450nm and 570nm were recorded with BioTEK plate reader. 
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2.7.3.5 Antigenic profile characterization of designed GT8-nano-vaccines 
Corning half-area 96-well plates were coated with 2ug/mL of GT8-monomer, or 
3BVE_GT8-24mer, eOD-GT8-60mer, CD4Mut_LS_GT8-60mer and PfV_GT8-180mer at 
4C overnight. The plates were then blocked with the buffer as described in the Section 
2.7.3.1 for 2 hours at room temperature, followed by incubation with serially diluted VRC01 
at room temperature for 2 hours. The plates were next incubated with anti-human Fc 
(cross-adsorbed against rabbits and mice) (Jackson Immunoresearch) at 1:10,000 dilution 
for 1 hour, followed by addition of TMB substrate for detection. Absorbance at 450nm and 
570nm were recorded with BioTEK plate reader. 
2.7.3.6 HA-binding ELISA 
Corning 96-well half area plates were coated at 4C overnight with 2ug/mL of recombinant 
HA(ΔTM)(H1N1/A/New Caledonia/20/1999) or HA(ΔTM)(A/California/04/2009)(H1N1) 
(Immune Technology), and blocked at room temperature for 2 hour with the buffer as 
described in the GT8-binding ELISA section. The plates were subsequently incubated with 
serially diluted mouse sera in PBS with 1% FBS and 0.1% Tween at 37C for 2 hours, 
followed by 1-hour incubation with anti-mouse IgG H+L HRP (Bethyl) at 1:20,000 dilution 
at room temperature and development with the use of TMB substrate. Absorbance at 
450nm and 570nm were recorded with BioTEK plate reader. 
2.8 Western blot 
For detection of ReCD4-Ig, 10uL of transfection supernatant was loaded onto pre-
cast 4–12% Bis-Tris gels under non-reducing condition and transferred to an Immobilon-
FL PVDF membrane (EMD Millipore Cat# IPFL10100) with wet transfer. ReCD4-Ig was 
identified with IRDye 800CW goat anti-human IgG (LI-COR Biosciences, Lincoln, NE) 
(which cross-reacts with Rhesus IgG2 Fc) at 1: 10,000 dilution. For detection of sulfated 
tyrosine in ReCD4-Ig (Fig 3.1e), the membrane was incubated overnight with 1:1000 
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mouse anti-sulfotyrosine (1C-A2) at 4°C and developed with IRDye 680RD goat anti-
mouse IgG (LI-COR Biosciences Cat# 926-32232, RRID:AB_10806644). As anti-mouse 
and anti-human antibodies are conjugated to dyes with different colors, it is possible to 
visualize ReCD4-Ig and sulfotyrosine bands simultaneously in a single membrane. For 
detection of sulfation enzymes expression in vivo, mice were sacrificed at indicated time 
points after DNA injections/ IM-EP. TA muscles were harvested and homogenized in T-
PER extraction buffer (ThermoFisher Cat# 78510) and protease inhibitor. Fifty micrograms 
of muscle homogenates were loaded onto 4-12% Bis-Tris gel under reducing condition 
and transferred to a PVDF membrane with wet transfer. The membrane was incubated 
overnight with polyclonal rabbit anti-TPST2 antibodies (Abcam Cat# ab87407), and 
monoclonal mouse anti-GAPDH antibody (Cell Signaling Cat# 97166S) at 4°C. The 
membrane was subsequently developed with IRDye 680RD goat anti-mouse IgG (LI-COR 
Biosciences Cat# 925-68070) and IRDye 800CW goat anti-rabbit IgG. All membranes 
were scanned with LI-COR Odyssey CLx (LI-COR Biosciences Cat# 926-32211). 
For pseudo-native and SDS PAGE in Chapter 5, tibialis anterior muscles of 
immunized animals were harvested and homogenized in T-PER extraction buffer 
(ThermoFisher) and protease inhibitor (Roche). Muscle homogenates were subsequently 
concentrated 20x with Amicon Ultra 0.5mL Centrifugation kits with 3kDA cut-offs (Milipore 
Sigma) and protein concentrations were quantified with BCA assays (ThermoFisher). For 
electrophoresis, 8uL supernatants of Expi293F cells transfected with pVAX, 
DLmono_GT8, eOD-GT8-60mer or 50ug muscle homogenates from mice immunized with 
the 80ug aforementioned constructs co-formulated with 12U hyaluronidase were loaded 
onto 4-12% SDS Bis-Tris Gel (SDS-PAGE) or 3-8% Tris-Acetate Gel (pseudo-Native 
PAGE) for electrophoresis. For SDS-PAGE, all samples were reduced with heating of the 
samples in the presence of a reducing agent and LDS sample buffer (ThermoFisher) at 
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70C for 10min. For Pseudo-Native PAGE, samples were only incubated with the LDS 
buffer at room temperature and loaded directly onto the 3-8% TA gel without boiling. 
Proteins were subsequently transferred to PVDF membrane from the gels, and stained 
with 3ug/mL of VRC01 and 1ug/mL anti-human GAPDH (for SDS-PAGE only, Clone 
D4C6R, Cell Signaling) in Odyssey Blocking Buffer/ PBS/ 0.1% Tween (LI-COR 
Biosciences) overnight at 4C, and 1:10,000 IRDye 800CW goat anti-human IgG (LI-COR 
Biosciences) in Odyssey Blocking Buffer/ 0.1% Tween/ 0.1% SDS at room temperature 
for 1 hour, and then scanned with LI-COR Odyssey CLx. 
2.9 Fluorescence microscopy 
Eight-well chamber slides (Nunc Cat# 154534) were pre-coated with poly-L-lysine 
solution (SigmaAldrich Cat# P8920) before HEK293T cells were seeded at a density of 
2×105 per well overnight. The cells were then transfected with 1.0ug of p-reCD4-Ig and 
0.05ug of p-TPST2, p-IgE-TPST2 or p-ΔTM-TPST2 with GeneJammer. Forty-eight hours 
after transfection, the cells were fixed and permeabilized with 4% formaldehyde in PBS 
and 0.5% Triton-X-100 (Image-It-Fixation/Permeation Kit, ThermoFisher Cat# R37602) 
and blocked with 3% BSA in PBS at room temperature for 1 hour. The cells were then 
stained overnight at 4°C with 1:200 dilution of anti-Golgin 97 antibody (LI-COR 
Biosciences Cat# 926-32211) in 1% BSA/PBS-T, and 1:200 dilution of polyclonal rabbit 
anti-TPST2 antibody (Abcam Cat# ab87407, RRID:AB_10672926). The cells were then 
washed with PBS-T and stained with 1:500 dilution of Goat anti-Rabbit Alexa Fluor 594 
(Thermo Fisher Scientific Cat# A-11037), and goat anti-mouse Alexa Fluor 488 (Thermo 
Fisher Scientific Cat# A32723). For nuclear staining, the cells were incubated with 
0.5ug/mL of DAPI (SigmaAldrich Cat # D9542) in PBS-T and mounted with cover slips 
using Prolonged Diamond AntiFade Mountant (ThermoFisher Cat# P36970). Z-stack 
images were then acquired with Leica TCS SP5 II Scanning Confocal Microscope with a 
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64× objective. Maximal projections of the Z-stacks, deconvolution, and regions of interest 
analyses were performed with Leica LASX software to obtain Pearson correlation 
coefficients. 
For lymph node staining in Chapter 5, 7 days after BALB/c mice were immunized 
with 80ug DNA co-formulated with 12U Hyaluronidase (Sigma) encoding GT8-monomer 
or DLnano_LS_GT8, tibialis anterior muscles of the mice were injected with 5ug of anti-
mouse CD35 BV421 (BD-Bioscience) for in situ labelling of follicular dendritic cells 16 
hours prior to harvest. Ipsilateral iliac lymph nodes from the mice were harvested the next 
day and preserved in O.C.T medium (Fisher) for cryo-sectioning. The sections were fixed 
with 4% paraformaldehyde, then blocked in 3% BSA/ PBS for 1 hour at room temperature, 
followed by overnight staining with 6ug/mL VRC01. The sections were then washed and 
stained with anti-human Alexa Fluor 488 antibody and imaged with Leica SP5 confocal 
microscopes. 
For muscle staining in Chapter 5, four days after BALB/c mice were immunized 
with 80ug DNA encoding GT8-monomer, DLnano_LS_GT8, DLnano_3BVE_GT8 or 
DLnano_PfV_GT8 co-formulated with 12U Hyaluronidase in the tibialis anterior muscles 
of the mice were harvested the and preserved in 4% PFA/PBS for 2 hours at room 
temperature and then stored overnight in 70% EtOH/H2O at 4C. The tissues were then 
serially dehydrated and blocked in 3% BSA/ PBS for 1 hour at room temperature, followed 
by overnight staining with 6ug/mL VRC01. The sections were then washed, and stained 
with anti-human Alexa Fluor 488 antibody, counterstained with 0.5ug/mL DAPI and 
imaged with Leica SP5 confocal microscopes. 
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2.10 Immunohistochemistry 
For immunohistochemistry staining of muscle sections, BALB/C mice were 
immunized with 80ug DLmono_GT8 or DLnano_LS_GT8 co-formulated with 12U 
hyaluronidase (Sigma). Transfected muscles were harvested seven days post 
immunization, cryo-sectioned, fixed, permeabilized, and blocked as described in the 
Immunofluorescence section. The muscle sections were then stained with goat anti-
mouse MBL at 1:200 dilution in 1% BSA/PBS (R&D system) overnight, and then with 
secondary Rabbit anti-goat (H+L) HRP conjugated at 1:500 dilution (BioRad) and DAB 
substrates for development. 
2.11 TUNEL assay 
TUNEL assay was performed on fixed muscle specimen according to 
manufacturer’s protocol (Abcam). Briefly, four days post treatments with DNA or protein 
vaccine, tibialis anterior muscles were harvested and fixed in 4% paraformaldehyde/ PBS 
for 3 hours at 4C. The tissues were then dehydrated and paraffin-embedded, the sample 
sections were then rehydrated by serial transfer of the tissues from 100% Ethanol to 70% 
Ethanol/ water. The specimen was then permeabilized by treatment with Proteinase K at 
room temperature for 20 minutes. Endogenous peroxidase was then quenched by 
treatment of tissue sections with 3% H2O2 in methanol. The sections were then incubated 
with TdT enzyme in the equilibration buffer at room temperature for 1.5 hours in a 
humidified chamber, and the reactions were stopped with the stop solution provided in the 
kit. The sections were then blocked with provided blocking buffer at room temperature for 
10 minutes and labelled with provided detection conjugate diluted 1:25 in blocking buffer 
at room temperature for 30 minutes. The sections were then developed with DAB 
substrate at room temperature for 15 minutes and then counter stained with methyl green 
before they were imaged with Nikon Eclipse 80i under 20x and 60x magnification. 
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2.12 Electron microscopy 
2.12.1 Transmission EM of muscles 
Tibialis anterior muscles from BALB/c mice immunized with 80ug DLmono_GT8 or 
DLnano_LS_GT8 co-formulated with 12U hyaluronidase were collected seven d.p.i. The 
muscles were then fixed in 2.5% glutaraldehyde, serially dehydrated in acetone/ ethanol 
solvents, and then embedded in epoxy and LR white resin. The resin was then sectioned 
to a thickness of 70nm and deposited onto a metal grid, blocked overnight in 3% BSA/PBS, 
followed by staining with 60ug/mL VRC01 (diluted in 3% BSA/PBS) overnight, and with 
1:200 anti-human 6nm gold nanoparticles (Jackson Immunoresearch) for 1 hour. The 
sections were then washed with 0.1% Tween in PBS, and water, followed by post-staining 
fixation with 2.5% glutaraldehyde in PBS for 5 minutes at room temperature followed by 
staining with 2% Uranyl acetate for 1 hour. The grids were subsequently imaged with JEOL 
JEM 1010 transmission electron microscope. For quantitative analyses, total number of 
gold-labeled clusters, and order of each cluster were manually counted. Frequency of a 
cluster of a particular order in a field of view was normalized relative to the total number 
of clusters observed. 
2.12.2 Negative Stain EM of purified nanoparticles 
The nanoparticles were produced in Expi293 cells, purified using Agarose bound 
lectin beads (Agarose Galanthus Nivalis Lectin, Vector Laboratories) followed by size 
exclusion chromatography (GE Healthcare) using the Superose 6 Increase 10/300 GL 
column. The proteins were further dialyzed into Tris-buffered saline (TBS). A total of 3 μL 
of purified proteins was adsorbed onto glow discharged carbon-coated Cu400 EM grids. 
The grids were then stained with 3 μL of 2% uranyl acetate, blotted, and stained again 
with 3 μL of the stain followed by a final blot. Image collection and data processing was 
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performed on a FEI Tecnai T12 microscope equipped with a Oneview Gatan camera at 
90,450X magnification at the camera and a pixel size of 1.66 Å. 
2.13 ELISpot Assay 
Spleens from immunized mice were collected 5 weeks post the first immunization 
(2 weeks post the second) and homogenized into single cell suspension with a tissue 
stomacher in 10% FBS/ 1% Penicillin- streptomycin in RPMI 1640. Red blood cells were 
subsequently lysed with ACK lysing buffer (ThermoFisher) and percentage of viable cells 
were determined with Trypan Blue exclusion. 200,000 cells were then plated in each well 
in the mouse IFNγ ELISpot plates (MabTech), followed by addition of peptide pools that 
span both the lumazine synthase, GT8 or HA domains at 5ug/mL of final concentration for 
each peptide (GenScript). The cells were then stimulated at 37C for 16-18 hours, followed 
by development according to the manufacturer’s instructions. Spots for each well were 
then imaged and counted with ImmunoSpot Macro Analyzer. 
2.14 Intracellular cytokine staining 
Single cell suspension from spleens of immunized animals were prepared as 
described in the previous section and stimulated with 5ug/mL of peptides spanning both 
the lumazine synthase, GT8 or HA domains(GenScript) for 5 hours at 37C in the presence 
of 1:500 protein transport inhibitor (ThermoFisher) and anti-mouse CD107a-
FITC(ThermoFisher). The cells were then incubated with live/dead for 10 min at room 
temperature, surface stains (anti-mouse CD4 BV510, anti-mouse CD8 APC-Cy7, anti-
mouse CD62L BV711 and anti-mouse CD44 AF700) (BD-Biosciences) at room 
temperature for 30minutes. The cells were then fixed and permeabilized according to 
manufacturer’s instructions for BD Cytoperm Cytofix kit and stained with intracellular 
stains anti-mouse IL-2 PE-Cy7, anti-mouse IFN-γ APC, anti-mouse CD3e PE-Cy5 and 
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anti-mouse TNFα BV605 (BioLegend) at 4C for 1 hour. The cells were subsequently 
analyzed with LSR II 18-color flow cytometer. 
2.15 Determination of the antigen-specific B-cells in spleen 
Recombinant 3BVE-GT8 was labelled with FITC with the lightning link kits 
according to manufacturer’s instructions (Expedon). Spleens were harvested five weeks 
post the second immunization of 25ug of DLnaono_LS_GT8, DLmono_GT8 or from Naïve 
mice. Single cells were then labelled with Live/Dead dye ultraviolet reactive 
(ThermoFisher) at room temperature for 10min and incubated with mouse Fc-Block (Clone 
93, ThermoFisher) at 1:200 dilution. Avi-Tagged GT8 was biotinylated and tetramerized 
with an excess of APC-streptavidin (ThermoFisher) as previously described (Jardine et 
al., 2015). The cells were washed with PBS and incubated with 1:200 A488-3BVE-GT8 
and 1:200 APC-GT8-tetramer at 4C for 30min. Without being washed, the cells were 
incubated with 1:200 anti-mIgD-APC/Cy7 (BioLegend), anti-mIgM-BV711 (Fisher 
Scientific), anti-mCD19-PECy7 (Biolegend), anti-mIgG-BV510 (Biolegend) in 1% 
FBS/PBS solution. The cells were then resuspended in 1x BDFix buffer and analysed with 
LSR II 18-color flow cytometer. 
2.16 In vivo imaging 
For B16-F10-Luc2 challenge study, tumor challenged mice received 150mg/kg 
administration of VivoGlo™ Luciferin (Promega) at each timepoint formulated in sterile 
PBS, and then imaged with IVIS Spectrum CT for Bioluminescence with the auto-exposure 
settings (or for 60s, whichever is shorter) 10 minutes post injection. 
2.17 Ex vivo neutralization assay 
Synthesis of HIV Env pseudotyped viruses and TZM-bl assays were performed as 
previously described (Sarzotti-Kelsoe et al., 2014). Briefly, HEK293 T cells were 
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transfected with 4ug of plasmid encoding HIV envelope and 8ug of plasmid encoding HIV 
backbone pSG3Δenv (NIH-ARP Cat# 11051) with GeneJammer. Forty-eight hours after 
transfection, the supernatants were filtered with Steriflip (MiliporeSigma Cat# 
SCGP00525) and stored at -80°C. Pseudoviruses were titrated with a TZM-bl luciferase 
reporter assay using Britelight Plus (PerkinElmer Cat# 6066769) to determine a titer that 
corresponds to at least 150,000 RLU. Mice sera were heat inactivated at 56°C for 10 
minutes for the TZM-bl neutralization assays to determine serum concentration/titer that 
would result in 50% virus neutralization (IC50). 
2.18 HAI assay 
Mice sera were treated with receptor-destroying enzyme (RDE, 1:3 ratio) at 37°C 
overnight for 18–20 h followed by complement and enzyme inactivation at 56°C for 45 min. 
RDE-treated sera were subsequently cross-adsorbed with 10% rooster red blood cells 
(Lampire Biologicals) in PBS at 4C for 1 hour. The cross-adsorbed sera were then serially 
diluted with PBS in a 96-well V-bottom microtiter plates (Corning). Four hemagglutinating 
doses (HAD) of A/Solomon Islands/03/06 virus, A/New Caledonia/20/99, or 
A/California/07/2009 (BEI) were added to each well and the serum–virus mixture was 
incubated at room temperature for 1 hour and then incubated with 50 µl 0.5% v/v rooster 
red blood cells in 0.9% saline for 30 min at room temperature. The HAI antibody titer was 
scored with the dot method, and the reciprocal of the highest dilution that did not exhibit 
agglutination of the rooster red blood cells was recorded.  
2.19 Infectious molecular clones (IMC) 
The HIV-1 reporter virus used were replication-competent IMC designed to encode 
the env genes of DU151 (subtype C; GeneBank No. DQ411851) in cis within a Nef 
deficient isogenic backbone that expresses the Renilla luciferase reporter gene. All the 
IMCs were built using the original NL-LucR.T2A-ENV.ecto backbone as previously 
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described (Adachi et al., 1986). Reporter virus stocks were generated by transfection of 
293T cells with proviral IMC plasmid DNA, and virus titer was determined on TZM-bl cells 
for quality control.  
Infection of CEM.NKRCCR5 cell line with HIV-1 IMCsCEM.NKRCCR5 (NIH AIDS 
Reagent Program, Division of AIDS, NIAID, NIH) cells were infected with HIV-1 IMCs as 
previously described (Pollara et al., 2011). Briefly, IMCs were titrated in order to achieve 
maximum expression within 48-72 hours post-infection as determined by detection of 
Luciferase activity and intracellular p24 expression.  IMC infections were performed by 
incubation of the optimal dilution of virus with CEM.NKRCCR5 cells for 0.5 hour at 37oC 
and 5% CO2 in presence of DEAE-dextran (7.5 μg/ml).  The cells were subsequently 
resuspended at 0.5x106/ml and cultured for 48-72 hours in complete medium containing 
7.5μg/ml DEAE-dextran. For each ADCC assay, the frequency infected target cells were 
monitored by intracellular p24 staining. Assays performed using infected target cells were 
considered reliable if cell viability was ≥60% and the percentage of viable p24+ target cells 
on assay day was ≥20%. 
2.20 Luciferase ADCC Assay 
ADCC activity was determined by a luciferase (Luc)-based assay as previously 
described (Pollara et al., 2014). Briefly, CEM.NKRCCR5 cells were used as targets after 
infection with the HIV-1 IMCs. PBMC obtained from a HIV-seronegative donor with the 
heterozygous 158F/V and 131H/R genotypes for FcR3A and FcR2A, respectively, were 
used as a source of effector cells, and were used at an effector to target ratio of 30:1. Sera 
from NHPs inoculated with dMAb plasmids for PDGM1400 and PGT121 were initially 
diluted to reach an initial concentration ranging from 4 to 6µg/ml of dMAb and tested 
across a range of concentrations using 5-fold serial dilutions. The reference mAbs were 
tested across a range of concentrations using 5-fold serial dilutions starting at 50 µg/ml. 
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The effector cells, target cells, and Ab dilutions were plated in opaque 96-well half area 
plates and were incubated for 6 hours at 37C in 5% CO2. The final read-out was the 
luminescence intensity (relative light units, RLU) generated by the presence of residual 
intact target cells that have not been lysed by the effector population in the presence of 
ADCC-mediating mAb (ViviRen substrate, Promega). The percent of specific killing was 
calculated using the formula: percent specific killing = [(number of RLU of target and 
effector well − number of RLU of test well)/number of RLU of target and effector well] ×100. 
In this analysis, the RLU of the target plus effector wells represents spontaneous lysis in 
absence of any source of Ab. The ADCC detectable in NHP serum is reported after 
subtracting the activity observed in the serum before dMAb injection (baseline subtracted 
activity). Results are considered positive if percent specific killing is greater than 15%. 
The RSV-specific mAb Palivizumab was used as a negative control and a combination of 
C1/C2 A32, CD4bs CH44, glycosylation site 2G12, and gp41 7B2 mAbs (mAb mix) was 
used as positive control. 
2.21 Lethal H1/A/California/07/09 influenza challenge 
6-8 week old female BALB/c mice (Jackon Laboratory) were immunized with 1ug
of pVAX vector, DLmono_HA_CA09 or DLnano_3BVE_HA_CA09 twice three weeks 
apart. The mice were subsequently transferred to BioQual Inc for challenge experiment. 
35 days post the second immunization, the mice were intranasally inoculated with 10LD50 
H1/A/California/07/09 in PBS. Weights of the mice were pre-recorded prior to the 
challenge and daily after the challenge until 7 days post inoculation, at which lungs from 
the mice were harvested and snap-frozen for viral load assay by RT-qPCR and histo-
pathology by H&E staining. At any point, mice exhibiting more than 20% of weight loss as 
compared to baseline were euthanized (humane endpoint). 
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2.22 RT-qPCR assay for viral load determination 
The amounts of RNA copies per gram lung tissue was determined using a real-
time quantitative PCR (qPCR) assay. This assay utilized primers and a probe specifically 
designed to amplify and bind to a conserved region of the NP gene of influenza virus. The 
signal was compared to a known standard curve and calculated to give copies per gram 
tissue. Viral RNA was extracted from lung homogenates using MiniElute Virus Spin Kit 
(Qiagen). TAQMAN RT-PCR kit (Applied Biosystems, Inc., Carlsbad, CA) was used for 
amplification of viral RNA in the presence of 600nM primers (CAL-1-U: 
ATGGCGTCTCAAGGCACCAA and CAL-1-D: GCACATTTGGATGTAGAATCTC) and 
140nM probe (CAL-1-P:  6FAM-CAGAGCATCTGTCGGAAGAATGATTG-TAMRA) with 
the following Thermocycler setting: 48oC for 30 minutes, 95oC for 10 minutes followed by 
40 cycles of 95oC for 15 seconds, and 1 minute at 60oC. 
2.23 Statistics 
Power analysis was performed with R based on our preliminary data to determine 
the smallest sample size that would allow us to achieve a power of 0.9 with a pre-set α-
value of 0.05. One-way ANOVA analysis and pair-wise T-tests (with Holm-Bonferroni 
Adjustments in the case of multiple comparisons) or Two-tailed Mann Whitney Rank Tests 
were performed with GraphPad Prism 8.0. IC50 values were computed with a non-linear 
regression model of percentage neutralization versus log (reciprocal serum dilution) 
using Prism 8.0. P-values less than 0.05 were considered as statistically significant. 
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Chapter 3 Co-delivery of Synthetic DNA encoding a complex anti-HIV-1 biologic with a 
DNA-encoding enzyme promotes in vivo expression and post-translational modification 
Xu, Z., Wise, M.C., Choi, H., Perales-Puchalt, A., Patel, A., Tello-Ruiz, E., Chu, J.D., 
Muthumani, K., and Weiner, D.B. (2018). Synthetic DNA delivery by electroporation 
promotes robust in vivo sulfation of broadly neutralizing anti-HIV immunoadhesin eCD4-
Ig. EBioMedicine 35, 97-105. 
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3.1. Abstract 
Despite vigorous and ongoing efforts, active immunizations have yet to induce 
broadly neutralizing antibodies (bNAbs) against HIV-1. An alternative approach is to 
achieve prophylaxis with long-term expression of potent biologic HIV-1 inhibitors with 
Adeno-associated Virus (AAV), which could however be limited by hosts’ humoral and 
cellular responses. An approach that facilitates in vivo production of these complex 
molecules independent of viral-vectored delivery will be a major advantage. We used 
synthetic DNA and electroporation (DNA/EP) to deliver an anti-HIV-1 immunoadhesin 
eCD4-Ig in vivo. In addition, we engineered a TPST2 enzyme variant (IgE-TPST2), 
characterized its intracellular trafficking patterns and determined its ability to post-
translationally sulfate eCD4-Ig in vivo. With a single round of DNA injection, a peak 
expression level of 80-100ug/mL was observed in mice 14 days post injection (d.p.i). The 
engineered IgE-TPST2 enzyme trafficked efficiently to the Trans-Golgi Network (TGN). 
Co-administrating low dose of plasmid IgE-TPST2 with plasmid eCD4-Ig enhanced the 
potency of eCD4-Ig by three-fold in the ex vivo neutralization assay against the global 
panel of HIV-1 pseudoviruses. This work provides a proof-of-concept for delivering anti-
HIV-1 immunoadhesins by advanced nucleic acid technology and modulating protein 
functions in vivo with targeted enzyme-mediated post-translational modifications. 
3.2 Introduction 
There are currently 37 million people living with HIV/AIDS worldwide, and two 
million people are newly infected each year (Tetteh et al., 2017). 15-50% of patients 
chronically infected with HIV have developed antibodies that are considered broadly 
neutralizing (Hraber et al., 2014). However, to date, active vaccination with HIV envelope 
immunogens have failed to elicit bNAbs in NHPs and humans (Sok et al., 2017). In 
contrast, passive transfer of bNAbs have protected NHPs from SHIV challenges (Julg et 
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al., 2017a; Moldt et al., 2012; Shingai et al., 2014). Additionally, bNAb 10-1074 could 
transiently suppress viremia in HIV viremic patients (Caskey et al., 2017), while bNAb 
3BNC117 can delay viral rebound in HIV patients on analytic interruptions of ART (ATI) 
(Scheid et al., 2016). Viral rebound in these patients, typically occurring seven to ten 
weeks after ATI, is potentially driven by the emergence of HIV viruses resistant to the 
bNAb.  
Recently, AAV-delivery of a potent immunoadhesin construct eCD4-Ig 
demonstrated protection of Rhesus Macaques (RhM) from repeated challenges of SHIV-
AD8 and SIV-Mac239 (Gardner et al., 2015). eCD4-Ig is a fusion protein consisting of 
(from N to C-terminus) extracellular D1-D2 domains of CD4, IgG-Fc, and a 15-amino acid 
CCR5-mimetic peptide. As eCD4-Ig targets the conserved receptor and co-receptor 
binding sites on HIV envelope, it has demonstrated extreme breadth and potency, 
neutralizing all isolates tested with IC50<5ug/mL (Gardner et al., 2015). In addition, 
mutations that allow HIV-1 to escape from eCD4-Ig potentially come at a fitness cost to 
the virus by lowering the affinity of Env to CD4 and CCR5. To further enhance the potency 
of eCD4-Ig, AAV-encoded TPST2 was co-administered with AAV-encoded eCD4-Ig 
because TPST2 can specifically sulfate tyrosine residues in the CCR5 mimetic peptide of 
eCD4-Ig (Gardner et al., 2015).  
While the utility of AAV gene delivery is well-established (Naso et al., 2017), its 
successful use in targeting non-immuno-privileged tissues (livers or skeletal muscles) is 
frequently hindered by pre-existing neutralizing antibodies against the capsid (Fitzpatrick 
et al., 2018), which are extremely prevalent in the human population. For example, 
neutralizing antibodies to AAV2 are found in 30%-60% of human sera analyzed across 
different studies (Li et al., 2012; Mimuro et al., 2014). In addition, delivery by AAV induces 
seroconversion, which precluded the possibility of redosing the biologics with the same 
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vector (Tse et al., 2017). Even after successful transduction of target tissues, cytotoxic T-
lymphocytic response against the viral capsids may result in premature loss of the 
transgenes (Manno et al., 2006).  
Advances in electroporation technologies (EP) have increased in vivo DNA 
plasmid driven expression by 100 fold or more, (Sardesai and Weiner, 2011) which has 
recently been translated with success in the vaccine space in the clinic (Tebas et al., 2017; 
Trimble et al., 2015). As plasmid delivery is serologically independent, DNA/EP represents 
a more reproducible approach for gene deliveries (Almqvist et al., 2011). Our group has 
recently demonstrated the ability of DNA/EP to deliver high levels of plasmid-encoded 
monoclonal antibodies (DMAbs) against pseudomonas and influenza that can protect 
mice from lethal challenges (Elliott et al., 2017; Patel et al., 2017). Here, we built on this 
technology and demonstrated that DNA/EP could express a non-native, highly structured 
molecule, eCD4-Ig, in vivo. We also showed, for the first time, DNA/EP-mediated in vivo 
delivery of enzyme IgE-TPST2 that can colocalize with and post-translationally sulfate 
eCD4-Ig to improve its functionality. 
3.3. Results 
3.3.1 Transfection of HEK293T cells enables expression and secretion of ReCD4-Ig in 
vitro 
Since AAV-delivered Rhesus eCD4-Ig (ReCD4-Ig) protected RhMs against SHIV 
challenges (Gardner et al., 2015), we had focused our current work on ReCD4-Ig for 
downstream comparisons. An optimized transgene encoding ReCD4-Ig with an N-terminal 
IgG kappa-leader sequence was designed and synthesized de novo and cloned into a 
modified pVAX-1 plasmid backbone. Expression of this engineered p-ReCD4-Ig DNA 
construct was studied in vitro by transfecting HEK293T cells followed by ELISA 
quantification. In both the transfection supernatant and cell lysate, robust expression of 
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ReCD4-Ig was detected (Fig 3.1a). Western blot of the transfection supernatant with anti-
human IgG confirmed secretion of ReCD4-Ig (Fig 3.1b). 
3.3.2 Co-transfection of p-ReCD4-Ig and p-TPST2 variants allows in vitro sulfation of 
ReCD4-Ig 
Previous studies have demonstrated that tyrosine sulfation of CCR5 mimetic 
peptide by trans-Golgi resident enzymes, TPST2, enhances potency of ReCD4-Ig 
(Gardner et al., 2015; Seibert et al., 2002). As ReCD4-Ig is targeted to the secretory 
pathway early in the translation process by the IgG leader sequence, tyrosine sulfation of 
ReCD4-Ig could only occur if the TPST2 variant is also expressed in the secretory 
compartment.  
To highlight our ability to target TPST2 to the right subcellular compartment, we 
co-transfected HEK293T cells with p-ReCD4-Ig and plasmids encoding TPST2 enzyme 
variants. The p-IgE-TPST2, a construct with an IgE leader sequence upstream of TPST2, 
was predicted to sulfate ReCD4-Ig since the IgE leader sequence facilitates trafficking of 
TPST2 into the endoplasmic reticulum. A second TPST2 construct with a deletion in the 
transmembrane (TM) motif, p-ΔTM-TPST2, was not expected to sulfate ReCD4-Ig since 
the TM deletion removes the signal anchor sequence required for Trans-Golgi Network 
(TGN) targeting of TPST2. Finally, a control plasmid, p-HS3SA, was tested. HS3SA is a 
Golgi-resident enzyme which can transfer sulfate groups to heparin sulfate and has a 
similar catalytic site as compared to TPST2 (Teramoto et al., 2013). Varying doses of 
DNA-encoded enzymes (1:5000 to 1:20, enzyme: ReCD4-Ig) were used to determine the 
minimal dose required to maximize sulfation of ReCD4-Ig. Using an anti-sulfotyrosine 
binding ELISA on cell supernatant, higher sulfation was observed for both TPST2 and IgE-
TPST2 groups, even at the lowest enzyme dose of 1:5000, as compared to the baseline 
ReCD4-Ig only group (Fig 3.1c). Furthermore, for both TPST2 and IgE-TPST2, sulfation 
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signals were saturated at a remarkable 1:1000 enzyme dose, and higher dose of DNA did 
not increase sulfation. In comparison, RecCD4-Ig sulfation for both the ΔTM-TPST2 and 
HS3SA groups were not higher than the baseline. The lack of sulfation with the HS3SA 
group indicates remarkable specificity of sulfotransferases. To further confirm enzyme-
mediated sulfation of ReCD4-Ig, the supernatants were analyzed with Western blots (Fig 
3.1d). Again, stronger sulfotyrosine bands were observed for the 1:1000 TPST2 and IgE-
TPST2 groups than for the ReCD4-Ig only, ΔTM, and HS3SA groups. Taken together, 
these results suggest that DNA-encoded TPST2, and IgE-TPST2 can mediate in vitro 
sulfation of ReCD4-Ig at a remarkably low dose. 
3.3.3 Incorporation of the N-terminal IgE leader sequence enhances targeting of TPST2 
to TGN 
We used fluorescence microscopy to determine whether IgE leader sequence can 
improve trafficking of DNA-encoded IgE-TPST2 to the cellular secretory compartment. 
HEK293T cells were transfected with either p-ReCD4-Ig only, or p-ReCD4-Ig in 
combination with p-TPST2, p-IgE-TPST2, or p-ΔTM-TPST2. 48 hours after transfections, 
cells were harvested and stained with DAPI (blue), anti-TPST2 (red), and anti-Golgin 97 
(green). Golgin-97 is a trans-Golgi resident protein commonly used to determine the 
expression of a protein of interest in TGN (Lu et al., 2004). Confocal microscopy images 
of harvested cells illustrate robust expression of TPST2, IgE-TPST2 and ΔTM-TPST2 
upon transfection (Fig 3.2a). More importantly, IgE-TPST2 appears to co-localize with 
Golgin 97 to a greater extent than TPST2, whereas ΔTM-TPST2 does not co-localize with 
Golgin 97. To quantify the extent of co-localization between Golgin 97 and TPST2 
variants, we analyzed the Pearson correlation coefficients (PCC) between red and green 
channels for 16 regions of interests for each group (Fig 3.2b). The global one-way ANOVA 
analysis yields a p-value<0.0001 and post-hoc pairwise T-test shows PCC for the IgE-
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TPST2 group (PCC=0.542) is significantly higher than that for the TPST2 group 
(PCC=0.275, p<0.0001). To ensure co-transfection with ReCD4-Ig did not change enzyme 
localization, we also co-transfected HEK293T cells with plasmid enzymes and pVAX1 
backbone, and observed similar colocalization patterns (Supplemental Fig 3.1). Taken 
together, the results support that while both TPST2 and IgE-TPST2 can traffic to TGN, 
IgE-TPST2 can be targeted to the secretory compartment more efficiently than TPST2, 
potentially because the N-terminal IgE leader sequence is recognized by signal 
recognition particle (SRP) more efficiently than the internal signal anchorage sequence of 
TPST2.  
3.3.4 DNA/EP mediates in vivo expression of ReCD4-Ig and sulfation enzymes 
We next determined whether we can express ReCD4-Ig and the sulfation enzyme 
TPST2 in vivo with DNA/EP. We observed strong TPST2 expression in the injected as 
compared to the contralateral legs of mice for at least 56 days (Fig 3.3a). DNA/EP also 
mediated robust in vivo expression of IgE-TPST2 (Supplemental Fig 3.2). Since ReCD4-
Ig sequence is RhM based, strong anti-drug antibodies could develop in immune 
competent mice and influence the expression profile of ReCD4-Ig. Thus, immunodeficient 
B6.Cg-Foxn1nu/J (nude) mice were used initially. We observed a high level of expression 
of ReCD4-Ig, which peaked at an average of 35ug/mL 14 days post injection (d.p.i) (Fig 
3.3b). Remarkably, expression was detected as early as 3 d.p.i (average 5.7ug/ml) and 
lasted for at least 150 days (average 3.1ug/ml). In addition, ReCD4-Ig expression profile 
in transiently immune-depleted BALB/c mice demonstrated a similar pattern. 
3.3.5 Low dose of p-IgE-TPST2 leads to in vivo sulfation of ReCD4-Ig without decreasing 
its expression 
We next tested the ability of DNA-encoded IgE-TPST2 to sulfate ReCD4-Ig in vivo 
in transiently immune-depleted BALB/c mice. Remarkably, we observed that 1:1000 dose 
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of IgE-TPST2 can saturate the sulfation OD450 signals detected in the mice sera 7 d.p.i, 
as compared to 1:20 IgE-TPST2 dose group (Fig 3.3c). Additionally, sulfation of ReCD4-
Ig was significantly higher, even at a lower 1:5000 dose of the enzyme, as compared to 
the baseline ReCD4-Ig only group. Previous studies describe that co-transfection of a high 
dose of TPST2 with its target proteins in vitro could lead to decreased secretion of the 
target proteins (Chen et al., 2016). We observed a similar phenomenon both in vitro and 
in vivo (Fig 3.3d and Supplemental Fig 3.3a). To study if we could find an effective dose 
that would not limit ReCD4-Ig expression, we titrated the amount of IgE-TPST2 co-
administered in vivo. A high dose (1:20) of IgE-TPST2 co-transfected with ReCD4-Ig 
resulted in 67% and 70% decreases in the expression of ReCD4-Ig in transfection 
supernatants and mice sera, respectively, as compared to ReCD4-Ig only groups. 
Additionally, suppression of ReCD4-Ig secretion is not directly driven by IgE-TPST2-
mediated sulfation since co-administration of p-ReCD4-Ig and 1:20 p-HS3SA also reduces 
ReCD4-Ig expression by 52% (Supplemental Fig 3.3b). Importantly, at the minimal 1:1000 
dose of p-IgE-TPST2 required for optimal sulfation of ReCD4-Ig, we did not observe a 
difference in ReCD4-Ig expression 7 d.p.i between ReCD4-Ig only and ReCD4-Ig + 1:1000 
IgE-TPST2 groups (Fig 3.3d). Such pattern was again observed when the mice injected 
with either pReCD4-Ig alone or pReCD4-Ig + 1:1000 p-IgE-TPST2 were followed over 
time for ReCD4-Ig expression (Fig 3.3e). In addition, using binding ELISA to assess the 
durability of sulfation of ReCD4-Ig by IgE-TPST2 in vivo, we observed peak levels of 
sulfation in the co-treated mice between 7 and 14 d.p.i (Fig 3.3f). Sulfation of ReCD4-Ig in 
these co-treated mice declines over time but remains significantly higher than the mice 
which did not receive plasmid enzyme co-treatment for at least three weeks. Taken 
together, these results illustrate that plasmid encoded enzymes delivered by 
electroporation can enable in vivo sulfation of ReCD4-Ig at a remarkably low dose without 
decreasing the expression of ReCD4-Ig. 
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3.3.6 In vivo sulfation increases the potency of ReCD4-Ig 
We next determined if in vivo sulfation of ReCD4-Ig can enhance its potency. 
Similar levels of ReCD4-Ig expression (40ug/mL) was again observed for both p-ReCD4-
Ig only and p-ReCD4-Ig + 1:1000 p-IgE-TPST2 groups 7 d.p.i in immune-depleted BALB/c 
mice (Fig 3.4a). We first tested the ability of in vivo produced ReCD4-Ig to neutralize one 
of the pseudoviruses from the global panel (25710, Tier 2, clade C) using the standard 
TZM-bl assay (deCamp et al., 2014). Sulfation mediated by IgE-TPST2 significantly 
enhanced the ability of ReCD4-Ig to neutralize this isolate, as evidenced by a right-ward 
shift in the neutralization curve (Fig 3.4b). We then evaluated the effects of ReCD4-Ig 
sulfation with a panel of 13 pseudoviruses comprising of the global panel and the tier 3 
isolate SIVmac239 (deCamp et al., 2014). We observed that ReCD4-Ig neutralized all 13 
viruses in the panel with an IC50 less than 5ug/mL and a mean IC50 of 0.83ug/mL (Fig 3.4c 
and Fig 3.4d). Naïve mice sera, in comparison, did not neutralize any of the pesudovirus 
at a titer of 1:20. Our results validated the remarkable breadth of eCD4-Ig as described in 
previous studies (Gardner et al., 2015). In addition, sulfation of ReCD4-Ig enhances its 
potency in neutralizing 8/12 pseudoviruses in the global panel (CE1176, 25710, X2278, 
TRO, BJOX, X1632, CH119, CNE55) and Mac239 (Fig 3.4c-d and Supplemental Fig 3.4). 
Sulfation exhibits the most drastic effect on the ability of ReCD4-Ig to neutralize CE1176, 
with a 10-fold drop in IC50 (0.57 ± 0.27 ug/mL to 0.05 ± 0.02 ug/mL). Overall, IgE-TPST2 
mediated sulfation led to a decrease in the geometric mean of IC50 against the viral panel 
from 0.83ug/mL to 0.27ug/mL. Of note, the IC50 of sulfated ReCD4-Ig in neutralization of 
Mac239 is 0.16 ± 0.06 ug/mL, similar to the IC50 reported for AAV delivered ReCD4-Ig 
(Gardner et al., 2015). Taken together, our results validated in vivo sulfation of ReCD4-Ig 
by plasmid-encoded IgE-TPST2 from a functional standpoint and demonstrated the ability 
of DNA-encoded enzymes to modulate biological functions of a target protein through 
post-translational modification (PTM). 
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3.4. Discussion 
Sulfation plays an important role in molecular interactions between CCR5, gp120, 
and CD4 to support HIV infection. Sulfated tyrosine residues on the N-terminus of CCR5 
and CD4i antibody (412d) mediate their intermolecular interactions with the V3 loop of Env 
in the CD4-bound post-fusion state (Farzan et al., 1999). As such, sulfated CD4i 
antibodies neutralize primary HIV-1 isolates more potently than non-sulfated prototypical 
CD4i antibodies 17b and 48d (Choe et al., 2003). In addition, the CDRH3s of many V2-
apex bNAbs (PGDM1400, PG9) are also tyrosine sulfated (Moore et al., 2017). By using 
DNA/EP to express both ReCD4Ig and IgE-TPST2 in vivo, we have significantly increased 
potency of the immuneadhesin through post-translational sulfation, validating and 
extending prior findings (Gardner et al., 2015). 
Importantly, this is the first report utlizing DNA to encode an enzyme that can carry 
out PTM of a target protein in vivo. Through modulating protein function in vivo, DNA/EP 
provides a platform with diverse applications. For example, by modifying the glycosylation 
pattern in the Fc portion of immunoglobulin, we can fine-tune its effector functions. 
Afucosylation of IgG1 Fc with endoglycosidase/ fucosidase, for instance, can potentially 
enhance antibody-dependent cell-mediated cytotoxicity (ADCC) of the modified antibody. 
Terminal sialylation, in the context of core fucosylation, exhibits an opposite effect (Arnold 
et al., 2007; Li et al., 2017). In the area of vaccine design, PTMs of an antigen can create 
new epitopes for recognition by the immune system. For instance, both germline encoded 
and somatically mutated antibodies in the CAP256.VRC26 lineage recognize sialic-acid 
bearing glycans at N160, or N156 positions of the HIV envelope (Andrabi et al., 2017). 
Co-administration of DNA-encoded HIV Env antigens and sialytransferases could likely 
elicit such glycan-dependent neutralizing antibodies. 
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Our results illustrate that a remarkably low dose of 1:1000 p-IgE-TPST2 is required 
for in vivo sulfation of ReCD4-Ig. We expected this finding since a single molecule of the 
enzyme should be able to turn over multiple copies of target proteins. Specifically, since 
TPST2 has a turnover number (kcat) of 5.1 × 10−3s-1 (for a mono-sulfated CCR8 peptide) 
and half-life of a Golgi-resident enzyme is about 20 hours, a single copy of TPST2 enzyme 
should be able to turnover at least hundreds of copies of ReCD4-Ig (Danan et al., 2010; 
Strous, 1986). Of note, the dose required to sulfate ReCD4-Ig is much lower for DNA-
encoded IgE-TPST2 (1:1000) than AAV-encoded TPST2 (1:4). This demonstrates the 
high efficiency of DNA/EP mediated enzyme delivery and that muscle cells have received 
separate copies of both p-IgE-TPST2 and p-ReCD4-Ig simultaneously. This is likely due 
to directionally pulsed electric fields that can create transient pores in the plasma 
membrane, and move polyanionic plasmid DNA directly into the cells to improve 
transfection efficiency by 100-1000 folds (Sardesai and Weiner, 2011). In comparison, 
uptake of AAV-encoded genetic materials (ReCD4-Ig and TPST2) into cells requires 
clathrin-dependent endocytosis or micropinocytosis (Stoneham et al., 2012; Weinberg et 
al., 2014), and transduction of muscles cells by both AAV-TPST2 and AAV-eCD4-Ig can 
occur in a stochastic fashion.  
The results also support an approach to target an enzyme to a specific subcellular 
compartment to maximize its functions. While the efficiency of IgE-TPST2 mediated 
sulfation appears similar to that of TPST2-mediated sulfation (Fig 3.1d), selective targeting 
of the IgE-TPST2 can potentially reduce cytosolic expression of the enzyme and off-target 
effects. This approach can be further extended to target proteins to other subcellular 
compartments for therapeutic and investigational purposes. Specifically, an N-terminal 
sequence consisting of 10-70 amino acids that forms amphipathic helices could target 
proteins to the mitochondria; a dileucine motif DXXLL, or a tyrosine-based motif YXXØ, in 
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the cytoplasmic tail of a transmembrane protein could target it to the lysosome; whereas 
a unit of 5 basic positively charged amino acids could target a protein to the nucleus 
(Braulke and Bonifacino, 2009; Regev-Rudzki et al., 2008).  
Finally, we have demonstrated the ability of DNA/EP to enable robust and long-
term in vivo expression of immunoadhesins like ReCD4-Ig. With a single round of injection, 
a peak expression level of 80-100ug/mL in mice was observed, with levels that remains 
above 3ug/mL for 150 days. The decline in ReCD4-Ig expression between 28 and 42 d.p.i 
(Fig 3b) and in ReCD4-Ig sulfation between 14 and 28 d.p.i (Fig 3f) is under further 
investigation. Approaches such as modifications to the plasmid backbone to reduce in vivo 
promoter silencing (Chen et al., 2008) and protein engineering to increase enzyme half-
lives are worthy of future investigations. The in vivo folding of ReCD4-Ig into its proper 
conformational state is confirmed by the observation that DNA-encoded ReCD4-Ig 
demonstrates excellent potency and breadth in neutralizing all isolates from the global 
panel with an IC50 less than 5ug/mL and a mean IC50 of 0.27ug/mL. Recently, our 
preliminary studies demonstrate microgram per milliliter levels of expression of other 
monoclonal antibodies can be achieved in NHPs with Cellectra EP delivered DNA, 
supporting the potential translation of this approach (work in progress). This study 
illustrates the utility of DNA/EP for in vivo expression and subcellular targeting of an 
enzyme and provides a strategy for modifying protein functions in vivo through PTM. 
Further study to determine whether the DNA/EP can be a tool to deliver and modify 
immunoadhesins and other important biologics to prevent and control HIV-1 infection and 
other diseases is likely important.  
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Figure 3. 1 In vitro expression and sulfation of ReCD4-Ig. 
Error bars represent standard deviations. 
(A) Expression of ReCD4-Ig in transfection lysate and supernatant of HEK293T cells
(n=4).
(B) Western blot of supernatants of HEK293T cells transfected with either p-ReCD4-Ig or
pVAX-1.
(C) Binding ELISA to detect tyrosine sulfation of ReCD4-Ig in transfection supernatant.
HEK293 T cells were transfected with p-ReCD4-Ig or p-ReCD4-Ig with varying doses
of plasmid enzyme constructs at (normalized to p-ReCD4-Ig, n=3).
(D) Western blot of supernatants of HEK293T cells transfected with either p-ReCD4-Ig
alone or p-ReCD4-Ig and 1:1000 plasmid enzymes. The lower and upper panels show
the total amount of ReCD4-Ig and sulfotyrosine respectively.
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Figure 3. 2 Subcellular targeting of IgE-TPST2. 
(A) Confocal microscopy to determine colocalization between TPST2 variant (red) and
Golgin 97 (green). Nuclei are stained with DAPI (blue). 
59
(B) Quantification of colocalization between TPST2 variants and Golgin 97 with PCC
and regions of interest analyses (n=16). P-values from posthoc pairwise T-tests are 
indicated: **, p<0.005, ****, p<0.0005. 
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Figure 3. 3 In vivo expression and sulfation of ReCD4-Ig. 
Each dot represents an individual mouse; error bars represent standard deviation. P-
values were computed with pairwise T-tests: *, p<0.05, **, p<0.005, ***, p<0.0005, ****, 
p<0.0005. 
(A) Western blot of muscle homogenates 7-56 d.p.i demonstrates expression of
TPST2 (43kDa) in the injected legs as compared to the contralateral legs. GAPDH 
(37kDa) serves as loading controls. 
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(B) Serum expression of ReCD4-Ig in B6.Cg-Foxn1nu/J and transiently immune-
depleted BALB/c from a single round of DNA injection (160ug). N=5 for each group. 
(C) Binding ELISA to determine ReCD4-Ig tyrosine sulfation in sera of BALB/c mice
injected with p-ReCD4-Ig alone or p-ReCD4-Ig with varying doses of p-IgE-TPST2. 
(D) Serum expression level of ReCD4-Ig in mice cotreated with 320ug p-ReCD4-Ig
and varying plasmid IgE-TPST2 doses 7 d.p.i. 
(E) Serum expression level of ReCD4-Ig at different timepoints in BALB/c treated with
either 320ug of p-ReCD4-Ig or 320ug of p-ReCD4-Ig and 0.32ug of p-IgE-TPST2. Each 
line represents an individual mouse. 
(F) Average sulfation signals of ReCD4-Ig in the sera of BALB/c treated with 320ug of
p-ReCD4- and 0.32ug of p-IgE-TPST2. N=5 for the group. Dotted line represents average
sulfation signals of ReCD4-Ig in the sera of BALB/c treated with 320ug of p-ReCD4 alone 
7 d.p.i. 
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Figure 3. 4 Functional characterization of IgE-TPST2 mediated sulfation on ReCD4-Ig. 
Each dot represents an individual mouse; error bars represent standard deviation. P-
values were computed with pairwise T-tests. 
(A) Serum concentrations of ReCD4-Ig at the time of terminal bleed (7 d.p.i) in
immune-depleted BALB/c mice injected with 320ug of p-ReCD4-Ig alone or p-ReCD4-Ig 
+ 1:1000 p-IgE-TPST2.
(B) Neutralization of 25710 pseudovirus versus serum concentration of ReCD4-Ig.
(C) Comparison of ReCD4-Ig IC50 with or without IgE-TPST2 treatment.
(D) IC50 values of ReCD4-Ig in sera of mice with and without IgE-TPST2 treatment.




Supplemental Figure 3. 1 Fluorescence microscopy images of HEK293T cells 
transfected with pVAX backbone plasmid alone, or pVAX with plasmid encoded.  
Golgin 97 (green), TPST2 (red) and nuclei (blue) are stained as described in Fig 2(a). 
Overlay of the three channels show enhanced trafficking of IgE-TPST2 to TGN as 
compared to TPST2 and ΔTM-TPST2. 
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Supplemental Figure 3. 2 Western blot of muscle homogenates 7 d.p.i demonstrates 
expression of IgE-TPST2 (43kDa) in the injected legs as compared to the contralateral 
legs.  
GAPDH (37kDa) serves as loading controls. 
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Supplemental Figure 3. 3 In vitro cotransfection and in vivo co-delivery of a Golgi-
resident enzyme decrease ReCD4-Ig expression.  
Pairwise T-tests were used to compare level between each group: *, p<0.05, **, p<0.005. 
(A) Quantification of ReCD4-Ig in supernatants of HEK293T cells transfected with p-
ReCD4-Ig and varying doses of p-IgE-TPST2.
(B) Serum concentrations of ReCD4-Ig 7 d.p.i in transiently immune-depleted BALB/c
mice injected with 320ug of p-reCD4-Ig alone, or 320ug of p-reCD4-Ig with 16ug of p-
TPST1/ p-HS3SA.
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Supplemental Figure 3. 4 IC50 values of ReCD4-Ig with or without sulfation in ex vivo 
neutralization assay.  
Each dot represents IC50 value computed from a single mouse, and p-value for each virus 
is computed with pairwise T-test with Holm adjustment for multiple comparisons. The 
panels are separated into (A) viruses in which sulfated ReCD4-Ig has significantly 
enhanced potency (virus X2278 is borderline significant) and (B) viruses in which the 
potency of sulfated ReCD4-Ig is not significantly higher. 
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CHAPTER 4 Harnessing synthetic DNA for in vivo expression of multiple different bNAbs 
against HIV-1 
Wise, M.C.*, Xu, Z.*, Tello-Ruiz, E., Beck, C., Trautz, A., Patel, A., Elliott, S.T., 
Chokkalingam, N., Kim, S., Kerkau, M.G., et al. (2020). In vivo delivery of synthetic DNA-
encoded antibodies induces broad HIV-1-neutralizing activity. J Clin Invest 130, 827-837. 
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4.1 Abstract 
Interventions to prevent HIV-1 infection and alternative tools in HIV cure therapy 
remain pressing goals. Recently, numerous broadly neutralizing HIV-1 monoclonal 
antibodies (bNAbs) have been developed which possess the characteristics necessary for 
potential prophylactic or therapeutic approaches.  However, formulation complexities 
especially for multi-antibody deliveries, long infusion times, and production issues could 
limit the use of these bNAbs when deployed globally impacting their potential application. 
Here, we describe an approach utilizing synthetic DNA-encoded monoclonal antibodies 
(dMAbs) for direct in vivo production of prespecified neutralizing activity.  We designed 16 
different bNAbs as dMAbs cassettes and studied their activity in small and large animals. 
Sera from animals administered dMAbs neutralized multiple HIV-1 isolates with similar 
activity to their parental recombinant MAbs.  Delivery of multiple dMAbs to a single animal 
led to increased neutralization breadth.  Two dMAbs, PGDM1400 and PGT121, were 
advanced into non-human primates for study. High peak circulating levels (between 6-
34µg/ml) of these dMAbs were measured and the sera of all animals displayed broad 
neutralizing activity. The dMAb approach provides an important local delivery platform for 
the in vivo generation of HIV-1 bNAbs and for other infectious disease antibodies.   
4.2 Introduction 
In just over four decades since its global emergence, the AIDS epidemic has taken 
millions of lives. While there have been exceptional advances in antiretroviral therapies, 
there remains a need for preventive treatments and interventions to eliminate HIV-1 
infection (Maartens et al., 2014). In recent years, multiple monoclonal antibodies with 
potent neutralization capacity have been isolated from HIV-1 infected persons (McCoy 
and Burton, 2017; Pegu et al., 2017). A few of these broadly neutralizing antibodies 
(bNAbs) have demonstrated efficacy in preventing infection after a single dose of 
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intravenous recombinant protein in non-human primates (Gautam et al., 2018). Such 
observations have generated enthusiasm in the field and progressed HIV-1 bNAbs into 
the clinic for studies of prevention (NCT02256631, NCT02568215, NCT02716675) as well 
as for HIV treatment towards cure strategies (Bar et al., 2016; Bar-On et al., 2018; Cohen 
and Caskey, 2018; Mendoza et al., 2018; Scheid et al., 2016). Recently, clinical trials have 
explored the capability of these antibodies to lower viral loads or prevent rebound after 
analytical treatment interruption (ATI) (Bar et al., 2016; Scheid et al., 2016). Most notably, 
a study by Mendoza et al. demonstrated that a combination of two bNAbs, 3BNC117 and 
10-1074, prevented viral rebound for a median of 21 weeks in a subset of individuals 
compared to 2.3 weeks in historical controls (Mendoza et al., 2018).   
 The widespread use of passive delivery of recombinant antibodies is impacted due 
to infusion time, formulations issues, product temperature stability, re-dosing requirements 
and significant manufacturing costs (Awi and Teow, 2018). Viral vector delivery with 
adeno-associated virus (AAV) has been previously evaluated as a delivery platform for 
HIV-1 bNAbs, with high-level and long-term expression of the transgene antibody (Balazs 
et al., 2011; Johnson et al., 2009; Saunders et al., 2015). However, AAV delivery can be 
limited in populations by pre-existing neutralizing antibodies to the vector, safety concerns 
of permanent gene marking of the patient, temperature stability, manufacturing cost, as 
well as vector seroconversion potentially preventing re-administration ultimately resulting 
in reduced antibody levels in many subjects (Fuchs and Desrosiers, 2016). Recent clinical 
results of recombinant AAV-1 delivered PG9 demonstrated limited detection of circulating 
PG9 in healthy males who were delivered a range of vector doses (4x1012 – 1.2x1014 
vector genomes) (Priddy et al., 2019). In this study, we explored the use of synthetic DNA 
encoded monoclonal antibodies (dMAb) as a possible alternative, serology-independent, 
approach to passive transfer and AAV delivery. Upon injection and electroporation of 
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optimized plasmid DNA with transgenes encoding antibody, locally transfected cells 
become the in vivo bio-factory for antibody production. We have previously demonstrated 
this dMAb technology was able to induce protective levels of antibody in mice against 
important infectious disease targets, including influenza A and B viruses, Pseudomonas 
aeruginosa, Zaire Ebolavirus, dengue virus, Zika virus and chikungunya virus (Elliott et 
al., 2017; Esquivel et al., 2019; Flingai et al., 2015; Muthumani et al., 2016; Patel et al., 
2017; Patel et al., 2018a).   
Here, we studied the activity of a panel of 16 engineered dMAbs encoding HIV-1 
specific monoclonal antibodies that exhibit broad neutralizing activity. Following dMAb 
administration, we observed rapid expression and sustained blood levels for months in 
small animals. These in vivo produced dMAbs were functionally active and neutralized to 
varying degrees the 12 global panel viruses in an envelope-pseudotyped virus 
neutralization assay (deCamp et al., 2014).  To decrease the possibility of viral escape, 
we next explored administration of multiple (up to four) dMAbs into a single animal and 
demonstrated expansion of serum neutralizing breadth.  Based on in vivo dMAb levels 
and neutralizing potency, we advanced two dMAbs, PGT121 and PGDM1400, for a pilot 
non-human primate (NHP) study. In this study, NHP were delivered a single dMAb 
(PGDM1400) or a combination of the two (PGT121 and PGDM1400). Strong expression 
was observed in both groups with a range from 6-34.3 µg/ml at peak levels. All animals 
expressed dMAbs and the serum demonstrated strong tier-2 neutralization breadth. 
Additionally, the levels of dMAb observed in this study were, on average, more than ten 
times higher compared to an initial NHP dMAbs study (Esquivel et al., 2019). This provides 
evidence for further development of this platform, which represents an alternative modality 
for in vivo antibody production against HIV-1 and other biological targets.  
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4.3 Results 
4.3.1 Robust expression of optimized HIV-1 dMAbs expressed in vitro and in vivo 
dMAbs utilize optimizations that were developed to increase plasmid uptake and 
expression in context of delivery by adaptive electroporation (Sardesai and Weiner, 2011). 
These improvements resulted in significant enhancement of in vivo expression launched 
from plasmids. Here we adapted multiple HIV-1 specific bNAbs and tested their 
expression and in vivo levels. We compared 16 different bNAbs targeting five different 
regions of the HIV-1 envelope: CD4 binding site (VRC01, N6, 12A21, 3BNC117, IOMA, 
NIH45-46); high mannose glycan patch (PGT121, PGT128, 10-1074, PGT130); apex 
(PGT145, PGDM1400, PG9); gp120-gp41 interface (PGT151, 35O22) and gp41 fusion 
domain (VRC34.01) (Gristick et al., 2016; Huang et al., 2016; McCoy and Burton, 2017; 
Scheid et al., 2011; Walker et al., 2011). Broadly neutralizing antibodies encoded as 
dMAbs were selected based on target epitope, neutralization capacity and other 
characteristics such as length of heavy chain complementarity-determining regions 3 
(CDR3) and percent of somatic hypermutation to obtain a range of antibody characteristics 
(Table S1). The heavy chain length of the CDR3 region ranged from 12 (3BNC117) to 35 
(PGDM1400) with an average length across all dMAbs of 22. The percent of amino acid 
somatic mutations from germline in the heavy chain ranged from 18% (IOMA) to 42% 
(VRC01) with an average of 28%. Plasmids encoding the heavy chain or the light chain of 
each of the broadly neutralizing antibodies were RNA and codon optimized, synthesized 
and cloned into the modified pVax1 backbone. All dMAbs were of the human IgG1 isotype. 
Expression levels in vitro of all dMAbs were confirmed using transient transfection of HEK 
293T cells (Figure S4.1).  
Next we proceeded to assess in vivo expression in transiently immunodepleted 
mice to prevent the development of anti-drug antibodies responses against the human 
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IgG1. Mice were injected with plasmid dMAb constructs followed by intramuscular 
electroporation (IM-EP) using the CELLECTRA® 3P device. We observed dMAb 
expression in sera two days post injection with peak levels around Day 21 (Figure S4.2). 
dMAb was continuously detected in the sera for over 300 days. Peak levels of dMAbs 
varied from below 1µg/ml to greater than 80µg/ml (Figure 4.1A). The majority of dMAbs 
exhibited peak levels between 10-30µg/ml. There was minimal variability among mice 
receiving a given dMAb, supporting a model where the intrinsic properties of each antibody 
sequence influence the overall levels observed in vivo. We did not observe any correlation 
in dMAb levels for different families, heavy chain CDR3 length or percent somatic 
hypermutation rate of the heavy chain.  
4.3.2 Functionality of in vivo produced dMAbs is comparable to recombinant MAb 
counterparts 
 To further characterize in vivo produced dMAbs, we investigated their ability to 
bind to trimer as compared to recombinantly produced monoclonal antibodies. We 
observed similar strength of binding to trimer as compared to recombinant protein 
monoclonal antibody for all tested dMAbs (Figure 4.1B and Figure S4.3A). In agreement 
with our other dMAb studies, this suggests proper folding of the dMAb in vivo and supports 
retention of their antigen specificity (Elliott et al., 2017; Flingai et al., 2015; Muthumani et 
al., 2016; Patel et al., 2017; Patel et al., 2018a).   
 We next examined dMAb functionality in the context of neutralization using HIV-1 
envelope pseudotyped viruses representing the global diversity of HIV-1 glycoprotein 
(deCamp et al., 2014). We observed strong neutralization titers for all the studied dMAbs 
(Figure 4.1C-D). Importantly, there was low variability in neutralization titers among mice 
given a specific dMAb based on each specific group and serum neutralization titers (IC50) 
were similar to titers reported in the literature (Figure 4.1C and Figure S4.3B). The 
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neutralization data further confirm dMAbs were assembled, formed and properly folded in 
vivo and then exhibit similar potency to the recombinant protein monoclonal antibodies.  
4.3.3 Modifications improved production of low expressing N6 dMAb 
N6 is an extremely potent and broad neutralizing anti-HIV-1 antibody (Huang et 
al., 2016), however its in vivo levels were among the three lowest (Figure 4.1A). Based on 
these previous studies, we observed that single amino acid modification can significantly 
increase dMAb expression (Patel et al., 2018a).  Thus, we sought to increase its 
expression by designing modifications to both the heavy chain (HC) and light chain (LC) 
of the original N6 amino acid sequence at the C- and N-terminus of the variable region. 
These modifications were selected to make the antibody more similar to the human 
parental germline antibody sequence (Figure S4.4A). Mice injected with HC unmodified + 
LC modified (LCmod) or HC modified + LC unmodified (HCmod) dMAb had 3.5-fold 
increases in levels over the unmodified original N6 (Figure S4.4B). When both modified 
plasmids were used to assemble modified N6 (N6mod), levels increased 9-fold over 
unmodified and a 2.5-fold over each modified chain. Modifications to the variable regions 
can change an antibody’s ability to bind to its target and impact its functionality. Binding 
to trimer was similar between serum from mice injected with N6mod dMAb and 
recombinant unmodified N6 (Figure S4.4C). Furthermore, recombinant antibodies 
expressing either N6 or N6mod were able to neutralize multiple viruses from the global 
panel to similar degrees as levels previously reported in the literature (Figure S4.4D) 
(Huang et al., 2016). Thus, these modifications appear to be important for increasing 
overall production in vivo, resulting in increased serum levels of antibody while maintaining 
the functionality of this antibody. While there was marked improvement in the in vivo 
production levels of N6mod, these levels remain on the lower end and additional rounds 
of optimization could further improve in vivo levels.   
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4.3.4 Delivery of multiple dMAbs to provide enhanced coverage of viral mutations  
 Due to the high error rate of HIV-1 reverse transcription and resultant high 
antigenic variability, viral immune escape from a single-antibody therapy is likely (Cohen 
and Caskey, 2018). Additionally, escape mutations to the mAb may already exist in 
populations as no single mAb targets all circulating HIV-1 strains (Cohen and Caskey, 
2018).   In order to overcome such issues, we evaluated co-delivery of multiple bNAbs 
against distinct HIV-1 envelope epitopes in the dMAb delivery platform. We selected two 
combinations which are currently in clinical trials, 3BNC117 + 10-1074 (Bar-On et al., 
2018; Mendoza et al., 2018) and PGDM1400 + PGT121 (NCT0320591), as well as 
PGT121 + PGT145. PGT121 and PGT145 were chosen based on in vivo dMAb levels, 
target epitope and neutralization profile of the antibodies. Mice were dosed with either a 
single dMAb construct or with two dMAb constructs in separate distinct muscle sites. In 
vivo levels of each individual antibody were similar in the combination mice as compared 
to mice delivered only a single antibody (Figure 4.2A). Individually, bNAb targets between 
7 and 11 viruses in the global panel with various gaps in neutralization capacity (Figure 
4.1C). By expressing two dMAbs in a single mouse, we observed an increase in their 
overall breadth of neutralization, targeting never less than 11 different members of the 
global panel as compared to each of the individual dMAbs with the PGDM1400 + PGT121 
(NCT0320591) combination now providing 100% viral coverage (Figure 4.2B) (Julg et al., 
2017b).  
 We next sought to deliver and express four dMAbs in a single mouse using 
antibodies PGDM1400, PGT151, VRC01, and PGT121. Such deliveries of multiple 
antibodies are difficult in other methods.  For this study the antibodies were selected based 
on their neutralization capacity, overall in vivo levels, and ability to target distinct epitopes 
on the HIV-1 envelope. In these studies, animals were injected with a single dMAb or with 
75
all four. As we do not have anti-idiotype antibodies for these antibodies, we measured the 
total amount of the xenogeneic human antibody expressed in the mice (Figure 4.2C). The 
total serum hIgG1 dMAb levels in the mice administered with all four dMAb constructs 
were comparable to the sum of the levels of each dMAb construct administered 
individually (sum of mice injected the individual dMAbs: 26.01µg/ml vs combination dMAb 
mice: 25.10µg/ml). Once again, we observed increased neutralization breadth in the sera 
of mice that received all four dMAb constructs compared to neutralization breadth in the 
sera of mice that received each individual dMAb construct (Figure 4.2D). By delivering all 
four dMAb constructs at once, we observed neutralization IC50 levels below 0.1µg/ml 
across the entire global panel.  
4.3.5 HIV-1 dMAbs express in NHPs 
Based on the promising studies in mice, we next explored dMAb delivery of HIV-1 
specific dMAbs in a pilot NHP animal model which is more relevant for translation to 
humans. Two dMAbs were selected to move into NHPs, PGDM1400 and PGT121, based 
on high in vivo dMAb levels in mice (Figure 4.1). Two groups of four macaques were dosed 
with either 6mg of PGDM1400 dMAb plasmid construct (Group 1) or 3mg of PGDM1400 
plus 3mg of PGT121 dMAb plasmid construct (Group 2). Expression of human IgG1 
(hIgG1) was detected in NHP serum as early as 3 days post-injection and peaked at Day 
14 (Figure 4.3A, Figure S4.5A and S4.6A). Total human IgG1 levels at peak were slightly 
higher for the group receiving PGDM1400 dMAb alone (Group 1) compared to the two 
dMAbs PGDM1400 and PGT121 (Group 2) (Figure 4.3B). The total hIgG1 detected in the 
serum from Group 1 ranged between 11.2 and 34.3µg/ml (mean 25.1µg/ml) and for Group 
2 between 6.3 and 20.4µg/ml (mean 10.1µg/ml).  The levels of human IgG1 dMAb in the 
sera declined after Day 14 to undetectable levels by Day 35, which is expected in this 
context where a xenogeneic human IgG was being expressed in an immune-competent 
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NHP host (Gardner et al., 2019b; Kuriakose et al., 2016; Martinez-Navio et al., 2016). 
Accordingly, the decrease in dMAb levels after Day 14 corresponded with the 
development of NHP anti-human IgG-dMAb antibodies in the sera (Figure S4.5B and 
S4.6B). Using envelope antigen and secondary antibodies specifically recognizing hIgG1 
kappa (PGDM1400) versus hIgG1 lambda (PGT121) light chains, we were able to confirm 
expression of both PGDM1400 and PGT121 dMAbs in Group 2 NHP sera (Figure 4.3C, 
S4.5C and S4.6C).   
We proceeded to determine the anti-viral activity of the sera harboring the anti-
HIV-1 dMAbs. Pre-bleed sera (Day 0 (D0)) and sera from the peak dMAb level time point 
(Day 14 (D14)) were tested for neutralization against the global panel tier-2 viruses. NHP 
sera contained no neutralizing antibodies before dMAb administration (D0) and no non-
specific neutralization was detected against mouse leukemia virus (MLV) on D0 and D14 
(Table 4.1). Sera collected at peak dMAb levels were able to neutralize 11 out of 12 viruses 
(Group 1) and 12 out of 12 viruses (Group 2) (Figure 4.3D and Table 4.1). For several 
viruses, specifically 243F6, 25710, CE0217, CNE55, and CNE8, titers (IC50) for both 
groups were less than 0.1µg/ml. These pseudotype neutralization titers, originally 
performed at The Wistar Institute, were then retested and confirmed at Duke University. 
Similar Group 1 and Group 2 NHP neutralization titers (IC50) were obtained across the 9 
HIV-1 pseudotype viruses re-evaluated (Figure S4.7A). Delivery of a second dMAb in 
Group 2 modestly improved neutralization for some isolates and added neutralization 
coverage for two additional viruses, 398F1 and TRO.11. We further explored the anti-viral 
activity by exploring the antibody-dependent cell-mediated cytotoxicity (ADCC) against a 
subtype C HIV-1 infectious molecular clone (IMC) DU151 infected cells, chosen based on 
the sensitivity to both mAbs. Though ADCC activity of the serum was usually only detected 
at concentration >4µg/mL, it was comparable to the recombinant protein monoclonal 
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antibody activity (Figure 4.3E). No ADCC activity was observed for the negative control 
recombinant Palivizumab antibody (Figure S4.7B).  In summary, the NHP data support 
that HIV-1 dMAbs expressed at high levels, bind to envelope trimers, neutralize numerous 
tier-2 viruses and have effector functions and can complement each other in vivo. 
4.4 Discussion 
Recently, the use of protein monoclonal antibodies has become a first-line 
treatment for numerous cancers, and similarly plays a major role in autoimmune disease 
therapies (Singh et al., 2018).  In general though, the adoption of MAb for infectious 
disease is very exciting but to date there have been limited approvals (Singh et al., 2018). 
Due to their exceptional breadth and potency, clinical trials are in progress to explore the 
ability of broadly neutralizing antibodies (bNAbs) against HIV-1 to both prevent and treat 
infection (Cohen and Caskey, 2018).  Additional strategies for delivery are likely important 
especially for providing these strategies in the developing world (Sparrow et al., 2017). In 
this manuscript, we describe a recently developed DNA-encoded monoclonal antibody 
(dMAb) platform for delivering bNAbs and provide the first proof of concept for this delivery 
targeting HIV-1.  
Through iterative studies, we describe dMAb delivery resulting in expression of 
multiple HIV-1 specific antibodies up to 80µg/ml in mice.  To date, in vitro expression of 
bNAbs from transfected cell lines does not correlate or predict in vivo levels when 
delivered via the dMAb platform (Patel et al., 2018a).  Interestingly, similar variations in 
dMAb levels across multiple different antibodies were observed with AAV-mediated gene 
delivery (Balazs et al., 2011; Gardner et al., 2019b; Welles et al., 2018). Even within the 
same class of antibodies which share the germline VH gene (IGHV1-2) usage, dMAb 
levels vary significantly between 1.3µg/ml (N6) and 52.2µg/ml (IOMA) (Figure 4.1A). 
Furthermore, we did not observe any correlation of in vivo levels and heavy chain CDR3 
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length, light chain usage or rate of somatic hypermutation. We demonstrate that 
modifications to the beginning and end of N6 variable regions of the heavy and light chains 
improved in vivo levels while maintaining the antibody’s activity (Figure S4.4). As we 
acquire more data on antibody sequences and dMAb expression, a better understanding 
of in vivo sequence liabilities will be obtained. As HIV-1 bNAbs are highly somatically 
mutated, and many of these mutations are required for maintaining the functionality of the 
antibody, balancing mutations made for increasing dMAb levels will need to be weighted 
with impacts on functionality. DNA encoded monoclonal antibodies are an important tool 
for these studies since DNA can be easily modified to encode different amino acids and 
the effects on both in vivo expression as well as functionality can be quickly and cost-
effectively explored. Furthermore, the monoclonal antibody sequence rules which dictate 
the in vivo expression of dMAbs delivered to muscle tissue could translate to other 
platforms such as AAV where muscle expression is also being tested.  
 We demonstrated the ability to encode two HIV-1 specific bNabs in NHPs using 
the dMAb technology. We observed dMAb expression in NHP sera within three days of 
dMAb administration and levels that peaks around Day 14. We believe these peak levels 
(ranging from 6 to 34µg/ml) would be protective against multiple SHIV strains upon 
challenge based upon prior studies which utilized recombinant monoclonal antibody 
protein (Gautam et al., 2018; Julg et al., 2017a; Julg et al., 2017b; Moldt et al., 2012; 
Shingai et al., 2014). Specifically, Julg et al. demonstrated that NHPs delivered passive 
infusions of 2 and 0.4mg/kg of PGDM1400 one day before challenge with SHIV-325c were 
protected from infection (Julg et al., 2017b). The average level of PGDM1400 in the serum 
at time of challenge was 6.9 and 2.5 µg/ml for 2 and 0.4mg/kg infusions respectively.  
There was breakthrough infection in the group delivered 0.08mg/kg which corresponded 
to a serum level of 0.22 µg/ml at time of challenge. Additionally, PGT121 has 
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demonstrated protection against SHIV-SF162P3 and SHIV-AD8EO at levels of 15 and 22 
µg/ml respectively with partial infection at serum levels of 1.8 µg/ml (Moldt et al., 2012; 
Shingai et al., 2014). In the context of treatment, NHPs chronically infected with SHIV-
SF162P3 and delivered a single infusion of 10mg/kg of PGT121 were able to control viral 
loads to undetectable levels (Barouch et al., 2013). Rebound occurred in 3 out of 4 animals 
once mAb serum concentrations reached undetectable (<1µg/ml) with one animal having 
long-term virologic control. While we are unaware of a prior study for the use of 
PGDM1400 in pre-clinical treatment setting, the peak levels of this antibody in the NHPs 
might be relevant in therapeutic settings especially considering that the mean 
concentration of 3BNC117 and 10-1074 were between 1.9 and 14.8 µg/ml at the time of 
viral rebound in the study by Mendoza et al (Mendoza et al., 2018).  However, additional 
testing of the ability of dMAbs, that are developed as species matched antibodies, to 
impact challenge outcomes or control of infection will be informative.   
There was a decline in human dMAb levels the NHP study observed after Day 14 
corresponds with the development of anti-drug antibodies (ADA) due to the expression of 
the xenogeneic protein. The development of ADA against a cross-species human IgG has 
also been observed in NHPs following AAV, recombinant protein (Kuriakose et al., 2016), 
as well as RNA (Pardi et al., 2017) and adenovirus delivery of antibodies in mice 
(Badamchi-Zadeh et al., 2018). In studies of AAV delivery of HIV-1/SIV bNAbs, induction 
of ADA was closely associated with the distance of the variable regions from germline 
(Martinez-Navio et al., 2016). Furthermore, AAV delivery of fully rhesus monoclonal 
antibodies against SIV led to a lower incidence of ADA responses in rhesus macaques 
(Welles et al., 2018). In mice, we eliminated host immune responses to human IgG1 dMAb 
via transient immunosuppression. Additionally, we have observed that using a species 
matched fully murine dMAb in mice can avoided significant ADA development and allowed 
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for dMAb detection in the serum of several months (Khoshnejad et al., 2019). However, 
we have not yet developed fully simian dMAbs and future studies will test this principle. 
Ultimately, human studies will be particularly informative. In this regard, recent monoclonal 
antibody delivery clinical trials include an AAV vector encoding HIV-1 bNAb VRC07 
(NCT03374202), the first dMAb construct for expression of antibody against Zika virus 
(NCT03831503), and an mRNA platform for delivery of anti-chikungunya virus antibody 
(NCT03829384) will be particularly valuable to provide additional information on this 
important question.  
Depending on the application of the monoclonal antibody, different effector 
functions and modifications in the antibody Fc domain may be required. Monoclonal 
antibodies used for HIV-1 prevention and treatment will likely benefit from longer in vivo 
half-lives. Amino acid mutations to the Fc, including YTE and LS, yield prolonged 
recombinant in vivo antibody half-lives in both preclinical NHP studies and in the clinic 
(Kontermann, 2009). We have previously demonstrated the feasibility of dMAbs to encode 
Fc modifications such as the LALA mutation to prevent antibody dependent enhancement 
(ADE) in dengue virus infection (Flingai et al., 2015). Furthermore, modifications to the Fc 
region of the antibody can increase ADCC activity which is important in HIV-1 protection 
and control of infection (Margolis et al., 2017). Inclusion of these modifications to increase 
activity of dMAb against infected cells is imperative for therapeutic cure approaches. 
Exploration of half-life extension and Fc activity modification for HIV-1 dMAbs is ongoing. 
Our data describe a new important technology for in vivo HIV-1 antibody delivery. 
We demonstrated that dMAb constructs can be developed to encode multiple HIV-1 
specific IgG1 and that the in vivo expressed dMAbs retain their functional activity in both 
small and large animals. The observation that in vivo produced dMAbs had similar HIV-1 
envelope trimer binding and neutralization capacity as recombinantly produced 
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counterparts highlights the effective folding of the dMAb antibody in this system. 
Furthermore, the ability to deliver multiple antibodies, in this case four at one time, to limit 
viral escape and resistance may be important for HIV-1 prevention and treatment 
strategies. To our knowledge, this is the most comprehensive screening of multiple HIV-1 
antibodies delivered by the same platform, demonstrating how inherent antibody 
characteristics influence in vivo production.  Additionally, through numerous optimization 
efforts aiming at both the DNA synthetic design and the delivery technology, we were able 
to consistently reach greater than 5µg/ml of antibody in NHPs, with some NHPs reaching 
serum levels of more than 30µg/ml. These levels represent a significant improvement 
compared to the original NHP dMAb studies, which achieved on average a tenth the in 
vivo production observed here (Esquivel et al., 2019). These studies demonstrate the 
possibility of dMAbs as an approach to delivery of monoclonal antibody specificities in a 
simple to produce, temperature stable, and rapid delivery format.  Further study of the 
dMAb platform for anti-HIV strategies appears important.  
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Figure 4. 1 In vivo expression of dMAb-encoded HIV-1 bNabs in mice.  
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(A) Peak dMAb expression levels (Day 14) of HIV-1 broadly neutralizing antibodies in the
sera of transiently immunodepleted mice. Groups of mice (n=5) were administered dMAb 
constructs expressing one of sixteen different bNAbs.  
(B) Binding curves for four dMAbs against HIV-1 trimer BG505_MD39. Serum dMAb levels
were normalized for expression (colored lines, n=5 mice) and compared to the similar 
purified recombinant protein (black line) over various concentrations.  
(C) Individual mouse IC50 (n=5) for four dMAbs across the 12 viruses global panel (blue
circles) vs values reported in the literature (red squares). Literature values gathered from 
Los Alamos CatNaber.   
(D) Mean (n=5) IC50 pseudotype neutralization of Day 14 mouse sera against the 12
viruses of the global panel, and MLV control. Value of 45 corresponds to no neutralization 
at a 1:45 dilution the lowest dilution tested of the mouse serum. All other values are in 
µg/ml. Horizontal bars indicate mean; error bars represent standard error of the mean. 
Expression levels are representative of two experimental replicates, binding and 
neutralization testing performed once.  
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Figure 4. 2 Delivery of multiple dMAb constructs in a single mouse maintains individual 
dMAb expression levels and increases serum neutralization breadth.  
(A) Groups of mice (n=5) were administered a single dMAb (PG121, PGT145,
PGDM1400, 3BNC117 or 10-1074), or a combination of two dMAbs (PGT121 + PGT145, 
PGDM1400 + PGT121, 3BNC117+10-1074). Peak serum expression levels of human IgG 
were quantified by ELISA.  
(B) Mean (n=5) IC50 pseudotype neutralization against the 12 viruses of the global panel,
and MLV control, of sera collected at Day 14 from mice administered a single or two 
dMAbs. Value of 45 corresponds to no neutralization at a 1:45 dilution the lowest dilution 
tested of the mouse serum. All other values are in µg/ml.  
(C) Total human IgG serum expression levels following administration of individual dMAbs
(PGDM1400, PGT151, VRC01, and PGT121) and co-administration of all four dMAbs 
(combo) in mice (n=5).  
(D) Mean (n=5) IC50 pseudotype neutralization against the 12 viruses of the global panel,
and MLV, for sera collected from mice administered individual dMAbs and combination of 
the four dMAbs. Horizontal bars indicate mean, error bars represent standard error of the 
mean. Expression levels are representative of two experimental replicates, binding and 
neutralization testing performed once. 
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Figure 4. 3 PGDM1400 and PGT121 express as dMAbs in NHPs. 
Immune competent macaques were injected with human IgG1 (hIgG1) dMAb constructs 
(Day 0) and serially bled. Group 1 animals (n=4) received 6mg of PGDM1400-encoding 
plasmid DNA; Group 2 animals (n=4) received 3mg of PGDM1400 and 3mg of PGT121 
plasmid DNA.  
(A) Quantification of hIgG1 in the sera of Group 1 and Group 2 NHPs over time.
(B) Peak expression levels of total hIgG1 for each group at Day 14.
(C) Serum binding curves against HIV-1 Env trimer, BG505_MD39, using different
secondary antibodies to establish the binding of PGDM1400 (human IgG1 kappa light 
chain, blue), and PGT121 (human IgG1 lambda light chain, green).  
(D) Neutralization IC50 of serum across the 12-virus global pseudotype panel using serum
from peak dMAb expression (Day 14). 
(E) Baseline subtracted ADCC killing activity of serum for infectious molecular clone
DU151 compared to recombinant monoclonal antibodies PGDM1400 and PGT121. 
Horizontal bars indicate mean; error bars represent standard error of the mean. 
Expression levels and neutralization titers representative of two replications, all other test 
performed once. Two-tailed student t-test performed to determine significant difference in 
levels of expression between group 1 vs group 2. P < 0.05 was considered significant.  
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Table 4. 1 Neutralization ID50 of dMAb treated NHP serum across the global panel. 
ID50 neutralization titers for heat inactivated serum from Day 0 and Day 14 for NHP 
administered dMAb PGDM1400 (group 1) or PGDM1400 and PGT121 (group 2) across 
the global panel of pseudotype HIV-1 envelopes and non-specific MLV control. 
89
90
Supplemental Figure 4. 1 In vitro expression of various HIV-1 specific dMAbs. HEK293T 
cells were transiently transfected with plasmid dMAb constructs expressing 16 HIV-1 
antibodies. 
Quantification of human IgG expression in cell lysate (A) and supernatant (media) (B) 
using two technical replicates but representative of two experimental replicates.  
(C) Example Western blot of two dMAbs, 3BNC117 and PGT128, in the media of
transfected cells demonstrating expression of both the heavy and light chain. Lanes 1 and 
2 for each dMAb were biological replicates.  
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Supplemental Figure 4. 2 Time course expression of the CD4bs, Apex, HMG and 
Interface dMAbs in mice.   
Groups of mice (n=5) were transiently immunodepleted and delivered various dMAbs. 
Expression of dMAbs in the serum was followed over time for the CD4bs (A), apex and 
interface (B) and high mannose glycan (C) dMAbs as well as for naïve mice. Dots 
represent mean expression with bars displaying the standard error of the mean. 
Representative of two experimental replicates. 
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Supplemental Figure 4. 3 Functionality of HIV-1 bNabs dMAbs produced in vivo. 
(A) Binding curves of recombinant (black) and in vivo produced dMAbs (mice, Day 14,
colors, n= 5) against HIV-1 Env trimer (BG505_MD39). No trimer binding was detected 
using naïve mouse serum using the two secondary antibodies.  
(B) Individual mouse IC50 across the 12-virus global panel (blue circles) vs values reported
in the literature (red squares). Literature values gathered from Los Alamos CatNaber. 
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Supplemental Figure 4. 4 Amino acid sequence modifications to HIV-1 broadly 
neutralizing antibody N6 improve dMAb expression in vivo without compromising N6 
binding or function.  
(A) Modifications to the beginning and end of the heavy and light chain amino acid
sequence of human IgG1 monoclonal antibody N6 were produced. These modifications 
were selected to make the antibody sequence more similar to the human germline.  
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(B) Groups of mice (n=5) were transiently immunodepleted and injected with plasmid DNA
expressing original N6, heavy chain (HC) modified + light chain (LC) original (HCmod), HC 
original + LC modified (LCmod) or both HC and LC modified (N6mod). Expression levels of 
serum dMAb was determined on Day 14.  
(C) Serum binding of N6mod (green, triangle) to HIV-1 envelope trimer BG505_MD39 were
compared to binding of purified monoclonal N6 original (black, circle). 
(D) Neutralization IC50 (µg/mL) of recombinant N6 original vs N6mod against HIV-1
envelope pseudotype viruses representing 10 of the global panel in a TZM-bl assay. 
Reported values gather from Los Alamos CatNap.  
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Supplemental Figure 4. 5 Individual expression of human IgG1 and ADA development 
in group 1 dMAb administered NHPs.   
NHPs were injected on D0 with dMAb expressing PGDM1400 only. (A) Expression 
kinetics of human IgG1 in NHP serum for each of the four NHPs.  
(B) Expression of human IgG (left y-axis) vs ADA (right y-axis) against PGDM1400 (which
was administered as dMAb) and PGT121 (which was not administered to group 1) over 
time. Expression and ADA levels representative of two replications.  
(C) Serum binding curves against HIV-1 Env trimer, BG505_MD39, using different
secondary antibodies to establish the binding of PGDM1400 (human IgG1 kappa light 
chain, blue), and PGT121 (human IgG1 lambda light chain, green) for Day 0 pre-bleed 
serum. 
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Supplemental Figure 4. 6 Individual expression of human IgG1 and ADA development 
in group 2 dMAb administered NHPs.   
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NHPs were injected on D0 with dMAbs expressing PGDM1400 and PGT121.  
(A) Expression kinetics of human IgG1 in NHP serum for each of the four NHPs.  
(B) Expression of human IgG (left y-axis) vs ADA (right y-axis) against PGDM1400 (dMAb 
administered) and PGT121 (dMAb administered) over time. Expression and ADA levels 
representative of two replications.  
(C) Serum binding curves against HIV-1 Env trimer, BG505_MD39, using different 
secondary antibodies to establish the binding of PGDM1400 (human IgG1 kappa light 




Supplemental Figure 4. 7 Similar neutralization titers (IC50) for groups 1 and 2 of NHP 
dMAb study between in-house and collaborator assays and ADCC controls.  
(A) To validate neutralization titers observed at Wistar, serum collected from NHPs at
Days 0 and 14 were sent to Dr. Montefiori’s group at Duke to cross-validate data collected 
at Wistar. There was no significant difference between the IC50 titers determine between 
the two groups for all nine viruses selected from the global panel. A modified ANOVA with 
post-hoc Tukey test was performed to determine significant difference in titers between 
the two labs. P < 0.05 was considered significant.  
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(B) The RSV-specific monoclonal antibody, Palivizumab, was used as a negative control
and a mixture of A32, CH44, 2G12, and 7B2 monoclonal antibodies were used as positive 
controls for the ADCC assay. 
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Supplemental Table 4. 1 GenBank accession numbers used for the basis of HIV-1 
dMAbs. 
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CHAPTER 5 Harnessing synthetic DNA and protein engineering for direct in vivo 
assembly of nanoparticle vaccines for enhanced immune responses 
Xu, Z., Wise, M.C., Chokkalingam, N., Walker, S., Tello-Ruiz, E., Elliott, S.T.C., Perales-
Puchalt, A., Xiao, P., Zhu, X.Z., Pumroy, R.A., et al. (2020). In Vivo Assembly of 
Nanoparticles Achieved through Synergy of Structure-Based Protein Engineering and 




Nanotechnologies are considered to be of growing importance to the vaccine field. 
Through decoration of immunogens on multivalent nanoparticles, designed nano-vaccines 
can elicit improved humoral immunity. However, significant practical and monetary 
challenges in large-scale production of nano-vaccines have impeded their widespread 
clinical translation. Here, we illustrate an alternative approach integrating computational 
protein modeling and adaptive electroporation mediated synthetic DNA delivery thus 
enabling direct in vivo production of nano-vaccines. We demonstrated DNA-launched 
nanoparticles displaying an HIV immunogen spontaneously self-assembled in vivo. DNA-
launched nano-vaccines induced stronger humoral responses than their monomeric 
counterparts in both mice and guinea pigs, and uniquely elicited CD8+ effector T-cell 
immunity as compared to recombinant protein nano-vaccines. Improvements in vaccine 
responses were recapitulated when DNA-launched nano-vaccines with alternative 
scaffolds and decorated antigen were designed and evaluated. Finally, evaluation of 
functional immune responses induced by DLnano-vaccines demonstrated that, in 
comparison to control mice or mice immunized with DNA-encoded hemagglutinin 
monomer, mice immunized with a DNA-launched hemagglutinin nanoparticle vaccine fully 
survived a lethal influenza challenge, and had substantially lower viral load, weight loss 
and influenza-induced lung pathology. Additional study of these next-generation in vivo 
produced nano-vaccines may offer advantages for immunization against multiple disease 
targets. 
5.2 Introduction 
Vaccination is an extremely important public health measure that has 
demonstrated prophylactic and therapeutic utility against many infectious diseases(Gao 
et al., 2018; Lambert and Fauci, 2010; Plotkin, 2014), and impacted some forms of 
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cancer(Trimble et al., 2015). In the past decade, advances in material engineering has 
allowed for the development and study of a new generation of nanoparticle vaccines(Al-
Halifa et al., 2019; Gregory et al., 2013; Zhao et al., 2014). Hepatitis B and human 
papillomavirus (HPV) vaccines are such examples of self-assembling virus-like particles 
which have impacted millions of people (Harper and DeMars, 2017; Szmuness et al., 
1980). Nanoparticles may come in several shapes and forms. Inorganic materials(Cheng 
et al., 2012; Stone et al., 2013), nontoxic phospholipids(Giddam et al., 2012), virus-like 
particles (VLPs) or self-assembling protein nanoparticles (SAPN) (Fuenmayor et al., 2017; 
Kaba et al., 2018; Marcandalli et al., 2019; Xu and Kulp, 2019) can all scaffold and present 
antigens in repetitive multimeric manners to robustly stimulate immunity in animal 
models(Chattopadhyay et al., 2017; Marcandalli et al., 2019; Sliepen et al., 2015).  
However, some intrinsic production challenges have impeded broader translation 
of nano-vaccines into the clinical space(Desai, 2012; Feng et al., 2019). VLP vaccines are 
often produced at low yields in mammalian cell lines and are difficult to purify, requiring 
complex reassembly processes and additional post-hoc characterization(Fuenmayor et 
al., 2017; Lua et al., 2014; Urakami et al., 2017). Production of HPV VLPs, for example, 
requires three sequential purification steps of strong cation exchange chromatography, 
size-exclusion chromatography, and hydroxyapatite chromatography(Jiang et al., 2011). 
Large-scale production of liposome-based nano-vaccines is challenging, as slight 
variations in the methods of production result in heterogeneity of the liposomes 
produced(Desai, 2012). Production of nano-vaccines for a global market could therefore 
require specialized pipelines which raise costs. In addition, regulatory approval of drugs 
for use in humans can be complex for development of multicomponent nano-medicines 
(Eifler and Thaxton, 2011). Technologies that would allow de novo nanoparticle 
assemblies in the hosts from materials that are inexpensive, simple and stable, which 
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bypass these complex biochemical processes and downstream purifications, may be of 
interest. 
In this regard, computational protein engineering is an extremely powerful tool and 
has facilitated the design of novel biologics(Graham et al., 2019) as well as specific potent 
nano-vaccines(Tokatlian et al., 2019; Xu and Kulp, 2019). One such example is the eOD-
GT8-60mer, which is a priming immunogen engineered to activate precursors of HIV-1 
broadly neutralizing antibodies(Jardine et al., 2016; Jardine et al., 2015; Sok et al., 2016). 
When scaffolded with the C-terminus of the lumazine synthase (LS) enzyme from Aquifex 
Aeolicus, eOD-GT8 can assemble into a 60-mer nanoparticle to induce stronger humoral 
immunity and higher frequencies of antigen-specific IgG+ memory B cells(Jardine et al., 
2015). In terms of vaccine delivery, DNA vaccines have been studied for induction of 
humoral and cellular immunity (Davis et al., 2001; Dowd et al., 2016; Wang et al., 1993). 
Additionally, delivery of optimized DNA plasmids encoding monomeric immunogens via 
adaptively-controlled electroporation (EP) (Sardesai and Weiner, 2011) can result in 1000-
fold enhancement of in vivo expression and longer-term in vivo production of the encoded 
antigens (Khoshnejad et al., 2019; Wise et al., 2019; Xu et al., 2018). The newer DNA 
platform is also a robust method of eliciting adaptive immune responses in humans, having 
demonstrated immune potency in the clinic against such diseases as ZIKA, Ebola, HIV, 
MERS and clinical efficacy against HPV-driven cervical dysplasia (Kalams et al., 2013; 
Modjarrad et al., 2019; Tebas et al., 2019; Tebas et al., 2017; Trimble et al., 2015).   
While simple multimerization domains, such as heptamer domain IMX313P, have 
been employed to improve DNA vaccine responses (Brod et al., 2018; Tomusange et al., 
2016), we explored and expanded upon this concept focusing on induction of both B- and 
T-cell responses to large computationally designed nanoparticles (24, 60, and 180-mers) 
decorated with a variety of antigens. eOD-GT8-60mer is currently being clinically 
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evaluated as a recombinant protein vaccine , and was examined as a prototype for DNA 
delivery. We discovered that the DNA-Launched nanoparticle Lumazine Synthase 
decorated with an anti-HIV-1 immunogen eOD-GT8 (eOD-GT8-60mer in the literature 
(Jardine et al., 2016), herein referred as  DLnano_LS_GT8) could assemble in vivo into 
nanoparticles. DLnano_LS_GT8 induced stronger humoral responses than corresponding 
DNA-launched monomeric GT8 (DLmono_GT8) both in mice and guinea pigs, and also 
uniquely elicited CD8+ T-cell immunity unlike the corresponding protein nano-vaccines. 
We computationally designed alternative nanoparticle scaffolds and utilized different 
immunogens to evaluate this approach more broadly. Consistent improvements in the 
induction of adaptive immune responses were observed across multiple constructs, which 
was further shown to confer significant benefits in protecting mice from lethal influenza 
challenge. Synthetic DNA/EP technology can, therefore, be used to direct in vivo assembly 
of computationally designed nano-vaccines, which elicit more potent functional 
immunological responses. This combination is likely important for rapid development of 
vaccines and immunotherapies. 
5.3 Results  
5.3.1 DNA-launched GT8 nanoparticles expressed and assembled in vitro and in vivo 
To determine whether DNA/EP could be used to launch structurally designed, self-
assembling protein nanoparticles in vivo, we encoded the transgene eOD-GT8-60mer in 
the pVAX1 vector and optimized the DNA cassette for in vivo nanoparticle expression 
(Figure 5.1a). We first evaluated expression, secretion and assembly of plasmid encoded 
GT8 constructs in vitro. We engineered the GT8 constructs to incorporate an optimized 
human IgE-leader sequence(Xu et al., 2018) and found the in vitro intracellular expression 
of this construct to be strongly enhanced as compared to GT8 constructs without any 
leader sequence (Supplemental Figure 5.1a). We therefore used the IgE- constructs for 
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subsequent experiments. In addition, reducing SDS-PAGE analysis of transfection 
supernatants supported that both plasmid-encoded GT8-monomer and eOD-GT8-60mer 
could be secreted (Supplemental Figure 5.1b). Lectin-purified protein eOD-GT8-60mer 
eluted as a homogenous fraction by size-exclusion chromatography (SEC) (Supplemental 
Figure 5.1c). The assembled protein was observed to be approximately 2 MDa as 
determined by protein conjugate analysis with size-exclusion multiangle light scattering, 
SEC-MALS (Figure 5.1b). Negative stain electron microscopy (nsEM) also supported 
correct assembly of protein eOD-GT8-60mer with a diameter of around 32nm (Figure 
5.1c).  
Next, we examined the in vivo expression of both DNA-encoded GT8 monomer 
and nanoparticle constructs. Immunofluorescent staining of mouse muscles transfected 
with DNA/EP four days post injection (d.p.i) with VRC01 (a human broadly neutralizing 
antibody with high-affinity for GT8) showed that both DNA-encoded GT8 constructs 
expressed in vivo (Figure 5.1d). Reducing SDS-PAGE western analyses of muscle 
homogenates four d.p.i with VRC01 (in green) also confirmed in vivo expression of GT8 
antigens, even though in vivo expression of DLnano_LS_GT8 was stronger and more 
consistent than DLmono_GT8 (Figure 5.1e). The assembly states of in vivo produced 
DLnano_LS_GT8 as compared to DLmono_GT8 in mouse muscle homogenates was 
examined with pseudo-native PAGE. Well-formed 60mer GT8-nanoparticles, as defined 
by the migration pattern of SEC-purified recombinant protein eOD-GT8-60mer standard 
(STD 60mer on gel), was observed only in DLnano_LS_GT8 treated but not in 
DLmono_GT8 treated mice (Figure 5.1f). Minor bands that corresponded to monomeric 
and oligomeric GT8 band were also observed in DLnano_LS_GT8 muscle homogenates 
but were significantly less intense than the 60-mer band, and may represent newly 
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synthesized GT8-subunits or partially assembled GT8-oligomer transiting through cellular 
secretory networks.  
Next, we used a mannose binding lectin (MBL) labelling experiment to assess for 
in vivo antigen multimerization and nanoparticle assembly. MBL is a protein that can form 
hexamer and preferentially bind to highly repeated glycan structures on a 
pathogen/antigen surface(Abbink et al., 2016). A recent study by Tokatilian et al. 
demonstrated that only highly multimerized glycan structures (eOD-GT8-60mer but not 
eOD-GT8-monomer) could bind to MBL(Tokatlian et al., 2019). In our study, we similarly 
showed using ELISA that while VRC01 could bind to both protein GT8-60mer and GT8-
monomer, murine MBL could only bind to protein GT8-60mer (Supplemental Figure 5.1d 
and 5.1e). Using this assay as a multimerization readout, we demonstrated that in vivo 
produced DLnano_LS_GT8, but not DLmono_GT8 could bind to MBL (Supplemental 
Figure 5.1f and 5.1g). Further, we observed that DLnano_LS_GT8 could be strongly 
labelled by endogenous murine MBL via an immune-histochemistry experiment (Figure 
5.1g). 
As an additional way to assess in vivo nanoparticle formation, we employed a 
transmission electron microscopy-based technique, where thin sections of transfected 
muscles were stained with VRC01 and gold-conjugated anti-human IgG. Clusters of gold-
labelled macromolecules suggestive of in vivo launched nanoparticles decorated with 
multiple copies of GT8 were only observed in mice injected with DLnano_LS_GT8 but not 
with DLmono_GT8 (Figure 5.1h and Supplemental Figure 5.1h). In DLnano_LS_GT8 
immunized mice, these clusters often had a valency greater than 10 (Figure 5.1i). We 
expected some reduction in labelling valency due to both steric hindrance in binding of 
VRC01 to individual GT8 subunits and limited solvent exposure on nanoparticle surfaces 
with thin sample sectioning. Quantitative measurements of the orders of clusters in 
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different fields of interests demonstrated that partially formed (orders between 5 and 8) 
and well-formed (orders no less than 9) nanoparticles were significantly more frequent in 
mice treated with DLnano_LS_GT8 than with DLmono_GT8, confirming in vivo assembly 
of these complex nano-vaccines (Supplemental Figure 5.1i). 
5.3.2 DLnano_LS_GT8 elicited more rapid seroconversion and higher setpoint antibody 
titers than DLmono_GT8 and similar titers to protein eOD-GT8-60mer 
Using immunofluorescence staining with VRC01 (green), we determined that 
DLnano_LS_GT8 trafficked more efficiently to the draining lymph node and co-localized 
with the CD35+ follicular dendritic cells (in blue) in contrast with the DLmono_GT8 seven 
d.p.i. (Figure 5.2a). This observation is consistent with recent findings on trafficking of
recombinant protein nanoparticle vaccines(Tokatlian et al., 2019). To determine whether 
improved immunogen trafficking correlated with enhanced adaptive immunity, we followed 
humoral responses in immunized BALB/c mice. After seven d.p.i, we found that 
DLnano_LS_GT8 induced more rapid GT8-directed seroconversion than DLmono_GT8 
(Figure 5.2b). Decoration of the GT8-antigens on the LS nanoparticle core is essential for 
the observed early response as co-transfection of mice muscles with 1:1 ratio of 
DLmono_GT8 and DNA-encoded lumazine synthase core (DLnano_LS_core) did not lead 
to seroconversion at this timepoint (Supplemental Figure 5.2a). We next examined if GT8 
scaffolded with a simpler multimerization domain, IMX313P, would perform similarly. 
Heptameric DNA-encoded GT8-IMX313P (DL_GT8_IMX313P) led to limited 
seroconversion at seven d.p.i, but the induced antibody titer was 6.9-fold lower than that 
of DLnano_LS_GT8 (Supplemental Figure 5.2b). Antigen-specific circulating IgMs can 
play a role in protection from challenge(Bohannon et al., 2016). Here, we measured 
induced IgM responses and found that DLnano_LS_GT8 induced stronger IgM responses 
than DLmono_GT8 with two immunizations (Supplemental Figure 5.2c). Further, the IgG 
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titers were 1.3-log and 1.8-log higher for DLnano_LS_GT8 with single immunization 
(Supplemental Figure 5.2d) or two immunizations (Figure 5.2c) respectively. Consistent 
with this observation, we found the frequency of CD19+IgD-IgM-IgG+ GT8 antigen-
specific B cells in the spleens of mice immunized with DLnano_LS_GT8 to be 5.3-fold 
higher relative to mice immunized with DLmono_GT8 (Figure 5.2d), even though relatively 
few CD19+IgD-IgM-IgG+GT8-24mer+GT8-tetramer+ B cells have been recovered per 
million splenocytes analyzed (Supplemental Figure 5.2e). DLnano_LS_GT8 retained 
folding and presentation of a key conformational epitope in vivo, as elicited murine 
antibodies could outcompete VRC01 binding to GT8 in competition ELISA (Supplemental 
Figure 5.2f and Figure 5.2e). A striking dose-sparing effect was observed for 
DLnano_LS_GT8. While humoral responses were remarkably attenuated for 
DLmono_GT8 at 2 and 10ug doses (Supplemental Figure 5.2g), DLnano_LS_GT8 given 
at 2, 10 or 25ug doses all induced similar levels of antibody responses (Supplemental 
Figure 5.2h). Importantly, differences in antibody responses induced by DLnano_LS_GT8 
and DLmono_GT8 were probably not solely due to increased antigen expression for 
DLnano_LS_GT8 (Figure 5.1e), as DLnano_LS_GT8 still outperformed DLmono_GT8 at 
less than one tenth of the monomer dose (Figure 5.2f). 
The ability of DLnano_LS_GT8 to improve humoral responses was observed in 
other animal models. Strikingly, two immunizations in C57BL/6 mice of DLmono_GT8 
failed to induce seroconversion, while DLnano_LS_GT8 induced strong humoral 
responses (Supplemental Figure 5.2i). In genetically diverse CD1 mice, we also observed 
more rapid seroconversion and more robust responses for DLnano_LS_GT8 
(Supplemental Figure 5.2j). Additionally, we observed DLnano_LS_GT8 significantly 
improved humoral responses in both female (Figure 5.2c) and male (Figure 5.2g) BALB/c 
mice relative to DLmono_GT8. Finally, in guinea pigs, a single 50ug intradermal 
112
vaccination of DLnano_LS_GT8 remarkably induced seroconversion seven d.p.i and 1.2-
log higher antibody titers than DLmono_GT8 over time (Figure 5.2h). We proceeded with 
studies of intradermal (ID) vaccination in guinea pigs as ID delivery has additional 
advantages of simplicity, improved tolerability, and being dose sparing (Modjarrad et al., 
2019; Tebas et al., 2019). 
We next compared the antibody responses induced by protein eOD-GT8-60mer 
and DLnano_LS_GT8. Protein eOD-GT8-60mer was subcutaneously administered in 
mice to be consistent with prior studies involving administration of this immunogen to 
mice(Jardine et al., 2015; Sok et al., 2016); further, a relative high protein dose of 10ug 
was used in this study as compared to prior study for protein versus DNA 
comparison(Tokatlian et al., 2019). We observed that two sequential immunizations of 
protein eOD-GT8-60mer co-formulated with Sigma Adjuvant System or DLnano_LS_GT8 
in C57BL/6 mice induced similar humoral responses (Figure 5.2i). It has been recently 
reported that uptake and trafficking of protein-based nanoparticles are dependent on the 
mannose binding lectin (MBL) complement pathway (Selander et al., 2006; Tokatlian et 
al., 2019). We explored if DNA-launched nanoparticles depended on a similar mechanism. 
Similar to previous reports (Tokatlian et al., 2019), humoral responses elicited by protein-
based GT8 nanoparticles in transgenic MBL and CR2 knockout mice were attenuated as 
compared to in the wildtype C57BL/6 mice seven d.p.i (Figure 5.2j). Strikingly, similar 
humoral responses were induced in the MBL or CR2 knockout mice as compared to the 
wildtype C57BL/6 mice by DLnano_LS_GT8 (Figure 5.2j), highlighting DLnano 
immunogens may act independently of MBL-complement pathway, potentially through 
redundant mechanisms of antigen presentation. 
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5.3.3 DLnano_LS_GT8 elicited superior cellular responses than DLmono_GT8 and 
uniquely induced CD8+ T-cell responses relative to protein eOD-GT8-60mer 
We next examined the induction of antigen-specific cellular responses by DNA 
nano-vaccines. DLnano_LS_GT8 elicited significantly stronger antigen (GT8)-specific 
cellular responses than DLmono_GT8 in BALB/c mice as determined by IFNγ-ELIspot 
assays (Figure 5.3a). Intracellular cytokine staining (ICS) revealed that the scaffolding LS 
domain drove pre-dominantly CD4+ responses, since a higher proportion of effector 
memory CD3+CD4+CD44+CD62L- T-cells produced IFNγ, TNFα and IL-2 when 
stimulated by the LS peptides than by GT8 peptides (Figure 5.3b and Supplemental Figure 
5.3a and 5.3b). In contrast, we found that effector memory CD3+CD8+CD44+CD62L- T 
cells induced by DLnano_LS_GT8 were more reactive to the GT8 domain than to the LS 
domain. DLnano_LS_GT8 induced more antigen-specific effector memory CD8+ T-cells 
that expressed activation cytokines IFNγ and exhibited effector phenotypes (CD107a+) 
than DLmono_GT8 in BALB/c mice (Figure 5.3c through 5.3e).  
In C57BL/6 mice, we also found that DLnano_LS_GT8 elicited strong T-cell 
responses to the full immunogen. Both CD4+ and CD8+ responses were predominantly 
to the LS domain, possibly due to the lack of CD8+ T-cell epitope in the GT8 domain for 
this inbred strain (Supplemental Figure 5.3c through 5.3e). To determine the ability of 
DLnano_LS_GT8 to elicit T-cell responses to the antigenic domain in a model with more 
diverse HLA haplotypes, we used the outbred CD1 mice and found that DLnano_LS_GT8 
induced stronger CD4+ and CD8+ effector memory T-cell responses to the GT8 domain 
than DLmono_GT8 (Supplemental Figure 5.3f through 5.3h). In all mice strains studied, 
we observed DLnano_LS_GT8 elicited significantly higher frequencies of effector memory 
CD8+ T-cells than could DLmono_GT8 (Figure 5.3f and Supplemental Figure 5.3i). 
Additionally, DLnano_LS_GT8 was observed to induce stronger CD8+ T-cell responses 
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to the GT8 domain in both female (Figure 5.3d) and male (Supplemental Figure 5.3j) 
BALB/c mice.   
In comparison to protein eOD-GT8-60mer, we observed two immunizations of 
DLnano_LS_GT8 induced 2.2-fold higher T-cell responses by IFNγ-ELIspot assay (Figure 
5.3g). In addition, ICS revealed that while both protein and DNA-encoded GT8-
nanoparticles induced CD4+ responses (Supplemental Figure 5.3k), only DNA-launched 
but not protein-based nanoparticles elicited potent CD8+ T-cell responses (Figure 5.3h 
and Supplemental Figure 5.3l). Recombinant protein nanoparticle failed to induce CD8+ 
T-cell responses in both WT and transgenic MBL and CR2 knockout mice; whereas
DLnano_LS_GT8 induced robust CD8+ T-cell responses in these strains (Figure 5.3i), 
confirming our prior observations that DLnano-vaccines may act independently of the 
MBL-complement pathway. 
5.3.4 Designed DNA-launched GT8-nanoparticles with alternative scaffolds analogously 
induced improved adaptive immune responses 
To ensure that the observed phenomena were not limited to lumazine synthase 
scaffolded nanoparticles, we computationally designed additional GT8 nanoparticles. 
Using the crystal structures of ferritin from Helicobacter pylori (3BVE, a 24-mer), and PfV 
viral cage from Pyrococcus furiosus(2e0z, a 180-mer), we modeled GT8 at various 
geometries relative to the particle surface and designed appropriate flexible linkers. 3BVE-
GT8 homogeneously assembled into spherical nanoparticles by nsEM (Supplemental 
Figure 5.4a and Figure 5.4a). For PfV_GT8, we observed mixed species, but the 
predominant peak at 9.14mL retention time, which accounted for approximately 60% of 
overall intensity, corresponded to torus shaped nanoparticle by nsEM (Supplemental 
Figure 5.4b and Figure 5.4b). To demonstrate decoration of the designed nanoparticles 
with GT8, recombinantly produced protein 3BVE_GT8, eOD-GT8-60mer and PfV_GT8 
115
were all tested and observed to bind to VRC01 (Supplemental Figure 5.4c). 
Immunofluorescence demonstrated that both DLnano_3BVE_GT8 and DLnano_PfV_GT8 
expressed in vivo four d.p.i (Figure 5.4c), even though in vivo expression of 
DLnano_PfV_GT8 was found to be stronger on average than DLnano_3BVE_GT8 by 
SDS-PAGE analysis (Figure 5.4d). Functionally, BALB/c mice immunized with 
DLnano_3BVE_GT8, DLnano_LS_GT8 and DLnano_PfV_GT8 all rapidly sero-converted 
seven d.p.i and mounted stronger antibody responses over the five-week period than mice 
immunized with DLmono_GT8 (Figure 5.4e). In addition, BALB/c mice immunized with two 
doses of DLnano_3BVE_GT8, DLnano_LS_GT8 and DLnano_PfV_GT8 all developed 
stronger CD8+ effector memory T-cell responses to the antigenic GT8 domain than those 
immunized with DLmono_GT8 by IFNγ ELIspot and ICS assays (Figure 5.4f, 
Supplemental Figure 5.4d and 5.4e).  
Valency of nanoparticles was found to be relevant to the dose-sparing 
phenomenon observed (Figure 5.2f). At low DNA dose of 2ug, we found that 24, 60 and 
180-meric DNA-launched GT8 nanoparticle vaccines but not heptameric
DL_GT8_IMX313P was capable of inducing seroconversion in BALB/c mice at 7 d.p.i 
(Figure 5.4g). In terms of cellular immunity at this dose, we found that only 60- and 180-
meric but not hepta- and 24-meric DNA-launched GT8 nano-vaccines were capable of 
inducing improvement in CD8+ T-cell immunity relative to DLmono_GT8 (Figure 5.4h). 
Overall, we observed that the aforementioned nanoparticle domains can be designed to 
display antigens like GT8 to elicit rapid and strong adaptive immune responses. 
5.3.5 Designed DNA-launched hemagglutinin nano-vaccine induced improved functional 
antibody responses and stronger CD8+ T-cell immunity 
To determine if these findings could be applied to an immunogen relevant to a 
different infectious disease, we computationally designed a LS nanoparticle to display the 
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receptor binding domain of the head of influenza hemagglutinin (LS_HA_NC99) based on 
the H1N1 strain A/New Caledonia/20/1999 and confirmed its assembly into homogenous 
60-mer by both SEC, SEC-MAL and nsEM (Supplemental Figure 5.5a, Figure 5.5a and 
5.5b). A dose-sparing phenomenon was observed for DLnano_LS_HA_NC99, as at a 
remarkably low plasmid vaccine dose of 1ug, DLnano_LS_HA_NC99 induced significantly 
stronger humoral responses in BALB/c mice than DLmono_HA_NC99 (Figure 5.5c). 
Hemagglutinin inhibition titers (HAI) against the autologous NC99 strain were found to be 
higher than 1:40 (which correlated with 50% reduction in the risk of infections in 
humans(Benoit et al., 2015)) in 100% of mice immunized with two doses of 
DLnano_LS_GT8 and 0% in mice immunized with two doses of DLmono_HA_NC99 
(Figure 5.5d). At the final timepoint (56 d.p.i) after three immunizations, both the 
DLmono_HA_NC99 and DLnano_LS_HA_NC99 groups developed binding and HAI 
antibodies to the heterologous H1N1 influenza A/Solomon Island/3/06 strain 
(Supplemental Figure 5.5b and Figure 5.5e), and both the binding and HAI titers were still 
significantly higher for the DLnano_LS_HA_NC99 group. HAI of a more distant H1 strain, 
A/California/07/2009, was not detected in either group. 
Additionally, in terms of elicited cellular responses, two immunizations of 
DLnano_LS_HA_NC99 induced 8.4-fold higher effector memory CD8+ T-cell responses 
than DLmono_HA_NC99 at 10ug dose in terms of CD107a and IFNγ expression, similar 
to our prior findings (Figure 5.5f, Supplemental Figure 5.5c and 5.5d). 
Finally, we examined if homogenous in vitro assembly of the designed DLnano-
vaccine was a pre-requisite to its enhanced potency. To this end, we studied the in vivo 
properties of a poorly folded nanoparticle. We used an alternative lumazine synthase 
scaffolded influenza construct, DNA-encoded LS_HA_CA09, based on the 
A/California/07/2009 strain which did not pass our biophysical filters, as in vitro expression 
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of the construct showed 3+ peaks with the two largest peaks consisting of aggregates or 
smaller unassembled protein by SEC (Supplemental Figure 5.5e). We found DNA-
encoded LS_HA_CA09 could not induce the characteristic early sero-conversion in 
BALB/c mice (Supplemental Figure 5.5f). Even when the immunized mice were followed 
over time, the antibody responses induced by DNA-encoded LS_HA_CA09 still lagged 
behind those by DLnano_LS_HA_NC99, highlighting downstream success of DLnano-
vaccine predicated upon preliminary computational design and biophysical 
characterization. 
5.3.6 DNA-launched hemagglutinin nano-vaccine conferred improved protection to lethal 
pandemic influenza H1 A/California/07/09 challenge in mice 
To further evaluate the induction of functional immune responses by DLnano-
vaccines, we utilized a lethal influenza challenge model in mice. We constructed a ferritin-
scaffolded receptor binding domain of hemagglutinin from H1/California/07/09 strain, 
DLnano_3BVE_HA_CA09, that was leader sequence, codon and mRNA-optimized as 
compared to a previously reported construct(Kanekiyo et al., 2019). We first confirmed its 
in vitro assembly into nanoparticles by SEC and nsEM (Supplemental Figure 5.6a and 
5.6b). We then immunized three groups of mice twice with minimal doses (1ug) of DNA 
encoding either DLmono_HA_CA09, DLnano_3BVE_HA_CA09 or control backbone 
pVAX vector three weeks apart. We observed improved induction of binding antibody 
responses in mice immunized with DLnano_3BVE_HA_CA09 than those with 
DLmono_HA_CA09 (Figure 5.6a). Five weeks post the first immunization, we observed 
significant 8-fold improvement in HAI titers in mice immunized with 
DLnano_3BVE_HA_CA09 than those with DLmono_HA_CA09 (Figure 5.6b). We then set 
up two lethal influenza challenge experiments in these three groups of mice, five weeks 
post the final immunization. Each mouse was intranasally inoculated with 10LD50 
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homologous H1/California/07/09 virus and was followed for two weeks for weight loss. Any 
mouse losing more than 20% of baseline body weight would have met the humane 
endpoint for euthanasia. In this experiment, we observed only mice immunized with 
DLnano_3BVE_HA_CA09 fully survived the lethal challenge (Figure 5.6c), whereas 40% 
(2/5) of mice immunized with DLmono_HA_CA09 or 100% (5/5) of mice immunized with 
control pVAX backbone succumbed to infections. Additionally, amongst mice that survived 
the challenge, substantially lower weight loss was observed in mice immunized with 
DLnano_3BVE_HA_CA09 than DLmono_HA_CA09 (Figure 5.6d).  
In a separate set of experiments, we followed these three groups of immunized 
mice seven days post H1/CA09 challenge to determine lung viral load and pathology. It 
was observed, in this challenge study, that within the first seven days, 80% (4/5) of mice 
immunized with control pVAX vector succumbed to infection, but mice immunized with 
either DLmono_HA_CA09 and DLnano_3BVE_HA_CA09 survived the first seven days 
(Figure 5.6e), even though mice immunized with DLmono_HA_CA09 still lost substantially 
more weight than those immunized with DLnano_3BVE_HA_CA09 (Supplemental Figure 
5.6c). Additionally, we observed significant reduction in viral load of mice immunized with 
DLnano_3BVE_HA_CA09 as compared to mice immunized with pVAX (2186-fold 
reduction) or with DLmono_HA_CA09 (156-fold reduction) (Figure 5.6f). Finally, H&E 
staining of lung specimens at seven days post challenge or at the time of euthanasia 
revealed that mice immunized with DLnano_3BVE_HA_CA09 but not with 
DLmono_HA_CA09 were protected from lung pathology, including the observations of 
eosinophilic necrotic deposits within the alveolar spaces and or thickening of alveolar 
septa, associated with influenza infection (Figure 5.6g and Supplemental Figure 5.6d). 
The two lethal challenge studies illustrated that the DLnano-vaccine could confer 
significant functional advantages in an infectious disease model.  
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5.4. Discussion 
Development of vaccines can be a challenging endeavor due to poor 
immunogenicity of certain vaccine antigens, which results in the need to increase the 
number of required vaccinations, dose per vaccination, and the required interval for 
patients to complete the vaccine regime. Particulate vaccine formulations can help boost 
immunogenicity but can be slow to develop on a large scale due to manufacturing 
complexities. Synthetic nucleic-acid based methods for the delivery of vaccine antigens 
have shown great promises, as they are often produced at significantly lower costs than 
their protein counterparts, can be manufactured to scale and bypass complex processes 
of assembly (Kutzler and Weiner, 2008), offer superior safety profile(Lu et al., 2008) and 
demonstrate remarkable thermo-stability to allow for extended shelf-lives (Hobernik and 
Bros, 2018). 
In this study, through the use of computational modeling and biophysical 
characterization, we engineered multimeric forms of HIV and influenza antigens which 
folded properly in vitro and displayed the desired antigenic profiles. We showed that these 
designer nano-vaccines are likely to assemble in vivo when delivered using synthetic DNA 
and adaptive electroporation, through direct evidence from pseudo-Native PAGE analysis 
(Figure 5.1f) and transmission electron microscopy (Figure 5.1h and 5.1i), and indirect 
evidence of binding of murine MBL to in vivo produced DLnano_LS_GT8 but not to 
DLmono_GT8 (Figure 5.1g), as well as the improved trafficking (Figure 5.2a) and the 
resulting immune responses (Figure 5.2b and 5.2c). The in vivo nanoparticle assembly 
also resulted in rapid sero-conversion, higher binding and functional HAI antibody titers 
yet with significant dose sparing. Enhanced antibody responses were also induced when 
DLnano-vaccine was administered via intradermal DNA vaccination, a newer and clinically 
important route of DNA vaccination (Modjarrad et al., 2019; Tebas et al., 2017). 
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Importantly, enhanced immune responses induced by DLnano-vaccines also conferred 
functional advantages. The DLnano-vaccines were more efficient at driving HAI, CD8+ T-
cell responses, and ultimately generating protection to animals from intranasal influenza 
challenge. DNA vaccine approach can effectively synergize with structure-guided protein 
engineering to quickly produce in vivo designer nano-vaccine constructs for rapid 
evaluation. 
This work interrogated factors which might contribute to the enhanced adaptive 
immune responses of DLnano-vaccines. Homogeneous in vitro assembly of these 
computationally designed DLnano-vaccines is important for their downstream success, as 
poorly assembled DNA-encoded LS_HA_CA09 did not elicit similarly potent immune 
responses (Supplemental Figure 5.5f). Homogeneous in vitro assembly will likely help 
increase the fraction of more fully assembled nanoparticles in vivo, contributing to the 
overall immunogenicity of the vaccine. It is in theory possible that the improved 
immunogenicity described here can be attributed to differences in levels of antigen 
expression. However, two observations suggest that antigen expression is not solely 
responsible for improved responses. First, we showed that DLnano_LS_GT8 induced 
stronger humoral responses than DLmono_GT8 in BALB/c mice at less than one tenth of 
the dose (Fig 5.2f). Second, while DLnano_PfV_GT8 expressed at higher levels in vivo 
than DLnano_3BVE_GT8 (Fig 5.4d), DLnano_PfV_GT8 and DLnano_3BVE_GT8 induced 
similar antibody titers and T cell responses at 25ug dose (Fig 5.4e and 5.4f).  The exact 
contribution of nanoparticle assembly, expression and valency for the induction of optimal 
immune responses will require further investigation. 
When DNA-launched nano-vaccines were compared to recombinant protein nano-
vaccines, widely considered as an extremely potent vaccine formulation in terms of 
induction of antibody responses(Kanekiyo et al., 2013), we observed DLnano-vaccines 
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induced comparable humoral responses to recombinant protein nanovaccines, but 
uniquely induced potent CD8+ T-cell responses in an MBL-complement independent 
manner. The observation that DLnano-vaccines function independently of MBL-
complement pathway is likely of interest for clinical translation of such vaccines, as 
approximately 5-20% of human populations have MBL deficiency (plasma 
MBL<100ng/mL)(Dahl et al., 2004; Zinyama-Gutsire et al., 2015). The role of T cells in 
immune surveillance to mediate protection provides a strong rationale for exploring this 
unique property of DLnano-vaccine (Zhang and Bevan, 2011), especially for such 
diseases as liver-stage malaria(Van Braeckel-Budimir and Harty, 2014), influenza for the 
elderlies(Grant et al., 2016; Koutsakos et al., 2019), and cancer(Durgeau et al., 2018). 
The unique ability for DLnano vaccination to induce CD8+ T-cell responses may be related 
to its distinct mechanism of antigen uptake and presentation. Antigen presenting cells, 
such as macrophages, are known to migrate into the site of electroporation to scavenge 
antigens expressed through DNA cassettes associated with apoptotic cells(Kutzler and 
Weiner, 2008). Prior studies observed that co-delivery of DNA vaccines with pro-apoptotic 
mutated Caspase 2 or Fas significantly increased both CD4+ and CD8+ T-cell responses 
to the vaccine antigens (Chattergoon et al., 2000; Sasaki et al., 2001). Such distinct 
mechanism of antigen processing might lead to more efficient cross-presentation to the 
MHC Class I pathway. Additionally, APCs including DCs and macrophages may also be 
directly transfected with the inoculated DNA cassettes in vivo (Akbari et al., 1999; 
Chattergoon et al., 1998), and the two mechanisms may be synergistic in the induction of 
CD8+ T-cell immunity. Our findings also demonstrated that DLnano-vaccine could 
improve induced CD8+ T-cell responses by eight to ten-fold relative to their monomeric 
counterparts. Given that DNA-vaccines can already induce CD8+ T-cell responses in 
patients to cause histopathological regression of HPV-driven cervical dysplasia (Trimble 
 
 122
et al., 2015), the finding is relevant and whether DLnano-vaccines can further improve the 
clinical response rates should be explored.  
Importantly, significant dose sparing can be realized with DLnano-vaccines. A 
dose of 1ug of plasmid DNA, a dose at which we historically would not expect to observe 
robust sero-conversion (Yan et al., 2018), was able to induce clear functional HAI titers in 
mice. Fewer immunizations of DLnano-vaccine could induce the same, if not higher, titers 
of antibodies. Given recent advances in the electroporation technology has improved the 
potency and consistency of immune responses induced by DNA vaccines in patients 
(Akbari et al., 1999; Kalams et al., 2013; Patel et al., 2018b; Tebas et al., 2019; Tebas et 
al., 2017; Trimble et al., 2015), it will be important to determine whether DLnano-vaccines 
can also help to reduce doses used in the clinic and lower the number of clinical visits 
required for vaccination. These advances may have important implications for outbreak 
control, and for global deployment including of vaccinations in more resource limited 
settings. 
It will be important to build on these initial studies to improve DLnano-vaccines. 
For example, while it is hypothesized that cross-linking of B-cell receptors through 
multivalent antigen display can improve B-cell responses(Xu and Kulp, 2019), studies to 
examine other mechanisms to improve B-cell responses and the mechanisms for the 
improved CD8+ T-cell responses for DLnano-vaccines relative to their monomeric 
counterparts are also important. Due to the unique ability of DLnano-vaccine to elicit 
strong CD8+ T-cell immunity, new DLnano-vaccines should be designed and evaluated to 
target diseases like cancer and T-cell dependent infectious diseases. The combined 
advantages of a simplified cost-effective temperature-stable platform, with the ability to 
retain in vivo structural integrity may be of value for the development of additional vaccines 
for HIV, influenza as well as other infectious diseases.    
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5.5. Conclusion 
This work demonstrates that that advances in synthetic DNA and adaptive 
electroporation technologies have allowed for in vivo assembly of complex 
computationally designed particulate nano-vaccines to induce improved humoral and 
cellular responses, and to confer functional protective benefits in a survival study. As DNA 
can be rapidly manufactured to scale with low costs, it can be envisioned that 
computationally designed nano-vaccines can be rapidly evaluated to expedite clinical 
translational and global deployment of various promising vaccine candidates. 
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Figure 5. 1 Expression and assembly of in vitro produced protein eOD-GT8-60mer and 
GT8-monomer and in vivo produced DLnano_LS_GT8 and DLmono_GT8.  
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a. Predicted structure of eOD-GT8-60mer, LS inner scaffold is shown in purple, decorated
GT8 shown in green and N-linked glycans are represented as blue sticks. 
b. SECMAL trace showing the calculated molecular weight of SEC purified eOD-GT8-
60mer. 
c. Negative stain electron microscopy images of purified eOD-GT8-60mer.
d. In vivo expression of DLmono_GT8 or DLnano_LS_GT8 in BALB/c mice four d.p.i, as
probed by VRC01 and anti-human Alexa Fluor 488, nuclei staining with DAPI is shown in 
blue.  
e. Reducing SDS PAGE western analysis to determine in vivo expression of
DLmono_GT8 and DLnano_LS_GT8 four d.p.i in muscle homogenates with VRC01 (in 
green); GAPDH (in red) is used as the loading control.  
f. Pseudo-native PAGE analysis comparing migration of in vivo produced DLmono_GT8
and DLnano_LS_GT8 to in vitro produced SEC purified recombinant GT8-monomer 
(labelled as STD mono) and eOD-GT8-60mer (labelled as STD nano) protein standards. 
g. Murine MBL labelling of naïve mouse muscles or muscles transfected with
DLmono_GT8 and DLnano_LS_GT8 seven d.p.i. 
h. Transmission electron microscopy (TEM) images of muscle sections from mice injected
with DLmono_GT8 or DLnano_LS_GT8 seven d.p.i that were immunolabelled with VRC01 
and gold anti-human IgG. Red arrows highlight VRC01 staining.  
i. TEM image of muscle section showing an example of high-valency GT8 nanoparticle
assembled in vivo. 80ug plasmid DNA dose of DLmono_GT8 or DLnano_LS_GT8 used 
in d-i. 
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Figure 5. 2 Characterization of in vivo trafficking of DLnano_LS_GT8 and humoral 
responses induced by DLnano_LS_GT8 versus DLmono_GT8.  
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a. Trafficking of DLnano_LS_GT8 and DLmono_GT8 seven d.p.i in the draining lymph
nodes, as determined by VRC01 staining (green) and anti-CD35-BV421 staining (blue) for 
co-localization analyses. 
b. ELISA binding against monomeric GT8 using serum from female BALB/c immunized
with DLmono_GT8 or DLnano_LS_GT8 seven d.p.i. 
c. Endpoint titers to GT8 over time using serum from female BALB/c receiving two
immunizations of DLmono_GT8 or DLnano_LS_GT8 three weeks apart. 
d. Frequencies of CD19+IgM-IgD-IgG+ GT8 specific B-cells in the spleen of naïve female
BALB/c mice or female BALB/c mice immunized with two doses of DLmono_GT8 or 
DLnano_LS_GT8 five weeks post the second immunization.  
e. Percentage inhibition of VRC01-GT8 binding by naïve mice sera or post-immune sera
from the DLmono_GT8 or DLnano_LS_GT8 vaccinated mice at 1:200 dilution. 
f. Comparison of GT8 endpoint titers for female BALB/c mice receiving two doses of
DLmono_GT8 at 25ug dose or DLnano_LS_GT8 at 2ug dose. 
g. Comparison of GT8 endpoint titers for male BALB/c mice receiving two doses of
DLmono_GT8 or DLnano_LS_GT8 at 25ug dose. 
h. Comparison of endpoint titers in guinea pigs receiving single 50ug intradermal
immunization of DLmono_GT8 or DLnano_LS_GT8. 
i. Comparison of humoral responses induced by protein eOD-GT8-60mer adjuvanted by
Sigma Adjuvant System or DLnano_LS_GT8 as assessed in C57BL/6 mice. 
j. Humoral responses in wildtype C57BL/6, MBL KO or CR2 KO mice to protein eOD-GT8-
60mer (purple) and DLnano_LS_GT8 vaccinations (red) seven d.p.i. 80ug of plasmid DNA 
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used in a, 25ug plasmid DNA and 10ug recombinant protein used elsewhere in the figure 
unless otherwise specified. Each group except in j includes five animals; each group in j 
include four animals; each dot represents an animal; error bar represents standard 
deviation; arrow below the plot represents an immunization; two-tailed Mann-Whitney 
Rank Test used to compare groups; p-values were adjusted for multiple comparison where 
appropriate; *, p-value<0.05. 
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Figure 5. 3 Characterization of cellular responses induced by DLnano_LS_GT8 versus 
DLmono_GT8 in BALB/c mice and by protein eOD-GT8-60mer and DLnano_LS_GT8 in 
C57BL/6 mice.  
a. ELIspot responses to the LS peptides and GT8 peptides in BALB/c mice immunized
with two doses of DLmono_GT8 or DLnano_LS_GT8 at specified doses. 
b. Effector memory CD4+ T-cell responses (CD3+CD4+CD44+CD62L-) in immunized
BALB/c mice as in a. 
c-e. Effector memory CD8+ T-cell responses (CD3+CD8+CD44+CD62L-) in immunized
BALB/c mice in terms of IFNγ expression in d. and CD107a expression in e. 
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f. Comparison for the frequencies of CD8+ effector memory T-cell responses induced by 
DLmono_GT8 or DLnano_LS_GT8 immunizations in BALB/c mice.  
g. T-cell responses as determined by IFN-γ ELISpot assays for protein eOD-GT8-60mer 
and DLnano_LS_GT8 immunized C57BL/6 mice.  
h. CD4+ effector memory T-cell responses for protein eOD-GT8-60mer and 
DLnano_LS_GT8 immunized C57BL/6 mice as determined by ICS.  
i. Comparisons of CD8+ T-cell responses induced by protein eOD-GT8-60mer (purple) 
versus DLnano_LS_GT8 vaccinations (red) in in wildtype C57BL/6, MBL KO or CR2 KO 
mice. 25ug plasmid DNA and 10ug recombinant protein used in the figure unless 
otherwise specified. Each group except in i includes five mice; each group in i includes 
four animals; each dot represents a mouse; error bar represents standard deviation; two-
tailed Mann-Whitney Rank Test used to compare groups; p-values were adjusted for 
multiple comparison where appropriate; *, p-value<0.05. 
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Figure 5. 4 Design and evaluation of new DLnano GT8-vaccines with alternative scaffolds. 
a. nsEM image of SEC-purified fraction of in vitro produced 3BVE-GT8 nanoparticles.
b. nsEM image of SEC-purified fraction of in vitro produced PfV-GT8 nanoparticles.
c. In vivo expression of DLnano_3BVE_GT8 and DLnano_PfV_GT8 in transfected mouse
muscles as determined by immunofluorescence; VRC01 labelling is shown in green and 
nuclei labelling shown in blue.  
 
 133
d. Reducing SDS PAGE western analysis to determine in vivo expression of 
DLnano_3BVE_GT8 and DLnano_PfV_GT8 four d.p.i in muscle homogenates with 
VRC01 (in green); GAPDH (in red) is used as the loading control.  
e. Humoral responses in BALB/c mice immunized with two 25ug doses of DLmono_GT8, 
DLnano_3BVE_GT8, DLnano_LS_GT8 and DLnano_PfV-GT8.  
f. CD8+ effector memory CD107a+ T-cell responses to GT8 domain in BALB/c mice 
immunized with DLmono_GT8, DLnano_3BVE_GT8, DLnano_LS_GT8 and DLnano_PfV-
GT8 as in e.  
g. Humoral responses in BALB/c mice immunized with 2ug doses of DLmono_GT8, 
DL_GT8_IMX313P, DLnano_3BVE_GT8, DLnano_LS_GT8 and DLnano_PfV-GT8 seven 
d.p.i. h. CD8+ effector memory CD107a+ T-cell responses to GT8 domain in BALB/c mice 
immunized twice with 2ug  DLmono_GT8, DL_GT8_IMX313P, DLnano_3BVE_GT8, 
DLnano_LS_GT8 and DLnano_PfV-GT8 three weeks apart. 80ug of plasmid DNA used 
in c and d; 25ug plasmid DNA used elsewhere in e and f; 2ug plasmid DNA used in g and 
h. Each group contains five mice; each dot represents a mouse; error bar represents 
standard deviation; arrow below the plot represents an immunization; two-tailed Mann-
Whitney Rank Test used to compare groups; p-values were adjusted for multiple 
comparison where appropriate; *, p<0.05. 
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Figure 5. 5 Design and evaluation of new DLnano influenza hemagglutinin vaccine. 
a. SECMAL trace of lectin and SEC purified LS_HA_NC99.
b. nsEM image of SEC-purified fraction of in vitro produced protein LS_HA_NC99
nanoparticles. 
c. Humoral responses in BALB/c mice that received DLnano_LS_HA_NC99 or
DLmono_HA_NC99 at 1ug dose. 
d. Autologous HAI titers against the H1 NC99 strain at D0, D42 (post-dose #2) and D56
(post-dose #3) for mice treated with 1ug DLmono_HA_NC99 or DLnano_LS_HA_NC99. 
e. Heterologous HAI titers against the H1 SI06 strain at 56 d.p.i for mice treated with 1ug
DLmono_HA_NC99 or DLnano_LS_HA_NC99. 
f. CD8+ effector memory IFNγ+ T-cell responses to NC99 HA domain in naïve BALB/c
mice or mice immunized with two doses of 10ug DLmono_HA_NC99 or 
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DLnano_LS_HA_NC99. Each group contains five mice; each dot represents a mouse; 
error bar represents standard deviation; arrow below the plot represents an immunization; 
two-tailed Mann-Whitney Rank Test used to compare groups; p-values were adjusted for 
multiple comparison where appropriate; *, p<0.05. 
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Figure 5. 6 Functional evaluations of DLmono_HA_CA09 versus DLnano_3BVE_HA_ 
CA09 in H1 A/California/07/09 lethal challenge model.  
a. Binding endpoint titers to HA(CA09) over time in BALB/c mice immunized with two 1ug
doses of pVAX, DLmono_HA_CA09 or DLnano_3BVE_HA_CA09 three weeks apart. 
b. HAI titers to the autologous A/California/07/09 strain in BALB/c mice immunized with
1ug pVAX, DLmono_HA_CA09 or DLnano_3BVE_HA_CA09 five weeks from their first 
vaccination.  
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c. Percentages of vaccinated mice surviving the lethal 10LD50 H1/A/California/07/09
challenge over two-week period. 
d. Weight changes in mice immunized with pVAX, DLmono_HA_CA09 or
DLnano_3BVE_HA_CA09 over two-week period following 10LD50 H1/A/California/07/09 
challenge.  
e. Percentages of vaccinated mice surviving the lethal 10LD50 H1/A/California/07/09
challenge over seven-day period in a separate study. 
f. Lung viral load in challenged mice at seven days post challenge or at the time of
euthanasia as determined by RT-qPCR. 
g. H&E stain for lung histo-pathology in mice seven days post viral challenge or at the time
of euthanasia, normal lung histology is shown for comparison; scale bar represents 
100um. Each group contained 10 mice in panels a and b; each group contained five in the 
remaining panels; each dot represents a mouse; error bar represents standard deviation; 
arrow below the plot represents an immunization; two-tailed Mann-Whitney Rank Test 
used to compare groups; p-values were adjusted for multiple comparison where 





Supplemental Figure 5. 1 In vitro expression of protein eOD-GT8-60mer and GT8-
monomer and in vivo expression and assembly of DLnano_LS_GT8 and DLmono_GT8. 
a. Immunofluorescence analyses of intracellular expression of protein eOD-GT8-
monomer and -60mer with or without IgE leader sequence in transfected HEK293T cells 
as determined by staining with VRC01 (green) and DAPI (blue) staining.  
b. Reducing SDS-PAGE analysis of Expi293F transfection supernatants of pVAX
backbone plasmid, protein GT8-monomer, protein eOD-GT8-60mer. 
c. SEC trace of lectin column purified Expi293F transfection supernatant of eOD-GT8-
60mer. 
d-e. Binding of in vitro produced protein eOD-GT8-monomer and eOD-GT8-60mer to
VRC01 (d.) and MBL (e.) in ELISA assays. 
f-g. Binding of in vivo expressed DLmono_GT8 and DLnano_LS_GT8 seven d.p.i to
VRC01 (f.) and MBL (g.) in the ELISA assays. 
h. Additional TEM images of muscle sections from mice injected with DLmono_GT8 and
DLnano_LS_GT8. 
i. Quantitative determination of the frequencies of clusters of different orders in the TEM
images; *, p<0.05. 80ug of plasmid DNA used in vivo for panels f through i. 
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Supplemental Figure 5. 2 Humoral responses induced by DLnano_LS_GT8 versus 
DLmono_GT8 vaccination in female BALB/c, C57BL/6 and CD1 mice.  
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a. ELISA binding against monomeric GT8 using serum from BALB/c immunized with 1:1
ratio (25ug each) of DLmono_GT8 with pVAX backbone plasmid, DLmono_GT8 with 
DLnano_LS(core) or DLnano_LS_GT8 with pVAX backbone seven d.p.i.  
b. Endpoint titers at seven d.p.i in BALB/c mice immunized with DLmono_GT8,
DL_GT8_IMX313P, or DLnano_LS_GT8. 
c. IgM endpoint titers to GT8 over time in BALB/c mice immunized with two doses of
DLmono_GT8, or DLnano_LS_GT8. 
d. Endpoint titers to GT8 over time using serum from BALB/c receiving single
immunizations of DLmono_GT8 or DLnano_LS_GT8. 
e. Flow plot demonstration of gating of antigen-specific GT8-Tetramer-APC+ GT8-24mer-
FITC+ CD19+IgM-IgD-IgG+ B-cells in the spleens of BALB/c mice immunized with two 
doses of DLmono_GT8 or DLnano_LS_GT8 five weeks post the second immunization  
f. ELISA data showing competition of VRC01 binding at its corresponding EC70
concentration to GT8 by week five post-immune sera from mice immunized with two doses 
of DLmono_GT8 or DLnano_LS_GT8.  
g. Endpoint titers to GT8 using serum for BALB/c receiving two immunizations of varying
doses of DLmono_GT8. 
h. Endpoint titers to GT8 using serum from BALB/c mice receiving two immunizations of
varying doses of DLnano_LS_GT8. 




j. Humoral responses in CD1 mice immunized with two doses of DLnano_LS_GT8 or 
DLmono_GT8. 25ug of plasmid DNA used in these experiments unless otherwise 
specified. n=5 for BALB/c and C57BL/6 mice, n=10 for CD1 mice; each line represents an 
animal; error bar represents standard deviation; arrow below the plot represents an 





Supplemental Figure 5. 3 Generalizability of improved cellular responses of 
DLnano_LS_GT8 in BALB/c, C57BL/6 and CD1 mice strains; comparison of induced 
CD8+ T-cell responses by protein eOD-GT8-60mer versus DLnano_LS_GT8 in C57BL/6 
mice. 
a and b. Frequencies of TNFα and IL-2 expressing CD4+ effector memory T-cells specific 
to either the LS and GT8 domains in female BALB/c mice immunized twice with 
DLmono_GT8 or DLnano_LS_GT8.  
c. Comparisons of total cellular responses to the LS and GT8 domains as assessed by 
IFN-γ ELISpot assay in female C57BL/6 versus BALB/c mice.  
d. and e. Comparison of CD4+ (d.) and CD8+ (e.) effector memory T-cell responses to 
the LS and GT8 domains in female C57BL/6 and BALB/c mice.  
f-h. Overall T-cell (f), CD4+ effector memory (g), and CD8+ effector memory (h) T-cell 
responses in female CD1 mice immunized with two doses of DLnano_LS_GT8 as 
compared to DLmono_GT8.  
i. Frequencies of effector memory CD8+ T-cells in female C57BL/6 and CD1 mice 
immunized twice with DLnano_LS_GT8 and DLmono_GT8.  
j. Comparison of frequencies of GT8-specific CD8+ T-cell responses induced by two 
immunizations of DLnano_LS_GT8 versus DLmono_GT8 in male BALB/c mice.  
k. CD4+ effector memory T-cell responses induced by protein eOD-GT8-60mer and 
DLnano_LS_GT8 in C57BL/6 mice as determined by ICS.  
l. Flow plot demonstrating induction of CD8+ effector memory T-cell responses by 
DLnano_LS_GT8 in comparison to protein eOD-GT8-60mer in C57BL/6 mice as 
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determined. 25ug plasmid DNA and 10ug recombinant protein used in the figure unless 
otherwise specified. n=5 for BALB/c and C57BL/6 mice, n=10 for CD1 mice; each dot 
represents an animal; error bar represents standard deviation; two-tailed Mann-Whitney 





Supplemental Figure 5. 4 Characterization of biophysical profiles and immune responses 
induced by newly designed DLnano GT8-vaccines with alternative scaffolds.  
a. SEC trace of recombinantly produced designed 3BVE-GT8.  
b. SEC trace of designed PfV_GT8 immunogen shows partial assembly into the 180-mer 
form.  
c. Binding of in vitro produced protein GT8-monomer, 3BVE_GT8, eOD-GT8-60mer and 
PfV_GT8 to VRC01 by ELISA.  
d and e. Effector memory T-cell responses to GT8 domain in BALB/c mice immunized 
with two doses of 25ug DLmono_GT8, DLnano_3BVE_GT8, DLnano_LS_GT8 and 
DLnano_PfV_GT8 by IFNγ ELIspots (d) and ICS for CD8+ T-cells (e). n=5 per group; each 
dot represents an animal; error bar represents standard deviation; two-tailed Mann-
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Whitney Rank Test used to compare groups; p-values were adjusted for multiple 





Supplemental Figure 5. 5 Characterization of biophysical profiles and immune responses 
induced by newly designed DLnano influenza hemagglutinin-based vaccines. 
a. SEC trace of recombinantly produced designed LS_HA_NC99 nanoparticles.  
b. Binding of sera from BALB/c mice immunized with 1ug DLnano_LS_HA_NC99 or 
DLmono_HA_NC99 at 56 d.p.i (post-dose #3) to heterologous recombinant H1 (SI06) 
hemagglutinin protein.  
c and d. CD8+ effector memory T-cell responses to NC99 HA domain in BALB/c mice 
immunized with two 10ug doses of DLmono_HA_NC99 or  DLnano_LS_HA_NC99 in 
terms of IFNγ (c.) and CD107a (d.) expression.  
e. SEC trace of lectin purified recombinantly produced LS_HA_CA09.  
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f. Comparison of humoral responses induced by two 10ug doses of
DLnano_LS_HA_NC99, which homogeneously assembled and by DNA-encoded 
LS_HA_CA09, which did not homogeneously assemble in vitro. n=5 per group; each dot 
represents an animal; error bar represents standard deviation; two-tailed Mann-Whitney 
Rank Test used to compare groups; p-values were adjusted for multiple comparison where 
appropriate; *, p<0.05. 
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Supplemental Figure 5. 6 Improved protection from lethal H1/CA09 challenge in mice 
with DLnano_3BVE_HA_CA09 vaccination.  
a. SEC trace for lectin-purified recombinantly produced 3BVE_HA_CA09 nanoparticles.
b. nsEM image of SEC-purified 3BVE_HA_CA09 nanoparticles.
c. Weight changes in mice immunized with pVAX, DLmono_HA_CA09 or
DLnano_3BVE_HA_CA09 over seven-day period following 10LD50 H1/A/California/07/09 
challenge as in Figure. 5.6e.  
d.H&E stain for lung histo-pathology in remaining 12 mice seven days post viral challenge
or at the time of euthanasia as in Figure. 5.6e. 1ug DNA dose used in vivo for c and d. 
n=5 per group; each line represents an animal. 
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CHAPTER 6 Designing synthetic DNA launched nanoparticle vaccines against tumor 























Xu, Z., Chokkalingam, N., Tello-Ruiz, Wise, M.C., et al. (2020). DNA-launched nano-
particle vaccine elicits CD8+ T-cell immunity to promote in vivo tumor clearance by 
mediating transient tissue apoptosis and macrophage infiltration. Cancer Immunology 




Cytolytic T cells (CTL) play a pivotal role in defense against intracellular pathogens 
and surveillance against tumors. Induction of CTL response by vaccination may be 
challenging as it requires direct transduction of target cells, or special adjuvants to 
promote cross presentation. Here, we observed that combined DNA electroporation (EP) 
vaccinations of two different nanoparticle vaccines, but not vaccinations with 
corresponding recombinant protein nanoparticles, induced CTL responses. DNA/EP 
vaccinations uniquely induced tissue apoptosis and influx of antigen presenting cells, 
including pro-inflammatory M1 macrophages to scavenge antigens. Induced tissue 
apoptosis was observed to be transient and local to immunization site. Systemic depletion 
of macrophages prior to DNA vaccinations significantly attenuated CTL response. Finally, 
DNA but not recombinant protein vaccinations of nanoparticles scaffolding Gp100 and 
Trp2 epitopes induced CTL responses to these epitopes and suppressed tumor growth in 
mouse melanoma tumor models. Transient physical stress induced through vaccination 
can therefore be harnessed to create pro-inflammatory environments that promote 
infiltration, antigen uptake and cross-presentation by antigen-presenting cells for unique 
and robust induction of CTL against cancer.  
6.2 Introduction 
Cytolytic T cells (CTL) is an extremely important branch of adaptive immune 
system, which can selectively kill target cells through release of cytokines, granzyme and 
perforin, as well as mediating target cell apoptosis through Fas and Fas-Ligand 
interaction(Halle et al., 2017). T cells engineered with artificial receptors for anti-tumor 
activity is an exciting area of research but may come with limitations in throughput and 
costs. Therefore, induction of broad endogenous antigen-specific CTL through vaccination 
may, therefore, be an important approach to treat cancer(Farhood et al., 2019). 
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However, induction of CTL through vaccination can be challenging as it requires 
antigen presenting cells (APCs) to present HLA-restricted epitopes to the MHC I pathway 
and provide costimulatory signal to prime CD8+ T cells (Chen and Flies, 2013). Using viral 
vectors modified to encode target antigens is an approach to drive CTL responses, 
potentially through direct transduction of target cells (Tan et al., 2013). Additionally, special 
adjuvants can be used to facilitate cross-presentation of target antigens, which to varying 
degrees promote phago-lysosomal escape and retro-translocation of target antigens into 
the cytosol (Gros and Amigorena, 2019). Alternatively, dendritic cells (DCs) can be loaded 
ex vivo with saturating concentrations of peptides and adoptively transferred back into the 
host to prime CD8+ T cells (Saxena and Bhardwaj, 2018). Each approach has certain 
drawback: relatively few adjuvants have been demonstrated to help prime CD8+ T-cell 
responses in clinic (Cheng et al., 2012), viral-vectored vaccine can be limited by pre-
existing immunity against the viral vector(Fausther-Bovendo and Kobinger, 2014), and 
manufacturing issues with large-scale production of DC vaccines. 
DNA vaccination has also been observed to elicit CD8+ T-cell responses both in 
preclinical animal models and in clinical trials(Trimble et al., 2015), plausibly through a 
combination of direct transfection of target cells(Akbari et al., 1999) along with cross 
presentation of DNA-encoded antigens(Fu et al., 1997). Previously we have observed 
DNA vaccination of antigens scaffolded by in vivo assembled nanoparticles induced 
significantly improved CD8+ T-cell responses compared to DNA-encoding non-scaffolded 
antigens. In this work, we compared the ability of DNA and protein vaccinations of identical 
nanoparticle antigens to induce CTL responses in mice. We discovered that intramuscular 
DNA vaccination, but not RIBI adjuvanted protein vaccination, was capable of inducing 
robust CTL responses against influenza and HIV antigens. Mechanistic studies revealed 
that in comparison to protein vaccination, DNA launched nanoparticle vaccines uniquely 
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induced apoptosis of transfected muscle tissues, which was followed by infiltration of 
antigen presenting cells (APCs), including pro-inflammatory M1 macrophages, to 
scavenge antigens. Systematic depletion of macrophages significantly attenuated induced 
CTL response. Finally, DNA launched nanoparticle vaccines induced potent CTL 
responses against tumor-associated antigens Trp2 and Gp100 and facilitated tumor 
rejection in 80% of mice in the prophylactic B16-F10 melanoma model. This work therefore 
provides a demonstration that induction of transient physical stress through DNA-launched 
nanoparticle vaccination may be a safe, easy and robust way to facilitate antigen cross 
presentation and CTL priming to target cancer. 
6.3 Results 
6.3.1 DNA-launched but not recombinant protein nanoparticle vaccines induced CD8+ T-
cell responses to HIV and influenza antigens 
First, we compared adaptive immune responses induced by DNA vaccination and 
protein vaccination adjuvanted by Sigma Adjuvant System (or RIBI). We utilized two model 
antigens: a priming HIV antigen eOD-GT8-60mer and an influenza hemagglutinin (H1 
A/NewCaledonia/20/1999) 60mer antigen scaffolded by lumazine synthase (Jardine et al., 
2016). DNA-Launched nanoparticle Lumazine Synthase decorated with an anti-HIV-1 
immunogen eOD-GT8 (DLnano_LS_GT8, Supplemental Fig. 6.1a) and protein eOD-GT8-
60mer induced similar antibody titers in BALB/c mice after two immunizations, even 
though antibody titer induced by DLnano_LS_GT8 was slightly higher after a single 
immunization (Fig. 6.1a). Epitope mapping conducted in prior studies identified that CD4+ 
T-cell responses elicited by LS-scaffolded DLnano-vaccines were predominantly specific
for the LS domain. In this study, CD4+ T-cell responses to the LS domain after two 
vaccinations, as measured by intracellular cytokine staining (ICS) of splenocytes following 
peptide stimulations, were similar between DLnano_LS_GT8 and protein eOD-GT8-
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60mer (Fig. 6.1b). Strikingly, we observed robust induction of CD8+ T-cell responses to 
the GT8 domain in mice immunized with DLnano_LS_GT8 but not in those vaccinated 
with protein eOD-GT8-60mer as determined by ICS (Fig. 6.1c and 6.1d) and IFNγ ELISpot 
assay (Fig. 6.1e and 6.1f).  
We determined if the observation could be replicated when an alternative 
nanoparticle-scaffolded influenza antigen was evaluated. Indeed, two vaccinations of 
DLnano_LS_HA(NC99) and protein HA(NC99) _60mer induced similar binding antibody 
titers to recombinant NC99 hemagglutinin (Fig. 6.1g) as well as hemagglutination inhibition 
titers against the autologous A/NewCaledonia/20/1999 virus (Fig. 6.1h). CD4+ T-cell 
responses induced by DLnano_LS_HA(NC99) and protein HA(NC99)_60mer were also 
similar (Supplemental Fig. 6.1b). However, similar to what was observed for the HIV 
antigen, only DLnano_LS_HA(NC99) but not protein HA(NC99)_60mer induced CD8+ T-
cell response to the HA domain as measured by ICS (Supplemental Fig. 6.1c and Fig. 
6.1i) and by IFNγ ELIspot (Supplemental Fig. 6.1d and Fig. 6.1j). In addition, we 
determined that when protein antigens were administered in combination with EP, they 
induced slightly improved humoral responses (Supplemental Figs. 6.1e and 6.1f) and yet 
failed to induce CD8+ T-cell responses (Supplemental Fig. 6.1g). Thus, we have 
demonstrated that induction of CD8+ T-cell immunity, in this context, required expression 
of antigens in host cells from DNA-cassettes.  
6.3.2 Induction of tissue apoptosis and APC infiltration by DNA-launched nanoparticle 
vaccines were important for CD8+ T-cell priming 
We hypothesized distinct modality of antigen uptake and presentation for DNA-
launched nanoparticle vaccine as compared to protein nanoparticle vaccine may attribute 
to unique induction of CTL responses by DLnano-vaccines. Previous studies observed 
that co-administration of DNA-vaccines with DNA-cassettes encoding pro-apoptotic genes 
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led to significantly improved induced CTL responses(Chattergoon et al., 2000). We, 
therefore, hypothesized that DNA/EP vaccinations could create a pro-inflammatory 
environment at the site of transfection through the induction of tissue apoptosis, thereby 
promoting infiltration of APCs and antigen uptake. 
We first assessed the extent of muscle tissue damage upon vaccine administration 
with an immunofluorescence assay to stain for cleaved caspase 3, which would be present 
in cellular cytosol following apoptotic signaling events(Porter and Janicke, 1999). In 
C57BL/6 mice, four days post injection (d.p.i), hypercellularity and expression of cleaved 
caspase 3 were only observed in the muscles of mice immunized with DLnano_LS_GT8 
combined with EP but not in those vaccinated with protein eOD-GT8-60mer co-formulated 
in RIBI or in naïve mice (Fig. 6.2a). Alternatively, we used an additional Terminal 
deoxynucleotidyl transferase (TdT) dUTP nick end labeling (TUNEL) assay to assess for 
double stranded DNA breaks, a surrogate marker for apoptosis(Kyrylkova et al., 2012), in 
the vaccinated muscle tissues (Fig. 6.2b). To ensure robustness of staining, we generated 
a positive control specimen by incubating muscle specimen with DNAse I, which 
generated double-stranded DNA breaks throughout the specimen, resulting in brown 
staining of all nuclei in the specimen. The negative control sample was generated by 
staining of the specimen in the absence of TdT, resulting in green appearance of all nuclei 
because of methyl green counterstain (Fig. 6.2b). Four d.p.i, brown nuclei suggestive of 
cellular apoptosis were only observed in muscle tissues treated with DLnano_LS_GT8 
and electroporation but not in muscle sections from naïve mice or those treated with 
protein eOD-GT8-60mer formulated in RIBI. At a higher level of magnification, nuclei 
fragmentation was also observed in the DNA group (Fig. 6.2b). 
We performed a time course experiment and observed that DLnano_LS_GT8 
induced tissue apoptosis was transient, peaked at 6 d.p.i and was fully resolved by 14 
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d.p.i (Supplemental Fig. 6.2a). Additionally, tissue apoptosis should be limited locally to
the injection sites. Indeed, we did not observe indicators of tissue damage such as 
significant elevations of serum lactose dehydrogenase (LDH) and creatine kinase (CK) 
levels in mice immunized with DLnano_LS_GT8 or protein eOD-GT8-60mer relative to 
untreated control mice post injections (Supplemental Fig. 6.2b and 6.2c). 
We next examined the consequences of induced tissue apoptosis in terms of 
tissue APC infiltration. Indeed, seven d.p.i, we observed increased influx of 
CD11b+F4/80+ macrophages into muscles of mice treated with DLnano_LS_GT8 and EP 
compared to protein eOD-GT8-60mer formulated in RIBI (Fig. 6.2c and 6.2d). 
Furthermore, infiltrating macrophages were observed to be predominantly pro-
inflammatory M1 macrophages rather than anti-inflammatory M2 macrophages 
(Supplemental Fig. 6.2d and 6.2e). Increased influx of CD11c+MHC Class II+ dendritic 
cells (DCs) was also observed for mice treated with DLnano_LS_GT8 compared to those 
treated with protein eOD-GT8-60mer; however, infiltrating DCs are significantly less 
abundant than macrophages by approximately 20-fold (Fig. 6.2e). Finally, staining of 
antigen-presenting cells with VRC01 (broadly neutralizing antibody with high affinity for 
GT8)-FITC demonstrated that infiltrating macrophages induced by DLnano_LS_GT8 but 
not those induced by protein eOD-GT8-60mer had taken up the GT8 antigen (Fig. 6.2f 
and Supplemental Fig. 6.2f). 
To determine the functional roles played by macrophages in priming of CD8+ T-
cell responses by DNA-launched nanoparticle vaccines, we systemically depleted the 
macrophage populations in C57BL/6 mice prior to DNA vaccinations. Depletion was 
carried out through intravenous (IV) injection of clodrosome, which specifically depleted 
phagocytic macrophages(Weisser et al., 2012). Single IV infusion of clodrosome 
specifically depleted CD11b+F4/80+ macrophages but not CD11c+MHC Class II+ DCs in 
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the spleens of animals one d.p.i (Supplemental Fig. 6.2g-6.2i). Depletion of infiltrating 
macrophages in the muscles post vaccination required increased doses of clodrosome on 
-3, 0, and 3 d.p.i (with respect to DNA vaccination), which significantly reduced
macrophage infiltration into the muscles by approximately four-fold (Fig. 6.2g). 
Importantly, this depletion scheme significantly attenuated induced CD8+ T-cell responses 
to the GT8 domain following one vaccination of DLnano_LS_GT8 14 d.p.i by 
approximately three-fold (Fig. 6.2h), highlighting the importance of infiltrating macrophage 
populations in priming of CD8+ T-cells in DNA vaccination with in vivo launched 
nanoparticle vaccines. 
6.3.3 DNA-launched nanoparticle vaccines scaffolding Trp2188 and Gp10025 peptides 
mediated protection against melanoma challenge in mice 
To demonstrate the functional relevance of CD8+ T-cell priming by DNA-launched 
nanoparticle vaccines in the treatment of cancer, we designed novel nanoparticle vaccines 
displaying CD8+ T-cell epitopes. The self-assembling nanoparticles were engineered 
using a structure-guided process. In our preliminary experiments, Lumazine Synthase on 
its own does not express well in mammalian cell lines and we hypothesized that it could 
not be used on its own to scaffold anti-tumor peptide antigens. We engineered a new 
version of DLnano_LS_GT8 capable of displaying peptide antigens. In this construction, 
the heavily glycosylated GT8 domain facilitates solubilization and secretion of designed 
nanoparticles and could potentially be replaced by other heavily glycosylated domains. To 
ensure epitope accessibility and homogenous nanoparticle assembly, N-linked glycans in 
proximity to the C-terminus of GT8 were removed by mutations in the PNGS sequence; 
additionally, a 15 amino acid linker was also incorporated to the C-terminus of GT8 
upstream of the scaffolded anti-tumor peptide(s). We designed nanoparticles presenting 
60 copies of Trp2188 peptide (DLnano_LS_Trp2188) and Gp10025 peptide 
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(DLnano_LS_Gp10025). Homogenous in vitro assemblies of DLnano_LS_Trp2188 and 
DLnano_LS _Gp10025 were observed by Size Exclusion Chromatography, SEC, (Fig. 6.3a 
and Supplemental Fig. 6.3a) and by negative stain Electron Microscopy, nsEM (Fig. 6.3b 
and Supplemental Fig. 6.3b). Groups of C57BL/6 mice were immunized with designed 
DNA-launched nanoparticle Trp2188 or Gp10025 vaccines individually, and were observed 
to induce significantly improved CD8+ T-cell responses to the Trp2188 and Gp10025 
peptides compared to DNA vaccines encoding monomeric GT8-scaffolded Trp2188 and 
Gp10025 respectively (DLmono_Trp2188 and DLmono_Gp10025, Fig. 6.3c and 6.3d). To 
determine if we could delivery both epitopes at once, we performed a follow-up experiment 
where we co-administered DLnano_LS_Trp2188 and DLnano_LS_Gp10025 in separate 
sites in a single animal. The co-administration resulted in improved elicitation of CD8+ T-
cell responses to both Trp2 and Gp100 peptides as compared to DLmono_Trp2188 and 
DLmono_Gp10025 (Supplemental Fig. 6.3c).  
We next determined whether B16-F10 melanoma bearing mice can mount 
endogenous CD8+ T-cell responses to Trp2 (SVYDFFVWL) and Gp100 (EGPRNQDWL) 
epitopes, and whether protein versus DNA vaccinations of nanoparticles scaffolding 60 
copies of Trp2 and Gp100 peptides could induce CD8+ T-cell responses to confer 
protection against tumor growth. Anti-PD1 treatments were administered to three groups 
of mice (Groups 2-4) in the study three days post tumor inoculation and weekly thereafter 
(Fig. 6.3e) (Moynihan et al., 2016). We observed that 14 days post subcutaneous 
inoculation of 105 B16-F10 cells and following two combined vaccine/ anti-PD1 treatments, 
CD8+ T-cell responses to Trp2 was only observed in mice treated with DNA vaccinations 
but not those receiving anti-PD1 treatment alone or anti-PD1 with protein vaccinations 
(Fig. 6.3f). Induced CD8+ T-cells specific for Trp2 were observed to exhibit effector 
phenotypes, IFNγ+CD107a+ (Fig. 6.3g), and were also poly-functional as determined by 
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co-expression of IFNγ, TNFα and IL2 (Fig. 6.3h). Similar observations were also made in 
terms of CD8+ T-cell responses to Gp100, even though lower frequency of epitope-
specific poly-functional CD8+ T-cell was observed upon DNA vaccination (Supplemental 
Fig. 6.3d-6.3f). In the therapeutic model (vaccine, anti-PD1 treatments administered three 
days post tumor inoculation), DNA but not protein vaccination of Trp2188 and Gp10025-
60mer was observed to suppress B16-F10 tumor growth in mice (Fig. 6.3i). Additionally, 
DNA but not protein vaccination was observed to significantly prolong median survival of 
mice in the therapeutic model by 11 days (p-value=0.0177 by Log-Rank test) (Fig. 6.3j). 
The effect was even more pronounced when mice were vaccinated prior to tumor 
inoculation. Two vaccinations of DLnano_LS_Trp2188 and DLnano_LS_Gp10025 
administered prior to 105 B16-F10-Luc cell challenge completely prevented tumor growth 
in 80% (4/5) mice; whereas tumor growth was observed in all pVAX control mice or mice 
treated with protein Trp2188 and Gp10025-60mer (Fig. 6.3k). Additionally, while all mice in 
the pVAX and protein groups died, 80% of mice in the DNA group had tumor-free survival 
until the end of the study (Fig. 6.3l), highlighting therapeutic utility of CTL priming by 
DLnano-vaccines. 
6.4 Discussion 
CTL can play an extremely important role in surveillance against intracellular 
pathogens and tumors. In the cancer space, presence of tumor infiltrating CD8+ T-cell is 
correlated with improved prognosis in cancer patients(Gooden et al., 2011; Shimizu et al., 
2019). Induction of CD8+ T-cell responses also corresponds to improved tumor clearance 
and survival in various preclinical animal studies(Beyranvand Nejad et al., 2019). Such 
observations have led to the use of T-cell based therapies, such as DC vaccines or in vitro 
expansion and adoptive transfer of tumor infiltrating lymphocytes (TIL), in cancer patients, 
achieving varying degrees of success(Rohaan et al., 2018; Wu et al., 2012).  
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Induction of CTL responses by vaccination can be challenging and not readily 
achieved by vaccination with protein or inactivated virus. For example, the most advanced 
malaria vaccines under development, RTS,S, which contains repeat and T-cell epitopes 
of CircumSporozoite Protein fused to hepatitis B surface antigen to form protein particles, 
could induce antibody but not CD8+ T-cell response to the vaccine antigens(Moorthy and 
Ballou, 2009).  
DNA vaccines have been shown to elicit CD8+ T-cell responses both in preclinical 
animal models and in clinical trials (Duperret et al., 2018b; Trimble et al., 2015). Prior 
mechanistic studies highlighted plausible contributions by direct transfection of DCs and 
macrophages with DNA cassettes (Akbari et al., 1999). Additionally, cross presentation of 
DNA-cassettes encoded antigens was also believed to be important for priming CTL 
through more indirect evidence (Fu et al., 1997). In this work, we observed DNA/EP 
mediated tissue apoptosis followed by macrophage infiltration and antigen uptake, which 
may subsequently transfer sequestered peptides to cDCs for priming of CD8+ T cells 
(Huang et al., 2019). Induced tissue apoptosis was observed to be transient and local, as 
we would expect given strong safety profile of DNA vaccines in clinic(Trimble et al., 2015). 
We also demonstrated the importance of CD8+ T-cell priming by DNA-launched 
nanoparticle vaccines in a melanoma challenge model. We designed a novel and 
generalizable nanoparticle platform for displaying CD8+ T cell epitopes to various tumor 
antigens. As a proof-of-principle, we demonstrated nanoparticle vaccines scaffolding 60 
copies of CD8+ epitopes from Trp2 and Gp100 could be engineered.  Future studies 
should be explored to examine alternative nanoparticle sizes and shapes. Here, the anti-
melanoma LS-nanoparticles scaffolding Trp2 and Gp100 demonstrated significantly 
improved CTL responses could be elicited to both targets. DNA but not protein 
vaccinations of Trp2188 and Gp10025 60mer elicited CTL responses in mice, suppressed 
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tumor growth and prolonged overall survival in the therapeutic tumor challenge model, 
and conferred 80% protection when vaccines were prophylactically administered. The 
work provided a demonstration that robust CTL responses can be generated with great 
simplicity by harnessing physical injury to create a pro-inflammatory environment that 
favored APC infiltration, antigen uptake and cross-presentation. Induced CTL responses 
can be directed to whole antigens, such as to GT8 or to influenza (Fig. 6.1), or to selected 
peptides (Fig. 6.3), creating possibility of developing whole antigen or neoantigen peptide-
oriented DNA-launched nanoparticle vaccines against various cancer targets and creating 
a viable and attractive strategy in the exciting era of cancer immunotherapy. 
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Figure 6. 1 Comparison of immune responses induced by DLnano_LS_GT8 and protein 
eOD-GT8-60mer, as well as DLnano_LS_HA(NC99) versus HA(NC99)-60mer in BALB/c 
mice.  
a. Endpoint titers to GT8-monomer induced by DLnano_LS_GT8 in comparison with RIBI 
adjuvanted protein eOD-GT8-60mer.  
b. CD4+ IFNγ responses to the LS domain induced by DLnano_LS_GT8, protein eOD-
GT8-60mer or in naïve mice.  
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c and d. Flow cytometry plots and combined statistics for CD8+ IFNγ responses to the 
GT8 domain induced by DLnano_LS_GT8, protein eOD-GT8-60mer or in naïve mice.  
e and f. IFNγ ELISpot images and combined statistics for overall T-cell responses to the 
GT8 domain induced by DLnano_LS_GT8, protein eOD-GT8-60mer or in naïve mice  
g. Endpoint titers to NC99 hemagglutinin induced by DLnano_LS_HA(NC99) in 
comparison with RIBI adjuvanted protein HA(NC99)-60mer. 
h. HAI titers against autologous H1 A/NewCaledonia/20/1999 induced by 
DLnano_LS_HA(NC99), protein HA(NC99)-60mer or in naïve mice.  
i. ICS determination of CD8+ IFNγ responses to the HA domain induced by 
DLnano_LS_HA(NC99), protein HA(NC99)-60mer or in naïve mice.  
j. IFNγ ELISpot assays for overall T-cell responses to the HA domain induced by 
DLnano_LS_HA(NC99), protein HA(NC99)-60mer or in naïve mice. Each group includes 
five mice; each dot represents an animal; error bar represents standard deviation; arrow 
below the plot represents an immunization; two-tailed Mann-Whitney Rank Test used to 




Figure 6. 2 Determination of the role of tissue apoptosis and APC infiltration upon DNA 
vaccination in C57BL/6 mice.  
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a. Immunofluorescence staining for cleaved caspase 3 (red) or nuclei (blue) for muscle 
sections from naïve mice or those treated with protein eOD_GT8-60mer or 
DLnano_LS_GT8.  
b. TUNEL assay to determine presence of double-stranded DNA breaks (brown) or intact 
DNA (green) for muscle sections from naïve mice or those treated with protein eOD_GT8-
60mer or DLnano_LS_GT8.  
c and d. Flow cytometry plots and combined statistics for frequency of muscle infiltrating 
CD11b+F4/80+ macrophages in naïve mice, or those treated with protein eOD-GT8-
60mer or DLnano_LS_GT8 seven d.p.i.  
e. Flow determination of muscle infiltrating CD11c+MHC Class II+ DCs in naïve mice, or 
those treated with protein eOD-GT8-60mer or DLnano_LS_GT8 seven d.p.i.  
f. Flow determination for GT8-uptake by VRC01-FITC staining for muscle macrophages 
in naïve mice, or mice treated with protein eOD-GT8-60mer or DLnano_LS_GT8 seven 
d.p.i.  
g. Comparison for changes in frequencies of muscle infiltrating macrophages four d.p.i in 
mice treated with DLnano_LS_GT8 four days post DNA vaccination; the mice also 
received three doses of IV clodrosome or control encapsosome on D-3, 0 and 3.  
h. CD8+ T-cell responses induced by DLnano_LS_GT8 or protein eOD-GT8-60mer in 
mice that did or did not receive systematic macrophage depletion with clodrosome. Each 
group includes four mice in c-f and five mice in g-i; each dot represents an animal; error 
bar represents standard deviation; two-tailed Mann-Whitney Rank Test used to compare 
groups; p-values were adjusted for multiple comparison where appropriate; *, p-
value<0.05. 
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Figure 6. 3 Characterization of functional importance of CD8+ T-cell priming by DNA 
versus protein vaccination in melanoma challenge model in C57BL/6 mice.  
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a. SEC trace for designed LS_Trp2188-60mer.  
b. nsEM image of SEC purified LS_Trp2188-60mer nanoparticles.  
c. Comparison of CD8+ IFNγ T-cell responses to Trp2188 peptide in naïve mice or mice 
immunized with DLmono_Trp2188 or DLnano_LS_Trp2188.  
d. Comparison of CD8+ IFNγ T-cell responses to Gp10025 peptide in naïve mice or mice 
immunized with DLmono_Gp10025 or DLnano_LS_Gp10025.  
e. Treatment and vaccination schemes used to study CD8+ T-cell responses to both 
Trp2188 and Gp10025 peptides in naïve mice, B16F10-tumor bearing mice that received 
anti-PD1 treatment alone, or anti-PD1 treatment in combination with protein or DNA 
vaccination of LS-GT8 scaffoled 60mer nanoparticles presenting Trp2188 and Gp10025.  
f, g and h. Induced IFNγ+, IFNγ+CD107a+, or IFNγ+TNFα+IL-2+ CD8+ T-cell responses 
to Trp2188 in naïve tumor-free mice or B16-F10 bearing mice that received anti-PD1 
treatment alone, or anti-PD1 treatment in combination with protein Trp2188 and Gp10025-
60mer or DLnano_LS_Trp2188 and DLnano_LS_Gp10025.  
i and j, tumor growth (i) and overall survival (j) in mice challenged with 105 B16-F10 cells 
and then treated with received anti-PD1 treatment alone, or anti-PD1 treatment in 
combination with protein Trp2188 and Gp10025-60mer or DLnano_LS_Trp2188 and 
DLnano_LS_Gp10025 three days post tumor challenge.  
k. IVIS to determine in vivo tumor growth in the minimal disease model where mice first 
received two vaccinations of pVAX vector, combination of protein Trp2188 and Gp10025-
60mer, or combination of DLnano_LS_Trp2188 and DLnano_LS_Gp10025 and were then 
challenged with 105 B16-F10-Luc cells seven days post second immunization.  
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l. Survival curves for mice shown in k.  Each group includes five mice; each dot represents
a mouse; error bar represents standard deviation; two-tailed Mann-Whitney Rank Test 
used to compare groups; p-values were adjusted for multiple comparison where 
appropriate; *, p-value<0.05. 
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Supplemental Figure 6. 1 Comparison of immune responses induced by 
DLnano_LS_HA(NC99) versus HA(NC99)-60mer in BALB/c mice.  
a. Layout of all plasmids used in this study.
b. CD4+ IFNγ responses to the LS domain induced by DLnano_LS_HA(NC99),
HA(NC99)-60mer or in naïve mice. 
c. Flow cytometry plots for CD8+ IFNγ responses to the HA domain induced by
DLnano_LS_HA(NC99), HA(NC99)-60mer or in naïve mice. 
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d. IFNγ ELIspot images for overall T-cell responses to the HA domain induced by
DLnano_LS_HA(NC99), HA(NC99)-60mer or in naïve mice. 
e. Humoral responses in mice immunized with protein eOD-GT8-60mer with or without
electroporation. 
f. Humoral responses in mice immunized with protein HA(NC99)-60mer with or without
electroporation. 
g. CD8+ T-cell responses in mice immunized with protein HA(NC99)-60mer or eOD-GT8-
60mer with electroporation. Each group includes five mice; each dot represents an animal; 
error bar represents standard deviation; arrow below the plot represents an immunization; 
two-tailed Mann-Whitney Rank Test used to compare groups; p-values were adjusted for 




Supplemental Figure 6. 2 Characterization of muscle infiltrating APC induced by DNA 
vaccination.  
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a. Time course immunofluorescence images showing cleaved caspase 3 expression (red)
in transfected muscle tissue over time; images from two mice were shown at each 
timepoint; nuclei staining with DAPI is shown in blue.  
b and c. Serum LDH and CK enzymatic activity in mice immunized with DLnano_LS_GT8, 
RIBI adjuvanted protein eOD-GT8-60mer or untreated mice following injection.  
d. Flow plot for determination of macrophage polarization (M1 versus M2) by staining
CD11b+F4/80+ populations with CD206 and CD11c. 
e. Frequencies of M1 versus M2 macrophages in the muscles as determined by flow four
days post DLnano_LS_GT8 vaccination. 
f. Flow plot by VRC01-FITC staining for determination of GT8-uptake in muscle
macrophages from naïve mice, or mice treated with protein eOD-GT8-60mer or 
DLnano_LS_GT8 seven d.p.i.  
g. Flow plots for splenic CD11c+MHC Class II+ DC populations upon IV treatment of
clodrosome or control encapsosome. 
h. Flow plots for splenic CD11b+F4/80+ macrophage populations upon IV treatment of
clodrosome or control encapsosome. 
i. Comparison for changes in frequencies of splenic macrophages and DCs in Naïve mice
upon IV treatment of clodrosome or control encapsosome. Each group includes five mice 
in b-i; each dot represents an animal; error bar represents standard deviation; arrow below 
the plot represents an immunization; two-tailed Mann-Whitney Rank Test used to compare 





Supplemental Figure 6. 3 Characterization of CD8+ T-cell responses induced by 
DLnano_LS_Trp2188 and DLnano_LS_Gp10025.  
a. SEC trace for designed LS_Gp10025-60mer.  
b. nsEM image of SEC purified LS_Gp10025-60mer nanoparticles.  
c. Comparison of CD8+ IFNγ T-cell responses to both Trp2188 and Gp10025 peptide in 
naïve mice or mice immunized with both DLmono_Gp10025 and DLnano_LS_Trp2188 or 
DLnano_LS_Gp10025 and DLnano_LS_Trp2188.  
d, e and f. Induced IFNγ+, IFNγ+CD107a+, or IFNγ+TNFα+IL-2+ CD8+ T-cell responses 
to Gp10025 in naïve tumor-free mice or B16-F10 bearing mice that received anti-PD1 
treatment alone, or anti-PD1 treatment in combination with protein Trp2188 and Gp10025-
60mer or DLnano_LS_Trp2188 and DLnano_LS_Gp10025. Each group includes five mice; 
each dot represents an animal; error bar represents standard deviation; arrow below the 
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plot represents an immunization; two-tailed Mann-Whitney Rank Test used to compare 
groups; *, p-value<0.05. 
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CHAPTER 7 Conclusion and Future Directions 
7.1 Synthetic DNA/EP enables in vivo delivery of complex anti-HIV-1 biologic eCD4-Ig, 
simultaneous expression of multiple bNAbs, as well as their in vivo post-translational 
modifications through co-delivery of an DNA-encoded enzyme 
We have demonstrated that a single treatment of DNA-encoded eCD4-Ig in 
immunodeficient mice (transient immune-modulation through the passive transfer of 
antibody that blocks CD40L signaling) would enable robust systemic expression of the 
construct, with a peak level close to 100ug/mL and persistent expression for more than 
half a year. Furthermore, simultaneous delivery of plasmid eCD4-Ig with plasmid Golgi-
resident enzyme IgE-TPST2 would enable potent in vivo sulfation of eCD4-Ig to 
significantly enhance its potency in terms of neutralization against the global panel of 
pseudoviruses. Through engineering of the enzyme to traffic to trans-Golgi network (TGN) 
via incorporation of a stronger secretion signal (IgE leader sequence), the enzyme 
demonstrates superior colocalization with another TGN marker and achieves high catalytic 
efficiency, with only 1/1000 plasmid copies of IgE-TPST2 required for full in vivo sulfation 
of eCD4-Ig (Xu et al., 2018). This work demonstrates that combined DNA/EP enables 
robust and prolonged in vivo expression of complex biologic and enzyme, highlighting 
utility of such approach for in vivo delivery of additional biologics against diseases of 
interests. 
We further explored the use of DNA/EP for simultaneous in vivo expression of four 
distinct HIV-1 bNAbs targeting four different epitopes on HIV Env (PGT121, PGDM1400, 
3BNC117, and PGT151). In mice that are transiently immune depleted with anti-CD4/CD8 
antibodies, single treatment of four distinct HIV DMAb plasmids enables potent coverage 
of the entire global panel of HIV-1 pseudoviruses with significantly improved IC50 
neutralization titers in animals’ sera as compared to mice treated with an HIV DMAb 
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monotherapy. Two of the constructs PGT121 and PGDM1400 were further evaluated in 
NHPs. A single round of DMAb treatment enables potent level of expression for both 
DMAbs (higher than 10ug/mL) and confers broadly neutralizing as well as ADCC activity 
to the sera of the NHPs at the peak timepoint. Unfortunately, as the study involved delivery 
of human monoclonal antibodies into NHPs, anti-antibody responses were observed 
seven days after treatment, which ultimately led to decrease in sera DMAb levels beyond 
28 days of treatment (Wise et al., 2019). This study demonstrates the feasibility of co-
delivery of multiple biologics in a single animal to improve breadth and potency of 
coverage, and additionally, that DNA/EP may be a potent vehicle for in vivo delivery for 
both small and large mammals. 
 A major limitation for this approach is the decline in serum expression level over 
time even in immune incompetent mice. In the case of eCD4-Ig, peak expression usually 
occurred 14 days post injection, and expression level tended to decline (though still 
remained detectable) by approximately 40-fold over time. Waning systemic expression of 
the biologic may reduce potency of protection conferred by the biologics and could 
potentially be related to DNA methylation in the CMV promoter region of the plasmid, 
which subsequently contributed to silencing of the transgene expression (Mehta et al., 
2009). Additionally, in fully immunocompetent animals, rate of decline in systemic DMAb 
expression is even higher as animals develop ADA responses. Several approaches may 
be used to address these limitations. For example, a combinatorial use of both early (CMV) 
and late (chicken β-actin, CBA) promoters may be used for enhanced longer term DMAb 
pharmacokinetic profile (Gray et al., 2011). Additionally, human germline modification of 
the encoded monoclonal antibodies, as well as analysis and knockout of potential CD4+ 
helper epitopes in the protein sequence of the antibodies are both viable strategies to 
reduce immunogenicity of encoded DMAb by decreasing the antigenicity of the encoded 
biologics (Pratt, 2018). Overall, additional DMAb and DNA-encoded immunoadhesin 
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technologies may be needed for their successful translation into the clinical spaces. 
However, these two studies demonstrate the utility of DNA/EP technology to promote in 
vivo folding and assembly of complex protein domains, thus paving the way for us to 
investigate in vivo DNA-delivery of next-generation nanoparticle vaccine. 
7.2 Synthetic DNA/EP enables de novo assembly of macromolecular nanoparticle protein 
complexes to induce significantly enhanced functional adaptive immune responses 
We have harnessed insights obtained through our DMAb studies to engineer 
significantly more complex nanoparticle vaccines for in vivo expression. Using three 
complementary techniques (transmission electron microscopy and gold-conjugated 
antibody based immune-labelling, pseudo-Native PAGE, and lectin binding 
immunohistochemistry), we determined that DNA/EP could support direct de novo 
assembly of HIV-1 priming antigen eOD-GT8-60mer. As compared to DNA-encoded 
monomeric antigen, DNA-launched nanoparticle vaccines can induce extremely rapid 
sero-conversion seven days post the initial immunization in both mice and guinea pigs, 
and higher set-point antibody titers. DNA-launched nano-vaccines are extremely dose-
sparing, supporting robust induction of humoral responses at 1/50 to 1/10 of the 
conventional DNA vaccine doses. At an extremely low dose (1ug of DNA plasmid), DNA-
launched nanoparticle scaffolding influenza hemagglutinin (HA) antigen, but not DNA-
encoded monomeric HA, offered complete protection to vaccinated mice challenged with 
lethal doses of pandemic H1/California/07/09 virus (Xu et al., 2020).  
Additionally, DNA-launched nano-vaccines also induced significantly enhanced 
antigen-specific CTL responses, in terms of expression of intracellular Th1 cytokines 
(IFNγ, TNFα and IL-2) in splenocytes of the animals following antigen-specific peptide 
stimulation. This finding was harnessed for the design of novel nano-vaccine scaffolding 
tumor associated antigens (melanoma associated antigen Gp100 and Trp2). Treatments 
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of B16F10-bearing mice with a combination of anti-PD1 and Gp100/Trp2 DNA-
nanoparticle vaccines significantly prolonged median survival of animals as compared to 
those treated with anti-PD1 alone. Additionally, prophylactic vaccination of mice with DNA-
launched nano-vaccines followed by B16F10 challenge resulted in complete response in 
80% of the vaccinated mice, highlighting the functional importance of CTL responses 
induced by these DNA-launched nanoparticle vaccines. 
I performed a head-to-head comparison between protein nanoparticle vaccines 
and DNA-launched nanoparticle vaccines encoding eOD-GT8-60mer immunogen. While 
both protein and DNA-nanoparticle vaccines induced potent humoral responses, in terms 
of rate of sero-conversion and overall magnitudes, only DNA-launched nano-vaccine but 
not corresponding protein nano-vaccine adjuvanted by RIBI could elicit CTL responses. 
Mechanistic studies demonstrate that DNA/EP delivery of nano-vaccine induced unique 
pro-inflammatory environment in transfected muscle tissues, by causing transient 
apoptosis of transfected muscle fibers and infiltration of APCs, including pro-inflammatory 
M1 macrophages. Infiltrating APCs can subsequently scavenge cell-associated antigen 
for cross-presentation and CTL priming. Consequently, only DNA-launched nano-
vaccines but not protein nano-vaccines against tumor-associated antigens Trp2 and 
Gp100 elicited CTL responses, and conferred protection to mice challenged with B16F10 
melanoma cells. This study not only demonstrates that DNA/EP can be used for in vivo 
assembly of complex nanoparticle vaccines but also that unique immunological features 
can be driven by DNA-launched nanoparticles (dose-sparing, quick sero-conversion and 
induction of CTL responses). As such, we can envision that DNA-launched nano-vaccines 
represent a versatile platform with likely importance for different diseases and which could 
facilitate rapid clinical translation of promising next-generation vaccine candidates 
designed through protein engineering. 
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7.3 Future direction and Conclusion 
In this work, we have demonstrated that DNA/EP may be a potent tool for in vivo 
folding and assembly of complex protein domains and may be a versatile platform for 
sustained in vivo expression of biologics or delivery of next-generation vaccines that can 
induce unique immunological features (Figure 7.1). Additional studies may be pursued to 
further evaluate and demonstrate utility of DNA-encoded immunotherapies or DNA-
launched nano-vaccines in a highly clinically relevant model. For example, HIV-1 or SHIV 
challenge studies can be pursued to further evaluate potency of anti-HIV-1 
immunoadhesin eCD4-Ig or HIV-1 bNAbs to mediate immediate and/or persistent 
protection in a humanized mouse model or an NHP model respectively. Additional 
optimizations and developments may also be required to further enhance utility of this 
technology. Optimizations in the choice of plasmid promoters, as well as modifications to 
immune-silence delivered biologics (potentially through glycan masking), would be 
needed to further improve pharmacokinetic properties of in vivo expressed biologics. 
Additional strategies, such as DNA-launched RNA replicon technology, may also be 
included to further increase in vivo DNA-encoded biologic expression to enable potent and 
biologically relevant levels of expression in larger mammals and in humans (Zimmer, 
2010). 
In the case of DNA-launched nanoparticle vaccine DLnano_LS_GT8, further study 
can be pursued evaluating this immunogen in an animal model with a relevant human 
antibody repertoire (VRC01 germline transgenic mice, or H2L2 mouse developed by 
Harbor Biomed) to examine whether DNA-launched nano-vaccine is capable of priming 
and inducing the appropriate precursor antibody response, and whether that response can 
be further boosted sequentially with more native-like Envelop immunogens to increase 
breadth of neutralization. The proof-of-concept that DNA-launched influenza nano-vaccine 
can provide protection to mice from challenge at a low dose is likely important, and 
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suggests that additional DNA-launched nano-vaccines scaffolding influenza HA head 
immunogens (against H3N2 and influenza B) should be designed and evaluated, either 
individually and in combination. Additionally, it will also likely be important to evaluate 
DNA-launched influenza nano-vaccines in larger animals (rabbits, NHPs and pigs) to 
determine whether the DNA-launched nano-vaccine technology can overcome 
attenuation in vaccine immunogenicity when a DNA vaccine candidate is advanced from 
a smaller mammal to a larger mammal. Additionally, nanoparticle-scaffolding antigens 
against additional diseases may be pursued to further validate generalizability of the 
technology. Additional strategies should be considered to facilitate computational design 
of nanoparticle vaccines that will be able to spontaneously assemble when expressed, 
such that the technology can be rapidly deployed to target emerging infectious disease in 
an outbreak scenario. For instance, a bi-component nanoparticle assembly strategy has 
garnered significant interests recently and could be explored using the DNA technology 
(Georgiev et al., 2018). 
In the cancer space, DNA-launched nano-vaccines against melanoma-associated 
antigen appears to provide excellent protection to animals in a prophylactic vaccination 
setting but lacks potency to mediate durable control of tumors in a therapeutic vaccination 
setting when the tumor microenvironment is already well established. To address such 
limitation, a multi-modal treatment approach, which has been demonstrated to be effective 
in suppressing tumor growth, should be explored (Moynihan et al., 2016). It, therefore, can 
be envisioned a combinatorial approach in which DNA-encoded antibodies (checkpoint 
blockade, or antibody against tumor-associated antigen) maybe combined with DNA-
launched nano-vaccines (against tumor-associated antigens or neo-antigens) for potential 
synergy in the treatment of cancer (Duperret et al., 2018a). 
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With further optimizations/diversifications of the technology, DNA/EP may 
potentially facilitate rapid translation/evaluation of promising vaccine/ immunotherapy 






Figure 7. 1 Summary of major findings in the thesis with regards to DNA-encoded 




A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, 
Adjuvanted. https://ClinicalTrials.gov/show/NCT03547245. 
Abbink, P., Larocca, R.A., De La Barrera, R.A., Bricault, C.A., Moseley, E.T., Boyd, M., 
Kirilova, M., Li, Z., Ng'ang'a, D., Nanayakkara, O., et al. (2016). Protective efficacy of 
multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science 353, 
1129-1132. 
Abbott, R.K., Lee, J.H., Menis, S., Skog, P., Rossi, M., Ota, T., Kulp, D.W., Bhullar, D., 
Kalyuzhniy, O., Havenar-Daughton, C., et al. (2018). Precursor Frequency and Affinity 
Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-
Targeting HIV Vaccine Immunogens. Immunity 48, 133-146 e136. 
Aboutorabi, A., Hadian, M., Ghaderi, H., Salehi, M., and Ghiasipour, M. (2014). Cost-
effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer. 
Glob J Health Sci 7, 98-106. 
Adachi, A., Gendelman, H.E., Koenig, S., Folks, T., Willey, R., Rabson, A., and Martin, 
M.A. (1986). Production of acquired immunodeficiency syndrome-associated retrovirus 
in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59, 
284-291. 
Akbari, O., Panjwani, N., Garcia, S., Tascon, R., Lowrie, D., and Stockinger, B. (1999). 
DNA vaccination: transfection and activation of dendritic cells as key events for 
immunity. J Exp Med 189, 169-178. 
Al-Halifa, S., Gauthier, L., Arpin, D., Bourgault, S., and Archambault, D. (2019). 
Nanoparticle-Based Vaccines Against Respiratory Viruses. Front Immunol 10, 22. 
Almqvist, N., Winkler, T.H., and Martensson, I.L. (2011). Autoantibodies: Focus on anti-
DNA antibodies. Self Nonself 2, 11-18. 
186
Andrabi, R., Su, C.Y., Liang, C.H., Shivatare, S.S., Briney, B., Voss, J.E., Nawazi, S.K., 
Wu, C.Y., Wong, C.H., and Burton, D.R. (2017). Glycans Function as Anchors for 
Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development. Immunity 
47, 524-537 e523. 
Arnold, J.N., Wormald, M.R., Sim, R.B., Rudd, P.M., and Dwek, R.A. (2007). The impact 
of glycosylation on the biological function and structure of human immunoglobulins. 
Annu Rev Immunol 25, 21-50. 
Arvas, A. (2014). Vaccination in patients with immunosuppression. Turk Pediatri Ars 49, 
181-185.
Awi, N.J., and Teow, S.Y. (2018). Antibody-Mediated Therapy against HIV/AIDS: Where 
Are We Standing Now? J Pathog 2018, 8724549. 
Azoury, S.C., Straughan, D.M., and Shukla, V. (2015). Immune Checkpoint Inhibitors for 
Cancer Therapy: Clinical Efficacy and Safety. Curr Cancer Drug Targets 15, 452-462. 
Badamchi-Zadeh, A., Tartaglia, L.J., Abbink, P., Bricault, C.A., Liu, P.T., Boyd, M., 
Kirilova, M., Mercado, N.B., Nanayakkara, O.S., Vrbanac, V.D., et al. (2018). 
Therapeutic Efficacy of Vectored PGT121 Gene Delivery in HIV-1-Infected Humanized 
Mice. J Virol 92. 
Balazs, A.B., Chen, J., Hong, C.M., Rao, D.S., Yang, L., and Baltimore, D. (2011). 
Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 
481, 81-84. 
Bar, K.J., Sneller, M.C., Harrison, L.J., Justement, J.S., Overton, E.T., Petrone, M.E., 
Salantes, D.B., Seamon, C.A., Scheinfeld, B., Kwan, R.W., et al. (2016). Effect of HIV 
Antibody VRC01 on Viral Rebound after Treatment Interruption. N Engl J Med 375, 
2037-2050. 
Bar-On, Y., Gruell, H., Schoofs, T., Pai, J.A., Nogueira, L., Butler, A.L., Millard, K., 
Lehmann, C., Suarez, I., Oliveira, T.Y., et al. (2018). Safety and antiviral activity of 
187
combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med 24, 
1701-1707. 
Barouch, D.H., Whitney, J.B., Moldt, B., Klein, F., Oliveira, T.Y., Liu, J., Stephenson, 
K.E., Chang, H.W., Shekhar, K., Gupta, S., et al. (2013). Therapeutic efficacy of potent
neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. 
Nature 503, 224-228. 
Bas, M., Terrier, A., Jacque, E., Dehenne, A., Pochet-Beghin, V., Beghin, C., Dezetter, 
A.S., Dupont, G., Engrand, A., Beaufils, B., et al. (2019). Fc Sialylation Prolongs Serum
Half-Life of Therapeutic Antibodies. J Immunol 202, 1582-1594. 
Benoit, A., Beran, J., Devaster, J.M., Esen, M., Launay, O., Leroux-Roels, G., 
McElhaney, J.E., Oostvogels, L., van Essen, G.A., Gaglani, M., et al. (2015). 
Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against 
Seasonal A/H3N2 Influenza Disease. Open Forum Infect Dis 2, ofv067. 
Beyranvand Nejad, E., Ratts, R.B., Panagioti, E., Meyer, C., Oduro, J.D., Cicin-Sain, L., 
Fruh, K., van der Burg, S.H., and Arens, R. (2019). Demarcated thresholds of tumor-
specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates 
of protection. J Immunother Cancer 7, 25. 
Bohannon, C., Powers, R., Satyabhama, L., Cui, A., Tipton, C., Michaeli, M., Skountzou, 
I., Mittler, R.S., Kleinstein, S.H., Mehr, R., et al. (2016). Long-lived antigen-induced IgM 
plasma cells demonstrate somatic mutations and contribute to long-term protection. Nat 
Commun 7, 11826. 
Bonanni, P., Gershon, A., Gershon, M., Kulcsar, A., Papaevangelou, V., Rentier, B., 
Sadzot-Delvaux, C., Usonis, V., Vesikari, T., Weil-Olivier, C., et al. (2013). Primary 
versus secondary failure after varicella vaccination: implications for interval between 2 
doses. Pediatr Infect Dis J 32, e305-313. 
188
Borducchi, E.N., Liu, J., Nkolola, J.P., Cadena, A.M., Yu, W.H., Fischinger, S., Broge, T., 
Abbink, P., Mercado, N.B., Chandrashekar, A., et al. (2018). Antibody and TLR7 agonist 
delay viral rebound in SHIV-infected monkeys. Nature 563, 360-364. 
Braciale, T.J., and Hahn, Y.S. (2013). Immunity to viruses. Immunol Rev 255, 5-12. 
Braulke, T., and Bonifacino, J.S. (2009). Sorting of lysosomal proteins. Biochim Biophys 
Acta 1793, 605-614. 
Briney, B., Sok, D., Jardine, J.G., Kulp, D.W., Skog, P., Menis, S., Jacak, R., Kalyuzhniy, 
O., de Val, N., Sesterhenn, F., et al. (2016). Tailored Immunogens Direct Affinity 
Maturation toward HIV Neutralizing Antibodies. Cell 166, 1459-1470 e1411. 
Brod, F., Miura, K., Taylor, I., Li, Y., Marini, A., Salman, A.M., Spencer, A.J., Long, C.A., 
and Biswas, S. (2018). Combination of RTS,S and Pfs25-IMX313 Induces a Functional 
Antibody Response Against Malaria Infection and Transmission in Mice. Front Immunol 
9, 2780. 
Brune, K.D., Leneghan, D.B., Brian, I.J., Ishizuka, A.S., Bachmann, M.F., Draper, S.J., 
Biswas, S., and Howarth, M. (2016). Plug-and-Display: decoration of Virus-Like Particles 
via isopeptide bonds for modular immunization. Sci Rep 6, 19234. 
Burton, D.R., and Hangartner, L. (2016). Broadly Neutralizing Antibodies to HIV and 
Their Role in Vaccine Design. Annu Rev Immunol 34, 635-659. 
Caskey, M., Schoofs, T., Gruell, H., Settler, A., Karagounis, T., Kreider, E.F., Murrell, B., 
Pfeifer, N., Nogueira, L., Oliveira, T.Y., et al. (2017). Antibody 10-1074 suppresses 
viremia in HIV-1-infected individuals. Nat Med 23, 185-191. 
Chattergoon, M.A., Kim, J.J., Yang, J.S., Robinson, T.M., Lee, D.J., Dentchev, T., 
Wilson, D.M., Ayyavoo, V., and Weiner, D.B. (2000). Targeted antigen delivery to 
antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. 
Nat Biotechnol 18, 974-979. 
189
Chattergoon, M.A., Robinson, T.M., Boyer, J.D., and Weiner, D.B. (1998). Specific 
immune induction following DNA-based immunization through in vivo transfection and 
activation of macrophages/antigen-presenting cells. J Immunol 160, 5707-5718. 
Chattopadhyay, S., Chen, J.Y., Chen, H.W., and Hu, C.J. (2017). Nanoparticle Vaccines 
Adopting Virus-like Features for Enhanced Immune Potentiation. Nanotheranostics 1, 
244-260.
Chen, L., and Flies, D.B. (2013). Molecular mechanisms of T cell co-stimulation and co-
inhibition. Nat Rev Immunol 13, 227-242. 
Chen, P., Tian, J., Kovesdi, I., and Bruder, J.T. (2008). Promoters influence the kinetics 
of transgene expression following adenovector gene delivery. J Gene Med 10, 123-131. 
Chen, W., Bardhi, A., Feng, Y., Wang, Y., Qi, Q., Li, W., Zhu, Z., Dyba, M.A., Ying, T., 
Jiang, S., et al. (2016). Improving the CH1-CK heterodimerization and pharmacokinetics 
of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. MAbs 8, 761-774. 
Cheng, K., El-Boubbou, K., and Landry, C.C. (2012). Binding of HIV-1 gp120 
glycoprotein to silica nanoparticles modified with CD4 glycoprotein and CD4 peptide 
fragments. ACS Appl Mater Interfaces 4, 235-243. 
Cho, J.H., Youn, J.W., and Sung, Y.C. (2001). Cross-priming as a predominant 
mechanism for inducing CD8(+) T cell responses in gene gun DNA immunization. J 
Immunol 167, 5549-5557. 
Choe, H., Li, W., Wright, P.L., Vasilieva, N., Venturi, M., Huang, C.C., Grundner, C., 
Dorfman, T., Zwick, M.B., Wang, L., et al. (2003). Tyrosine sulfation of human antibodies 
contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114, 161-170. 
Cohen, Y.Z., and Caskey, M. (2018). Broadly neutralizing antibodies for treatment and 
prevention of HIV-1 infection. Curr Opin HIV AIDS 13, 366-373. 
190
Dahl, M., Tybjaerg-Hansen, A., Schnohr, P., and Nordestgaard, B.G. (2004). A 
population-based study of morbidity and mortality in mannose-binding lectin deficiency. J 
Exp Med 199, 1391-1399. 
Danan, L.M., Yu, Z., Ludden, P.J., Jia, W., Moore, K.L., and Leary, J.A. (2010). Catalytic 
mechanism of Golgi-resident human tyrosylprotein sulfotransferase-2: a mass 
spectrometry approach. J Am Soc Mass Spectrom 21, 1633-1642. 
Darvin, P., Toor, S.M., Sasidharan Nair, V., and Elkord, E. (2018). Immune checkpoint 
inhibitors: recent progress and potential biomarkers. Exp Mol Med 50, 1-11. 
Davis, B.S., Chang, G.J., Cropp, B., Roehrig, J.T., Martin, D.A., Mitchell, C.J., Bowen, 
R., and Bunning, M.L. (2001). West Nile virus recombinant DNA vaccine protects mouse 
and horse from virus challenge and expresses in vitro a noninfectious recombinant 
antigen that can be used in enzyme-linked immunosorbent assays. J Virol 75, 4040-
4047. 
deCamp, A., Hraber, P., Bailer, R.T., Seaman, M.S., Ochsenbauer, C., Kappes, J., 
Gottardo, R., Edlefsen, P., Self, S., Tang, H., et al. (2014). Global panel of HIV-1 Env 
reference strains for standardized assessments of vaccine-elicited neutralizing 
antibodies. J Virol 88, 2489-2507. 
Desai, N. (2012). Challenges in development of nanoparticle-based therapeutics. AAPS 
J 14, 282-295. 
Ding, K., Zhang, X., Mrazek, J., Kickhoefer, V.A., Lai, M., Ng, H.L., Yang, O.O., Rome, 
L.H., and Zhou, Z.H. (2018). Solution Structures of Engineered Vault Particles. Structure
26, 619-626 e613. 
Donate, A., Coppola, D., Cruz, Y., and Heller, R. (2011). Evaluation of a novel non-
penetrating electrode for use in DNA vaccination. PLoS One 6, e19181. 
 
 191
Dowd, K.A., Ko, S.Y., Morabito, K.M., Yang, E.S., Pelc, R.S., DeMaso, C.R., Castilho, 
L.R., Abbink, P., Boyd, M., Nityanandam, R., et al. (2016). Rapid development of a DNA 
vaccine for Zika virus. Science 354, 237-240. 
Duperret, E.K., Trautz, A., Stoltz, R., Patel, A., Wise, M.C., Perales-Puchalt, A., Smith, 
T., Broderick, K.E., Masteller, E., Kim, J.J., et al. (2018a). Synthetic DNA-Encoded 
Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In 
Vivo. Cancer Res 78, 6363-6370. 
Duperret, E.K., Wise, M.C., Trautz, A., Villarreal, D.O., Ferraro, B., Walters, J., Yan, J., 
Khan, A., Masteller, E., Humeau, L., et al. (2018b). Synergy of Immune Checkpoint 
Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT. Mol Ther 
26, 435-445. 
Durgeau, A., Virk, Y., Corgnac, S., and Mami-Chouaib, F. (2018). Recent Advances in 
Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Front 
Immunol 9, 14. 
Eifler, A.C., and Thaxton, C.S. (2011). Nanoparticle therapeutics: FDA approval, clinical 
trials, regulatory pathways, and case study. Methods Mol Biol 726, 325-338. 
Elliott, S.T.C., Kallewaard, N.L., Benjamin, E., Wachter-Rosati, L., McAuliffe, J.M., Patel, 
A., Smith, T.R.F., Schultheis, K., Park, D.H., Flingai, S., et al. (2017). DMAb inoculation 
of synthetic cross reactive antibodies protects against lethal influenza A and B infections. 
NPJ Vaccines 2, 18. 
Esquivel, R.N., Patel, A., Kudchodkar, S.B., Park, D.H., Stettler, K., Beltramello, M., 
Allen, J.W., Mendoza, J., Ramos, S., Choi, H., et al. (2019). In Vivo Delivery of a DNA-
Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus. Mol 
Ther 27, 974-985. 
Farhood, B., Najafi, M., and Mortezaee, K. (2019). CD8(+) cytotoxic T lymphocytes in 
cancer immunotherapy: A review. J Cell Physiol 234, 8509-8521. 
192
Farzan, M., Mirzabekov, T., Kolchinsky, P., Wyatt, R., Cayabyab, M., Gerard, N.P., 
Gerard, C., Sodroski, J., and Choe, H. (1999). Tyrosine sulfation of the amino terminus 
of CCR5 facilitates HIV-1 entry. Cell 96, 667-676. 
Fausther-Bovendo, H., and Kobinger, G.P. (2014). Pre-existing immunity against Ad 
vectors: humoral, cellular, and innate response, what's important? Hum Vaccin 
Immunother 10, 2875-2884. 
Fellinger, C.H., Gardner, M.R., Weber, J.A., Alfant, B., Zhou, A.S., and Farzan, M. 
(2019). eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly 
Neutralizing Antibody. J Virol 93. 
Feng, J., Markwalter, C.E., Tian, C., Armstrong, M., and Prud’homme, R.K. (2019). 
Translational formulation of nanoparticle therapeutics from laboratory discovery to 
clinical scale. Journal of Translational Medicine 17, 200. 
Fitzpatrick, Z., Leborgne, C., Barbon, E., Masat, E., Ronzitti, G., van Wittenberghe, L., 
Vignaud, A., Collaud, F., Charles, S., Simon Sola, M., et al. (2018). Influence of Pre-
existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction. 
Mol Ther Methods Clin Dev 9, 119-129. 
Flingai, S., Czerwonko, M., Goodman, J., Kudchodkar, S.B., Muthumani, K., and Weiner, 
D.B. (2013). Synthetic DNA vaccines: improved vaccine potency by electroporation and
co-delivered genetic adjuvants. Front Immunol 4, 354. 
Flingai, S., Plummer, E.M., Patel, A., Shresta, S., Mendoza, J.M., Broderick, K.E., 
Sardesai, N.Y., Muthumani, K., and Weiner, D.B. (2015). Protection against dengue 
disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. Sci Rep 5, 
12616. 
Fu, T.M., Ulmer, J.B., Caulfield, M.J., Deck, R.R., Friedman, A., Wang, S., Liu, X., 
Donnelly, J.J., and Liu, M.A. (1997). Priming of cytotoxic T lymphocytes by DNA 
 
 193
vaccines: requirement for professional antigen presenting cells and evidence for antigen 
transfer from myocytes. Mol Med 3, 362-371. 
Fuchs, S.P., and Desrosiers, R.C. (2016). Promise and problems associated with the 
use of recombinant AAV for the delivery of anti-HIV antibodies. Mol Ther Methods Clin 
Dev 3, 16068. 
Fuenmayor, J., Godia, F., and Cervera, L. (2017). Production of virus-like particles for 
vaccines. N Biotechnol 39, 174-180. 
Fynan, E.F., Webster, R.G., Fuller, D.H., Haynes, J.R., Santoro, J.C., and Robinson, 
H.L. (1993). DNA vaccines: protective immunizations by parenteral, mucosal, and gene-
gun inoculations. Proc Natl Acad Sci U S A 90, 11478-11482. 
Gao, Y., McKay, P.F., and Mann, J.F.S. (2018). Advances in HIV-1 Vaccine 
Development. Viruses 10. 
Gardner, M.R., Fellinger, C.H., Kattenhorn, L.M., Davis-Gardner, M.E., Weber, J.A., 
Alfant, B., Zhou, A.S., Prasad, N.R., Kondur, H.R., Newton, W.A., et al. (2019a). AAV-
delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges. 
Sci Transl Med 11. 
Gardner, M.R., Fetzer, I., Kattenhorn, L.M., Davis-Gardner, M.E., Zhou, A.S., Alfant, B., 
Weber, J.A., Kondur, H.R., Martinez-Navio, J.M., Fuchs, S.P., et al. (2019b). Anti-drug 
Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly 
Neutralizing Antibodies. Mol Ther 27, 650-660. 
Gardner, M.R., Kattenhorn, L.M., Kondur, H.R., von Schaewen, M., Dorfman, T., Chiang, 
J.J., Haworth, K.G., Decker, J.M., Alpert, M.D., Bailey, C.C., et al. (2015). AAV-
expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 
519, 87-91. 
Gautam, R., Nishimura, Y., Gaughan, N., Gazumyan, A., Schoofs, T., Buckler-White, A., 
Seaman, M.S., Swihart, B.J., Follmann, D.A., Nussenzweig, M.C., et al. (2018). A single 
194
injection of crystallizable fragment domain-modified antibodies elicits durable protection 
from SHIV infection. Nat Med 24, 610-616. 
Georgiev, I.S., Joyce, M.G., Chen, R.E., Leung, K., McKee, K., Druz, A., Van Galen, 
J.G., Kanekiyo, M., Tsybovsky, Y., Yang, E.S., et al. (2018). Two-Component Ferritin
Nanoparticles for Multimerization of Diverse Trimeric Antigens. ACS Infect Dis 4, 788-
796. 
Giddam, A.K., Zaman, M., Skwarczynski, M., and Toth, I. (2012). Liposome-based 
delivery system for vaccine candidates: constructing an effective formulation. 
Nanomedicine (Lond) 7, 1877-1893. 
Giri, M., Ugen, K.E., and Weiner, D.B. (2004). DNA vaccines against human 
immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev 17, 370-389. 
Gooden, M.J., de Bock, G.H., Leffers, N., Daemen, T., and Nijman, H.W. (2011). The 
prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review 
with meta-analysis. Br J Cancer 105, 93-103. 
Graham, B.S., Gilman, M.S.A., and McLellan, J.S. (2019). Structure-Based Vaccine 
Antigen Design. Annu Rev Med 70, 91-104. 
Grant, E.J., Quinones-Parra, S.M., Clemens, E.B., and Kedzierska, K. (2016). Human 
influenza viruses and CD8(+) T cell responses. Curr Opin Virol 16, 132-142. 
Grassly, N.C. (2014). Immunogenicity and effectiveness of routine immunization with 1 
or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis. J 
Infect Dis 210 Suppl 1, S439-446. 
Gray, S.J., Foti, S.B., Schwartz, J.W., Bachaboina, L., Taylor-Blake, B., Coleman, J., 
Ehlers, M.D., Zylka, M.J., McCown, T.J., and Samulski, R.J. (2011). Optimizing 
promoters for recombinant adeno-associated virus-mediated gene expression in the 
peripheral and central nervous system using self-complementary vectors. Hum Gene 
Ther 22, 1143-1153. 
195
Greenwood, B. (2014). The contribution of vaccination to global health: past, present 
and future. Philos Trans R Soc Lond B Biol Sci 369, 20130433. 
Gregory, A.E., Titball, R., and Williamson, D. (2013). Vaccine delivery using 
nanoparticles. Front Cell Infect Microbiol 3, 13. 
Gristick, H.B., von Boehmer, L., West, A.P., Jr., Schamber, M., Gazumyan, A., Golijanin, 
J., Seaman, M.S., Fatkenheuer, G., Klein, F., Nussenzweig, M.C., et al. (2016). Natively 
glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-
binding site. Nat Struct Mol Biol 23, 906-915. 
Gros, M., and Amigorena, S. (2019). Regulation of Antigen Export to the Cytosol During 
Cross-Presentation. Front Immunol 10, 41. 
Gruell, H., and Klein, F. (2018). Antibody-mediated prevention and treatment of HIV-1 
infection. Retrovirology 15, 73. 
Guo, C., Manjili, M.H., Subjeck, J.R., Sarkar, D., Fisher, P.B., and Wang, X.Y. (2013). 
Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res 119, 421-475. 
Halle, S., Halle, O., and Forster, R. (2017). Mechanisms and Dynamics of T Cell-
Mediated Cytotoxicity In Vivo. Trends Immunol 38, 432-443. 
Harper, D.M., and DeMars, L.R. (2017). HPV vaccines - A review of the first decade. 
Gynecol Oncol 146, 196-204. 
He, L., de Val, N., Morris, C.D., Vora, N., Thinnes, T.C., Kong, L., Azadnia, P., Sok, D., 
Zhou, B., Burton, D.R., et al. (2016). Presenting native-like trimeric HIV-1 antigens with 
self-assembling nanoparticles. Nat Commun 7, 12041. 
He, L., Kumar, S., Allen, J.D., Huang, D., Lin, X., Mann, C.J., Saye-Francisco, K.L., 
Copps, J., Sarkar, A., Blizard, G.S., et al. (2018). HIV-1 vaccine design through 
minimizing envelope metastability. Sci Adv 4, eaau6769. 




Holliger, P., and Hudson, P.J. (2005). Engineered antibody fragments and the rise of 
single domains. Nat Biotechnol 23, 1126-1136. 
Hraber, P., Seaman, M.S., Bailer, R.T., Mascola, J.R., Montefiori, D.C., and Korber, B.T. 
(2014). Prevalence of broadly neutralizing antibody responses during chronic HIV-1 
infection. AIDS 28, 163-169. 
Huang, J., Kang, B.H., Ishida, E., Zhou, T., Griesman, T., Sheng, Z., Wu, F., Doria-
Rose, N.A., Zhang, B., McKee, K., et al. (2016). Identification of a CD4-Binding-Site 
Antibody to HIV that Evolved Near-Pan Neutralization Breadth. Immunity 45, 1108-1121. 
Huang, M.-N., Nicholson, L.T., Batich, K.A., Swartz, A.M., Kopin, D., Wellford, S., 
Prabhakar, V.K., Woroniecka, K., Nair, S.K., Fecci, P.E., et al. (2019). Antigen-loaded 
monocyte administration induces potent therapeutic anti-tumor T cell responses. The 
Journal of Clinical Investigation. 
Huehls, A.M., Coupet, T.A., and Sentman, C.L. (2015). Bispecific T-cell engagers for 
cancer immunotherapy. Immunol Cell Biol 93, 290-296. 
Tebas, P., Roberts, C.C., Muthumani, K., Reuschel, E.L., Kudchodkar, S.B., Zaidi, F.I., 
White, S., Khan, A.S., Racine, T., Choi, H., et al. (2017). Safety and Immunogenicity of 
an Anti-Zika Virus DNA Vaccine - Preliminary Report. N Engl J Med. 
Jardine, J.G., Kulp, D.W., Havenar-Daughton, C., Sarkar, A., Briney, B., Sok, D., 
Sesterhenn, F., Ereno-Orbea, J., Kalyuzhniy, O., Deresa, I., et al. (2016). HIV-1 broadly 
neutralizing antibody precursor B cells revealed by germline-targeting immunogen. 
Science 351, 1458-1463. 
Jardine, J.G., Ota, T., Sok, D., Pauthner, M., Kulp, D.W., Kalyuzhniy, O., Skog, P.D., 
Thinnes, T.C., Bhullar, D., Briney, B., et al. (2015). HIV-1 VACCINES. Priming a broadly 
neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 
349, 156-161. 
197
Jiang, Z., Tong, G., Cai, B., Xu, Y., and Lou, J. (2011). Purification and immunogenicity 
study of human papillomavirus 58 virus-like particles expressed in Pichia pastoris. 
Protein Expr Purif 80, 203-210. 
Jin, Y., Cao, C., Li, P., Liu, X., Huang, W., Li, C., and Ma, Q. (2005). Boosting immune 
response to hepatitis B DNA vaccine by coadministration of Prothymosin alpha-
expressing plasmid. Clin Diagn Lab Immunol 12, 1364-1369. 
Johnson, M.L., Braiteh, F., Grilley-Olson, J.E., Chou, J., Davda, J., Forgie, A., Li, R., 
Jacobs, I., Kazazi, F., and Hu-Lieskovan, S. (2019). Assessment of Subcutaneous vs 
Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With 
Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial. JAMA Oncol 5, 999-1007. 
Johnson, P.R., Schnepp, B.C., Zhang, J., Connell, M.J., Greene, S.M., Yuste, E., 
Desrosiers, R.C., and Clark, K.R. (2009). Vector-mediated gene transfer engenders 
long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 
15, 901-906. 
Julg, B., Liu, P.T., Wagh, K., Fischer, W.M., Abbink, P., Mercado, N.B., Whitney, J.B., 
Nkolola, J.P., McMahan, K., Tartaglia, L.J., et al. (2017a). Protection against a mixed 
SHIV challenge by a broadly neutralizing antibody cocktail. Sci Transl Med 9. 
Julg, B., Tartaglia, L.J., Keele, B.F., Wagh, K., Pegu, A., Sok, D., Abbink, P., Schmidt, 
S.D., Wang, K., Chen, X., et al. (2017b). Broadly neutralizing antibodies targeting the
HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci Transl 
Med 9. 
Kaba, S.A., Karch, C.P., Seth, L., Ferlez, K.M.B., Storme, C.K., Pesavento, D.M., 
Laughlin, P.Y., Bergmann-Leitner, E.S., Burkhard, P., and Lanar, D.E. (2018). Self-
assembling protein nanoparticles with built-in flagellin domains increases protective 
efficacy of a Plasmodium falciparum based vaccine. Vaccine 36, 906-914. 
198
Kalams, S.A., Parker, S., Jin, X., Elizaga, M., Metch, B., Wang, M., Hural, J., Lubeck, M., 
Eldridge, J., Cardinali, M., et al. (2012). Safety and immunogenicity of an HIV-1 gag 
DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, 
HIV-1 uninfected adults. PLoS One 7, e29231. 
Kalams, S.A., Parker, S.D., Elizaga, M., Metch, B., Edupuganti, S., Hural, J., De Rosa, 
S., Carter, D.K., Rybczyk, K., Frank, I., et al. (2013). Safety and comparative 
immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and 
impact of intramuscular electroporation for delivery. J Infect Dis 208, 818-829. 
Kanekiyo, M., Bu, W., Joyce, M.G., Meng, G., Whittle, J.R., Baxa, U., Yamamoto, T., 
Narpala, S., Todd, J.P., Rao, S.S., et al. (2015). Rational Design of an Epstein-Barr 
Virus Vaccine Targeting the Receptor-Binding Site. Cell 162, 1090-1100. 
Kanekiyo, M., Joyce, M.G., Gillespie, R.A., Gallagher, J.R., Andrews, S.F., Yassine, 
H.M., Wheatley, A.K., Fisher, B.E., Ambrozak, D.R., Creanga, A., et al. (2019). Mosaic
nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell 
responses. Nat Immunol 20, 362-372. 
Kanekiyo, M., Wei, C.J., Yassine, H.M., McTamney, P.M., Boyington, J.C., Whittle, J.R., 
Rao, S.S., Kong, W.P., Wang, L., and Nabel, G.J. (2013). Self-assembling influenza 
nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102-106. 
Karch, C.P., Li, J., Kulangara, C., Paulillo, S.M., Raman, S.K., Emadi, S., Tan, A., Helal, 
Z.H., Fan, Q., Khan, M.I., et al. (2017). Vaccination with self-adjuvanted protein
nanoparticles provides protection against lethal influenza challenge. Nanomedicine 13, 
241-251.
Khoshnejad, M., Patel, A., Wojtak, K., Kudchodkar, S.B., Humeau, L., Lyssenko, N.N., 
Rader, D.J., Muthumani, K., and Weiner, D.B. (2019). Development of Novel DNA-




Kontermann, R.E. (2009). Strategies to extend plasma half-lives of recombinant 
antibodies. BioDrugs 23, 93-109. 
Koutsakos, M., Illing, P.T., Nguyen, T.H.O., Mifsud, N.A., Crawford, J.C., Rizzetto, S., 
Eltahla, A.A., Clemens, E.B., Sant, S., Chua, B.Y., et al. (2019). Human CD8(+) T cell 
cross-reactivity across influenza A, B and C viruses. Nat Immunol 20, 613-625. 
Kruger, S., Ilmer, M., Kobold, S., Cadilha, B.L., Endres, S., Ormanns, S., Schuebbe, G., 
Renz, B.W., D'Haese, J.G., Schloesser, H., et al. (2019). Advances in cancer 
immunotherapy 2019 - latest trends. J Exp Clin Cancer Res 38, 268. 
Kulkarni, V., Rosati, M., Valentin, A., Jalah, R., Alicea, C., Yu, L., Guan, Y., Shen, X., 
Tomaras, G.D., LaBranche, C., et al. (2013). Vaccination with Vaxfectin((R)) adjuvanted 
SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 
Viremia. Hum Vaccin Immunother 9, 2069-2080. 
Kulp, D.W., Subramaniam, S., Donald, J.E., Hannigan, B.T., Mueller, B.K., Grigoryan, 
G., and Senes, A. (2012). Structural informatics, modeling, and design with an open-
source Molecular Software Library (MSL). J Comput Chem 33, 1645-1661. 
Kuriakose, A., Chirmule, N., and Nair, P. (2016). Immunogenicity of Biotherapeutics: 
Causes and Association with Posttranslational Modifications. J Immunol Res 2016, 
1298473. 
Kutzler, M.A., and Weiner, D.B. (2008). DNA vaccines: ready for prime time? Nat Rev 
Genet 9, 776-788. 
Kutzler, M.A., Wise, M.C., Hutnick, N.A., Moldoveanu, Z., Hunter, M., Reuter, M., Yuan, 
S., Yan, J., Ginsberg, A., Sylvester, A., et al. (2016). Chemokine-adjuvanted 
electroporated DNA vaccine induces substantial protection from simian 
immunodeficiency virus vaginal challenge. Mucosal Immunol 9, 13-23. 
Kyrylkova, K., Kyryachenko, S., Leid, M., and Kioussi, C. (2012). Detection of apoptosis 
by TUNEL assay. Methods Mol Biol 887, 41-47. 
200
Labonte, J.W., Adolf-Bryfogle, J., Schief, W.R., and Gray, J.J. (2017). Residue-centric 
modeling and design of saccharide and glycoconjugate structures. J Comput Chem 38, 
276-287.
Lambert, L.C., and Fauci, A.S. (2010). Influenza vaccines for the future. N Engl J Med 
363, 2036-2044. 
Lee, G.Q., Reddy, K., Einkauf, K.B., Gounder, K., Chevalier, J.M., Dong, K.L., Walker, 
B.D., Yu, X.G., Ndung'u, T., and Lichterfeld, M. (2019). HIV-1 DNA sequence diversity
and evolution during acute subtype C infection. Nat Commun 10, 2737. 
Leneghan, D.B., Miura, K., Taylor, I.J., Li, Y., Jin, J., Brune, K.D., Bachmann, M.F., 
Howarth, M., Long, C.A., and Biswas, S. (2017). Nanoassembly routes stimulate 
conflicting antibody quantity and quality for transmission-blocking malaria vaccines. Sci 
Rep 7, 3811. 
Leyland-Jones, B. (2001). Dose scheduling--Herceptin. Oncology 61 Suppl 2, 31-36. 
Li, C., Narkbunnam, N., Samulski, R.J., Asokan, A., Hu, G., Jacobson, L.J., Manco-
Johnson, M.J., Monahan, P.E., and Joint Outcome Study, I. (2012). Neutralizing 
antibodies against adeno-associated virus examined prospectively in pediatric patients 
with hemophilia. Gene Ther 19, 288-294. 
Li, T., DiLillo, D.J., Bournazos, S., Giddens, J.P., Ravetch, J.V., and Wang, L.X. (2017). 
Modulating IgG effector function by Fc glycan engineering. Proc Natl Acad Sci U S A 
114, 3485-3490. 
Lu, L., Tai, G., and Hong, W. (2004). Autoantigen Golgin-97, an effector of Arl1 GTPase, 
participates in traffic from the endosome to the trans-golgi network. Mol Biol Cell 15, 
4426-4443. 
Lu, S., Wang, S., and Grimes-Serrano, J.M. (2008). Current progress of DNA vaccine 
studies in humans. Expert Rev Vaccines 7, 175-191. 
 
 201
Lua, L.H., Connors, N.K., Sainsbury, F., Chuan, Y.P., Wibowo, N., and Middelberg, A.P. 
(2014). Bioengineering virus-like particles as vaccines. Biotechnol Bioeng 111, 425-440. 
Maartens, G., Celum, C., and Lewin, S.R. (2014). HIV infection: epidemiology, 
pathogenesis, treatment, and prevention. Lancet 384, 258-271. 
MacGregor, R.R., Boyer, J.D., Ugen, K.E., Lacy, K.E., Gluckman, S.J., Bagarazzi, M.L., 
Chattergoon, M.A., Baine, Y., Higgins, T.J., Ciccarelli, R.B., et al. (1998). First human 
trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 
infection: safety and host response. J Infect Dis 178, 92-100. 
Mackness, B.C., Jaworski, J.A., Boudanova, E., Park, A., Valente, D., Mauriac, C., 
Pasquier, O., Schmidt, T., Kabiri, M., Kandira, A., et al. (2019). Antibody Fc engineering 
for enhanced neonatal Fc receptor binding and prolonged circulation half-life. MAbs 11, 
1276-1288. 
Mann, J.F., McKay, P.F., Fiserova, A., Klein, K., Cope, A., Rogers, P., Swales, J., 
Seaman, M.S., Combadiere, B., and Shattock, R.J. (2014). Enhanced immunogenicity of 
an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and 
intradermal routes. J Virol 88, 6959-6969. 
Manno, C.S., Pierce, G.F., Arruda, V.R., Glader, B., Ragni, M., Rasko, J.J., Ozelo, M.C., 
Hoots, K., Blatt, P., Konkle, B., et al. (2006). Successful transduction of liver in 
hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat 
Med 12, 342-347. 
Marcandalli, J., Fiala, B., Ols, S., Perotti, M., de van der Schueren, W., Snijder, J., 
Hodge, E., Benhaim, M., Ravichandran, R., Carter, L., et al. (2019). Induction of Potent 
Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for 
Respiratory Syncytial Virus. Cell 176, 1420-1431 e1417. 
Margolis, D.M., Koup, R.A., and Ferrari, G. (2017). HIV antibodies for treatment of HIV 
infection. Immunol Rev 275, 313-323. 
202
Martinez-Navio, J.M., Fuchs, S.P., Pedreno-Lopez, S., Rakasz, E.G., Gao, G., and 
Desrosiers, R.C. (2016). Host Anti-antibody Responses Following Adeno-associated 
Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys. Mol 
Ther 24, 76-86. 
Masavuli, M.G., Wijesundara, D.K., Torresi, J., Gowans, E.J., and Grubor-Bauk, B. 
(2017). Preclinical Development and Production of Virus-Like Particles As Vaccine 
Candidates for Hepatitis C. Front Microbiol 8, 2413. 
Masavuli, M.G., Wijesundara, D.K., Underwood, A., Christiansen, D., Earnest-Silveira, 
L., Bull, R., Torresi, J., Gowans, E.J., and Grubor-Bauk, B. (2019). A Hepatitis C Virus 
DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly 
Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice. Front Immunol 10, 
1145. 
McCoy, L.E., and Burton, D.R. (2017). Identification and specificity of broadly 
neutralizing antibodies against HIV. Immunol Rev 275, 11-20. 
Mehta, A.K., Majumdar, S.S., Alam, P., Gulati, N., and Brahmachari, V. (2009). 
Epigenetic regulation of cytomegalovirus major immediate-early promoter activity in 
transgenic mice. Gene 428, 20-24. 
Melo, M., Porter, E., Zhang, Y., Silva, M., Li, N., Dobosh, B., Liguori, A., Skog, P., 
Landais, E., Menis, S., et al. (2019). Immunogenicity of RNA Replicons Encoding HIV 
Env Immunogens Designed for Self-Assembly into Nanoparticles. Mol Ther 27, 2080-
2090. 
Mendoza, P., Gruell, H., Nogueira, L., Pai, J.A., Butler, A.L., Millard, K., Lehmann, C., 
Suarez, I., Oliveira, T.Y., Lorenzi, J.C.C., et al. (2018). Combination therapy with anti-
HIV-1 antibodies maintains viral suppression. Nature 561, 479-484. 
Michel, T., Luft, D., Abraham, M.K., Reinhardt, S., Salinas Medina, M.L., Kurz, J., 
Schaller, M., Avci-Adali, M., Schlensak, C., Peter, K., et al. (2017). Cationic 
 
 203
Nanoliposomes Meet mRNA: Efficient Delivery of Modified mRNA Using 
Hemocompatible and Stable Vectors for Therapeutic Applications. Mol Ther Nucleic 
Acids 8, 459-468. 
Mimuro, J., Mizukami, H., Shima, M., Matsushita, T., Taki, M., Muto, S., Higasa, S., 
Sakai, M., Ohmori, T., Madoiwa, S., et al. (2014). The prevalence of neutralizing 
antibodies against adeno-associated virus capsids is reduced in young Japanese 
individuals. J Med Virol 86, 1990-1997. 
Modjarrad, K., Roberts, C.C., Mills, K.T., Castellano, A.R., Paolino, K., Muthumani, K., 
Reuschel, E.L., Robb, M.L., Racine, T., Oh, M.D., et al. (2019). Safety and 
immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a 
phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 
Moldt, B., Rakasz, E.G., Schultz, N., Chan-Hui, P.Y., Swiderek, K., Weisgrau, K.L., 
Piaskowski, S.M., Bergman, Z., Watkins, D.I., Poignard, P., et al. (2012). Highly potent 
HIV-specific antibody neutralization in vitro translates into effective protection against 
mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A 109, 18921-18925. 
Moore, P.L., Gorman, J., Doria-Rose, N.A., and Morris, L. (2017). Ontogeny-based 
immunogens for the induction of V2-directed HIV broadly neutralizing antibodies. 
Immunol Rev 275, 217-229. 
Moorthy, V.S., and Ballou, W.R. (2009). Immunological mechanisms underlying 
protection mediated by RTS,S: a review of the available data. Malar J 8, 312. 
Morris, C.D., Azadnia, P., de Val, N., Vora, N., Honda, A., Giang, E., Saye-Francisco, K., 
Cheng, Y., Lin, X., Mann, C.J., et al. (2017). Differential Antibody Responses to 
Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and 
Native-Like gp140 Trimers. mBio 8. 
Moynihan, K.D., Opel, C.F., Szeto, G.L., Tzeng, A., Zhu, E.F., Engreitz, J.M., Williams, 
R.T., Rakhra, K., Zhang, M.H., Rothschilds, A.M., et al. (2016). Eradication of large 
 
 204
established tumors in mice by combination immunotherapy that engages innate and 
adaptive immune responses. Nat Med 22, 1402-1410. 
Muthumani, K., Block, P., Flingai, S., Muruganantham, N., Chaaithanya, I.K., Tingey, C., 
Wise, M., Reuschel, E.L., Chung, C., Muthumani, A., et al. (2016). Rapid and Long-Term 
Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against 
Chikungunya Virus. J Infect Dis 214, 369-378. 
Muthumani, K., Flingai, S., Wise, M., Tingey, C., Ugen, K.E., and Weiner, D.B. (2013). 
Optimized and enhanced DNA plasmid vector based in vivo construction of a 
neutralizing anti-HIV-1 envelope glycoprotein Fab. Hum Vaccin Immunother 9, 2253-
2262. 
Mylvaganam, G., Yanez, A.G., Maus, M., and Walker, B.D. (2019). Toward T Cell-
Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. 
Front Immunol 10, 2109. 
Nagasawa, D.T., Fong, C., Yew, A., Spasic, M., Garcia, H.M., Kruse, C.A., and Yang, I. 
(2012). Passive immunotherapeutic strategies for the treatment of malignant gliomas. 
Neurosurg Clin N Am 23, 481-495. 
Nahta, R., and Esteva, F.J. (2007). Trastuzumab: triumphs and tribulations. Oncogene 
26, 3637-3643. 
Naso, M.F., Tomkowicz, B., Perry, W.L., 3rd, and Strohl, W.R. (2017). Adeno-Associated 
Virus (AAV) as a Vector for Gene Therapy. BioDrugs 31, 317-334. 
Nasser, R., Pelegrin, M., Michaud, H.A., Plays, M., Piechaczyk, M., and Gros, L. (2010). 
Long-lasting protective antiviral immunity induced by passive immunotherapies requires 
both neutralizing and effector functions of the administered monoclonal antibody. J Virol 
84, 10169-10181. 
Ogun, S.A., Dumon-Seignovert, L., Marchand, J.B., Holder, A.A., and Hill, F. (2008). The 
oligomerization domain of C4-binding protein (C4bp) acts as an adjuvant, and the fusion 
205
protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine 
C4bp domain protects mice against malaria. Infect Immun 76, 3817-3823. 
Overbaugh, J., and Morris, L. (2012). The Antibody Response against HIV-1. Cold 
Spring Harb Perspect Med 2, a007039. 
Pardi, N., Secreto, A.J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., 
Mui, B.L., Tam, Y.K., et al. (2017). Administration of nucleoside-modified mRNA 
encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. 
Nat Commun 8, 14630. 
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B.L., Tam, Y.K., Madden, T.D., 
Hope, M.J., and Weissman, D. (2015). Expression kinetics of nucleoside-modified 
mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release 217, 
345-351.
Patel, A., DiGiandomenico, A., Keller, A.E., Smith, T.R.F., Park, D.H., Ramos, S., 
Schultheis, K., Elliott, S.T.C., Mendoza, J., Broderick, K.E., et al. (2017). An engineered 
bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a 
pneumonia challenge model. Nat Commun 8, 637. 
Patel, A., Park, D.H., Davis, C.W., Smith, T.R.F., Leung, A., Tierney, K., Bryan, A., 
Davidson, E., Yu, X., Racine, T., et al. (2018a). In Vivo Delivery of Synthetic Human 
DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse 
Model. Cell Rep 25, 1982-1993 e1984. 
Patel, P.M., Ottensmeier, C.H., Mulatero, C., Lorigan, P., Plummer, R., Pandha, H., 
Elsheikh, S., Hadjimichael, E., Villasanti, N., Adams, S.E., et al. (2018b). Targeting 
gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 
antibody induces potent T cell responses that are associated with favourable clinical 
outcome in a phase I/II trial. Oncoimmunology 7, e1433516. 
206
Pegu, A., Hessell, A.J., Mascola, J.R., and Haigwood, N.L. (2017). Use of broadly 
neutralizing antibodies for HIV-1 prevention. Immunol Rev 275, 296-312. 
Perales-Puchalt, A., Duperret, E.K., Yang, X., Hernandez, P., Wojtak, K., Zhu, X., Jung, 
S.H., Tello-Ruiz, E., Wise, M.C., Montaner, L.J., et al. (2019). DNA-encoded bispecific T
cell engagers and antibodies present long-term antitumor activity. JCI Insight 4. 
Pereira, N.A., Chan, K.F., Lin, P.C., and Song, Z. (2018). The "less-is-more" in 
therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-
dependent cellular cytotoxicity. MAbs 10, 693-711. 
Plotkin, S. (2014). History of vaccination. Proc Natl Acad Sci U S A 111, 12283-12287. 
Pollara, J., Bonsignori, M., Moody, M.A., Liu, P., Alam, S.M., Hwang, K.K., Gurley, T.C., 
Kozink, D.M., Armand, L.C., Marshall, D.J., et al. (2014). HIV-1 vaccine-induced C1 and 
V2 Env-specific antibodies synergize for increased antiviral activities. J Virol 88, 7715-
7726. 
Pollara, J., Hart, L., Brewer, F., Pickeral, J., Packard, B.Z., Hoxie, J.A., Komoriya, A., 
Ochsenbauer, C., Kappes, J.C., Roederer, M., et al. (2011). High-throughput quantitative 
analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 
79, 603-612. 
Porter, A.G., and Janicke, R.U. (1999). Emerging roles of caspase-3 in apoptosis. Cell 
Death Differ 6, 99-104. 
Pratt, K.P. (2018). Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or 
Reverse Biotherapeutic Immunogenicity. Antibodies (Basel) 7. 
Priddy, F.H., Lewis, D.J.M., Gelderblom, H.C., Hassanin, H., Streatfield, C., LaBranche, 
C., Hare, J., Cox, J.H., Dally, L., Bendel, D., et al. (2019). Adeno-associated virus 
vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised 
controlled trial. Lancet HIV 6, e230-e239. 
207
Puronen, C.E., Ford, E.S., and Uldrick, T.S. (2019). Immunotherapy in People With HIV 
and Cancer. Front Immunol 10, 2060. 
Ramsay, L.C., Buchan, S.A., Stirling, R.G., Cowling, B.J., Feng, S., Kwong, J.C., and 
Warshawsky, B.F. (2019). The impact of repeated vaccination on influenza vaccine 
effectiveness: a systematic review and meta-analysis. BMC Med 17, 9. 
Redding, L., and Weiner, D.B. (2009). DNA vaccines in veterinary use. Expert Rev 
Vaccines 8, 1251-1276. 
Regev-Rudzki, N., Yogev, O., and Pines, O. (2008). The mitochondrial targeting 
sequence tilts the balance between mitochondrial and cytosolic dual localization. J Cell 
Sci 121, 2423-2431. 
Rohaan, M.W., van den Berg, J.H., Kvistborg, P., and Haanen, J. (2018). Adoptive 
transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. J 
Immunother Cancer 6, 102. 
Romani, N., Flacher, V., Tripp, C.H., Sparber, F., Ebner, S., and Stoitzner, P. (2012). 
Targeting skin dendritic cells to improve intradermal vaccination. Curr Top Microbiol 
Immunol 351, 113-138. 
Roos, A.K., Moreno, S., Leder, C., Pavlenko, M., King, A., and Pisa, P. (2006). 
Enhancement of cellular immune response to a prostate cancer DNA vaccine by 
intradermal electroporation. Mol Ther 13, 320-327. 
Rush, C., Mitchell, T., and Garside, P. (2002). Efficient priming of CD4+ and CD8+ T 
cells by DNA vaccination depends on appropriate targeting of sufficient levels of 
immunologically relevant antigen to appropriate processing pathways. J Immunol 169, 
4951-4960. 
Saade, F., and Petrovsky, N. (2012). Technologies for enhanced efficacy of DNA 
vaccines. Expert Rev Vaccines 11, 189-209. 
208
Sant, A.J., Chaves, F.A., Krafcik, F.R., Lazarski, C.A., Menges, P., Richards, K., and 
Weaver, J.M. (2007). Immunodominance in CD4 T-cell responses: implications for 
immune responses to influenza virus and for vaccine design. Expert Rev Vaccines 6, 
357-368.
Sardesai, N.Y., and Weiner, D.B. (2011). Electroporation delivery of DNA vaccines: 
prospects for success. Curr Opin Immunol 23, 421-429. 
Sarzotti-Kelsoe, M., Bailer, R.T., Turk, E., Lin, C.L., Bilska, M., Greene, K.M., Gao, H., 
Todd, C.A., Ozaki, D.A., Seaman, M.S., et al. (2014). Optimization and validation of the 
TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J 
Immunol Methods 409, 131-146. 
Sasaki, S., Amara, R.R., Oran, A.E., Smith, J.M., and Robinson, H.L. (2001). Apoptosis-
mediated enhancement of DNA-raised immune responses by mutant caspases. Nat 
Biotechnol 19, 543-547. 
Saunders, K.O. (2019). Conceptual Approaches to Modulating Antibody Effector 
Functions and Circulation Half-Life. Front Immunol 10, 1296. 
Saunders, K.O., Wang, L., Joyce, M.G., Yang, Z.Y., Balazs, A.B., Cheng, C., Ko, S.Y., 
Kong, W.P., Rudicell, R.S., Georgiev, I.S., et al. (2015). Broadly Neutralizing Human 
Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates 
from Mucosal Simian-Human Immunodeficiency Virus Infection. J Virol 89, 8334-8345. 
Saxena, M., and Bhardwaj, N. (2018). Re-Emergence of Dendritic Cell Vaccines for 
Cancer Treatment. Trends Cancer 4, 119-137. 
Scheid, J.F., Horwitz, J.A., Bar-On, Y., Kreider, E.F., Lu, C.L., Lorenzi, J.C., Feldmann, 
A., Braunschweig, M., Nogueira, L., Oliveira, T., et al. (2016). HIV-1 antibody 3BNC117 
suppresses viral rebound in humans during treatment interruption. Nature 535, 556-560. 
Scheid, J.F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T.Y., Pietzsch, 
J., Fenyo, D., Abadir, A., Velinzon, K., et al. (2011). Sequence and structural 
209
convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 
1633-1637. 
Schlake, T., Thess, A., Thran, M., and Jordan, I. (2019). mRNA as novel technology for 
passive immunotherapy. Cell Mol Life Sci 76, 301-328. 
Sedic, M., Senn, J.J., Lynn, A., Laska, M., Smith, M., Platz, S.J., Bolen, J., Hoge, S., 
Bulychev, A., Jacquinet, E., et al. (2018). Safety Evaluation of Lipid Nanoparticle-
Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey. Vet 
Pathol 55, 341-354. 
Seibert, C., Cadene, M., Sanfiz, A., Chait, B.T., and Sakmar, T.P. (2002). Tyrosine 
sulfation of CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows 
a discrete pattern and temporal sequence. Proc Natl Acad Sci U S A 99, 11031-11036. 
Seidel, U.J., Schlegel, P., and Lang, P. (2013). Natural killer cell mediated antibody-
dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. 
Front Immunol 4, 76. 
Selander, B., Martensson, U., Weintraub, A., Holmstrom, E., Matsushita, M., Thiel, S., 
Jensenius, J.C., Truedsson, L., and Sjoholm, A.G. (2006). Mannan-binding lectin 
activates C3 and the alternative complement pathway without involvement of C2. J Clin 
Invest 116, 1425-1434. 
Shimizu, S., Hiratsuka, H., Koike, K., Tsuchihashi, K., Sonoda, T., Ogi, K., Miyakawa, A., 
Kobayashi, J., Kaneko, T., Igarashi, T., et al. (2019). Tumor-infiltrating CD8(+) T-cell 
density is an independent prognostic marker for oral squamous cell carcinoma. Cancer 
Med 8, 80-93. 
Shingai, M., Donau, O.K., Plishka, R.J., Buckler-White, A., Mascola, J.R., Nabel, G.J., 
Nason, M.C., Montefiori, D., Moldt, B., Poignard, P., et al. (2014). Passive transfer of 
modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block 
SHIV infection in macaques. J Exp Med 211, 2061-2074. 
210
Singh, S., Kumar, N.K., Dwiwedi, P., Charan, J., Kaur, R., Sidhu, P., and Chugh, V.K. 
(2018). Monoclonal Antibodies: A Review. Curr Clin Pharmacol 13, 85-99. 
Slaney, C.Y., Wang, P., Darcy, P.K., and Kershaw, M.H. (2018). CARs versus BiTEs: A 
Comparison between T Cell-Redirection Strategies for Cancer Treatment. Cancer 
Discov 8, 924-934. 
Sliepen, K., Ozorowski, G., Burger, J.A., van Montfort, T., Stunnenberg, M., LaBranche, 
C., Montefiori, D.C., Moore, J.P., Ward, A.B., and Sanders, R.W. (2015). Presenting 
native-like HIV-1 envelope trimers on ferritin nanoparticles improves their 
immunogenicity. Retrovirology 12, 82. 
Smith, T.R.F., Schultheis, K., Morrow, M.P., Kraynyak, K.A., McCoy, J.R., Yim, K.C., 
Muthumani, K., Humeau, L., Weiner, D.B., Sardesai, N.Y., et al. (2017). Development of 
an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against 
respiratory syncytial virus. Vaccine 35, 2840-2847. 
Sok, D., Briney, B., Jardine, J.G., Kulp, D.W., Menis, S., Pauthner, M., Wood, A., Lee, 
E.C., Le, K.M., Jones, M., et al. (2016). Priming HIV-1 broadly neutralizing antibody
precursors in human Ig loci transgenic mice. Science 353, 1557-1560. 
Sok, D., Le, K.M., Vadnais, M., Saye-Francisco, K.L., Jardine, J.G., Torres, J.L., 
Berndsen, Z.T., Kong, L., Stanfield, R., Ruiz, J., et al. (2017). Rapid elicitation of broadly 
neutralizing antibodies to HIV by immunization in cows. Nature 548, 108-111. 
Sparrow, E., Friede, M., Sheikh, M., and Torvaldsen, S. (2017). Therapeutic antibodies 
for infectious diseases. Bull World Health Organ 95, 235-237. 
Stachyra, A., Gora-Sochacka, A., and Sirko, A. (2014). DNA vaccines against influenza. 
Acta Biochim Pol 61, 515-522. 
Stevenson, F.K., Ottensmeier, C.H., Johnson, P., Zhu, D., Buchan, S.L., McCann, K.J., 
Roddick, J.S., King, A.T., McNicholl, F., Savelyeva, N., et al. (2004). DNA vaccines to 
attack cancer. Proc Natl Acad Sci U S A 101 Suppl 2, 14646-14652. 
 
 211
Stone, J.W., Thornburg, N.J., Blum, D.L., Kuhn, S.J., Wright, D.W., and Crowe, J.E., Jr. 
(2013). Gold nanorod vaccine for respiratory syncytial virus. Nanotechnology 24, 
295102. 
Stoneham, C.A., Hollinshead, M., and Hajitou, A. (2012). Clathrin-mediated endocytosis 
and subsequent endo-lysosomal trafficking of adeno-associated virus/phage. J Biol 
Chem 287, 35849-35859. 
Strous, G.J. (1986). Golgi and secreted galactosyltransferase. CRC Crit Rev Biochem 
21, 119-151. 
Suschak, J.J., Williams, J.A., and Schmaljohn, C.S. (2017). Advancements in DNA 
vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase 
immunogenicity. Hum Vaccin Immunother 13, 2837-2848. 
Swann, J.B., and Smyth, M.J. (2007). Immune surveillance of tumors. J Clin Invest 117, 
1137-1146. 
Szmuness, W., Stevens, C.E., Harley, E.J., Zang, E.A., Oleszko, W.R., William, D.C., 
Sadovsky, R., Morrison, J.M., and Kellner, A. (1980). Hepatitis B vaccine: demonstration 
of efficacy in a controlled clinical trial in a high-risk population in the United States. N 
Engl J Med 303, 833-841. 
Tan, W.G., Jin, H.T., West, E.E., Penaloza-MacMaster, P., Wieland, A., Zilliox, M.J., 
McElrath, M.J., Barouch, D.H., and Ahmed, R. (2013). Comparative analysis of simian 
immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by 
different adenovirus vectors. J Virol 87, 1359-1372. 
Tang, D.C., DeVit, M., and Johnston, S.A. (1992). Genetic immunization is a simple 
method for eliciting an immune response. Nature 356, 152-154. 
Tebas, P., Kraynyak, K.A., Patel, A., Maslow, J.N., Morrow, M.P., Sylvester, A.J., 
Knoblock, D., Gillespie, E., Amante, D., Racine, T., et al. (2019). Intradermal SynCon(R) 
212
Ebola GP DNA Vaccine is Temperature Stable and Safely Demonstrates Cellular and 
Humoral Immunogenicity Advantages in Healthy Volunteers. J Infect Dis. 
Tebas, P., Roberts, C.C., Muthumani, K., Reuschel, E.L., Kudchodkar, S.B., Zaidi, F.I., 
White, S., Khan, A.S., Racine, T., Choi, H., et al. (2017). Safety and Immunogenicity of 
an Anti-Zika Virus DNA Vaccine - Preliminary Report. N Engl J Med. 
Teramoto, T., Fujikawa, Y., Kawaguchi, Y., Kurogi, K., Soejima, M., Adachi, R., 
Nakanishi, Y., Mishiro-Sato, E., Liu, M.C., Sakakibara, Y., et al. (2013). Crystal structure 
of human tyrosylprotein sulfotransferase-2 reveals the mechanism of protein tyrosine 
sulfation reaction. Nat Commun 4, 1572. 
Tetteh, R.A., Yankey, B.A., Nartey, E.T., Lartey, M., Leufkens, H.G., and Dodoo, A.N. 
(2017). Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns. Drug Saf 40, 
273-283.
Todorova, B., Adam, L., Culina, S., Boisgard, R., Martinon, F., Cosma, A., Ustav, M., 
Kortulewski, T., Le Grand, R., and Chapon, C. (2017). Electroporation as a vaccine 
delivery system and a natural adjuvant to intradermal administration of plasmid DNA in 
macaques. Sci Rep 7, 4122. 
Tokatlian, T., Read, B.J., Jones, C.A., Kulp, D.W., Menis, S., Chang, J.Y.H., Steichen, 
J.M., Kumari, S., Allen, J.D., Dane, E.L., et al. (2019). Innate immune recognition of
glycans targets HIV nanoparticle immunogens to germinal centers. Science 363, 649-
654. 
Tomusange, K., Wijesundara, D., Gummow, J., Garrod, T., Li, Y., Gray, L., Churchill, M., 
Grubor-Bauk, B., and Gowans, E.J. (2016). A HIV-Tat/C4-binding protein chimera 
encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection 
in mice. Sci Rep 6, 29131. 
Trimble, C.L., Morrow, M.P., Kraynyak, K.A., Shen, X., Dallas, M., Yan, J., Edwards, L., 
Parker, R.L., Denny, L., Giffear, M., et al. (2015). Safety, efficacy, and immunogenicity of 
 
 213
VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 
18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-
blind, placebo-controlled phase 2b trial. Lancet 386, 2078-2088. 
Tse, L.V., Klinc, K.A., Madigan, V.J., Castellanos Rivera, R.M., Wells, L.F., Havlik, L.P., 
Smith, J.K., Agbandje-McKenna, M., and Asokan, A. (2017). Structure-guided evolution 
of antigenically distinct adeno-associated virus variants for immune evasion. Proc Natl 
Acad Sci U S A 114, E4812-E4821. 
Tuteja, R. (2002). DNA vaccine against malaria: a long way to go. Crit Rev Biochem Mol 
Biol 37, 29-54. 
Ulmer, J.B., Donnelly, J.J., Parker, S.E., Rhodes, G.H., Felgner, P.L., Dwarki, V.J., 
Gromkowski, S.H., Deck, R.R., DeWitt, C.M., Friedman, A., et al. (1993). Heterologous 
protection against influenza by injection of DNA encoding a viral protein. Science 259, 
1745-1749. 
Urakami, A., Ngwe Tun, M.M., Moi, M.L., Sakurai, A., Ishikawa, M., Kuno, S., Ueno, R., 
Morita, K., and Akahata, W. (2017). An Envelope-Modified Tetravalent Dengue Virus-
Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design. J Virol 91. 
Van Braeckel-Budimir, N., and Harty, J.T. (2014). CD8 T-cell-mediated protection 
against liver-stage malaria: lessons from a mouse model. Front Microbiol 5, 272. 
van Schooten, J., and van Gils, M.J. (2018). HIV-1 immunogens and strategies to drive 
antibody responses towards neutralization breadth. Retrovirology 15, 74. 
Voigt, E.A., Kennedy, R.B., and Poland, G.A. (2016). Defending against smallpox: a 
focus on vaccines. Expert Rev Vaccines 15, 1197-1211. 
Walker, L.M., Huber, M., Doores, K.J., Falkowska, E., Pejchal, R., Julien, J.P., Wang, 
S.K., Ramos, A., Chan-Hui, P.Y., Moyle, M., et al. (2011). Broad neutralization coverage 
of HIV by multiple highly potent antibodies. Nature 477, 466-470. 
214
Walters, J.N., Ferraro, B., Duperret, E.K., Kraynyak, K.A., Chu, J., Saint-Fleur, A., Yan, 
J., Levitsky, H., Khan, A.S., Sardesai, N.Y., et al. (2017). A Novel DNA Vaccine Platform 
Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and 
Induce Anti-tumor Immunity. Mol Ther 25, 976-988. 
Wang, B., Ugen, K.E., Srikantan, V., Agadjanyan, M.G., Dang, K., Refaeli, Y., Sato, A.I., 
Boyer, J., Williams, W.V., and Weiner, D.B. (1993). Gene inoculation generates immune 
responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 90, 
4156-4160. 
Weinberg, M.S., Nicolson, S., Bhatt, A.P., McLendon, M., Li, C., and Samulski, R.J. 
(2014). Recombinant adeno-associated virus utilizes cell-specific infectious entry 
mechanisms. J Virol 88, 12472-12484. 
Weisser, S.B., van Rooijen, N., and Sly, L.M. (2012). Depletion and reconstitution of 
macrophages in mice. J Vis Exp, 4105. 
Welles, H.C., Jennewein, M.F., Mason, R.D., Narpala, S., Wang, L., Cheng, C., Zhang, 
Y., Todd, J.P., Lifson, J.D., Balazs, A.B., et al. (2018). Vectored delivery of anti-SIV 
envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting 
dose intrarectal swarm SIVsmE660 challenge. PLoS Pathog 14, e1007395. 
Wilen, C.B., Tilton, J.C., and Doms, R.W. (2012). HIV: cell binding and entry. Cold 
Spring Harb Perspect Med 2. 
Wise, M.C., Xu, Z., Tello-Ruiz, E., Beck, C., Trautz, A., Patel, A., Elliott, S.T., 
Chokkalingam, N., Kim, S., Kerkau, M.G., et al. (2019). In vivo delivery of synthetic DNA-
encoded antibodies induces broad HIV-1-neutralizing activity. J Clin Invest. 
Wu, R., Forget, M.A., Chacon, J., Bernatchez, C., Haymaker, C., Chen, J.Q., Hwu, P., 
and Radvanyi, L.G. (2012). Adoptive T-cell therapy using autologous tumor-infiltrating 
lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 18, 
160-175.
215
Xu, Z., and Kulp, D.W. (2019). Protein engineering and particulate display of B-cell 
epitopes to facilitate development of novel vaccines. Curr Opin Immunol 59, 49-56. 
Xu, Z., Wise, M.C., Choi, H., Perales-Puchalt, A., Patel, A., Tello-Ruiz, E., Chu, J.D., 
Muthumani, K., and Weiner, D.B. (2018). Synthetic DNA delivery by electroporation 
promotes robust in vivo sulfation of broadly neutralizing anti-HIV immunoadhesin eCD4-
Ig. EBioMedicine 35, 97-105. 
Xu, Z.Y., Wise, M.C., Chokkalingam, N., Walker, S., Tello-Ruiz, E., Elliott, S.T.C., 
Perales-Puchalt, A., Xiao, P., Zhu, X.Z., Pumroy, R.A., et al. (2020). In Vivo Assembly of 
Nanoparticles Achieved through Synergy of Structure-Based Protein Engineering and 
Synthetic DNA Generates Enhanced Adaptive Immunity. Adv Sci. 
Yamamoto, H., and Matano, T. (2016). Patterns of HIV/SIV Prevention and Control by 
Passive Antibody Immunization. Front Microbiol 7, 1739. 
Yan, J., Morrow, M.P., Chu, J.S., Racine, T., Reed, C.C., Khan, A.S., Broderick, K.E., 
Kim, J.J., Kobinger, G.P., Sardesai, N.Y., et al. (2018). Broad cross-protective anti-
hemagglutination responses elicited by influenza microconsensus DNA vaccine. Vaccine 
36, 3079-3089. 
Yassine, H.M., Boyington, J.C., McTamney, P.M., Wei, C.J., Kanekiyo, M., Kong, W.P., 
Gallagher, J.R., Wang, L., Zhang, Y., Joyce, M.G., et al. (2015). Hemagglutinin-stem 
nanoparticles generate heterosubtypic influenza protection. Nat Med 21, 1065-1070. 
Zhang, N., and Bevan, M.J. (2011). CD8(+) T cells: foot soldiers of the immune system. 
Immunity 35, 161-168. 
Zhao, L., Seth, A., Wibowo, N., Zhao, C.X., Mitter, N., Yu, C., and Middelberg, A.P. 
(2014). Nanoparticle vaccines. Vaccine 32, 327-337. 
Zimmer, G. (2010). RNA replicons - a new approach for influenza virus 
immunoprophylaxis. Viruses 2, 413-434. 
216
Zinyama-Gutsire, R.B., Chasela, C., Madsen, H.O., Rusakaniko, S., Kallestrup, P., 
Christiansen, M., Gomo, E., Ullum, H., Erikstrup, C., Munyati, S., et al. (2015). Role of 
mannose-binding lectin deficiency in HIV-1 and schistosoma infections in a rural adult 
population in Zimbabwe. PLoS One 10, e0122659. 
Zoller, M., and Christ, O. (2001). Prophylactic tumor vaccination: comparison of effector 
mechanisms initiated by protein versus DNA vaccination. J Immunol 166, 3440-3450. 
